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Introduction 
The present work is included in the research field of the optical biomedical imaging 
on small animals that, in the last years, has reached a prodigious growth due to various 
factors of different kind. We will remember, on the one hand, the quick and easy 
implementation of the optical techniques supported by the technological development of 
the instrumentation, with the availability of highly sensitive PC controlled sensors 
(typically CCD camera), in parallel with  the development of sophisticated software for the 
images acquisition and analysis. On the other hand, the genetic and biomolecular 
revolution has allowed approaching the biological phenomena by a completely new point 
of view: let think to the sequencing of the human genoma, and then of the mouse genoma, 
in combination with animal models of human diseases, as a link between in vitro and 
clinical studies. Finally, the birth of the combinatorial chemistry has produced a large 
amount of molecules that can interact with a particular biological target of interest. The 
integration of these factors has been fostered by the erosion of traditional boundaries that 
separated the different scientific fields and by the consequent establishment of 
interdisciplinary teams and programmes, where are involved physicians, pathologists, 
histologists, physicists, chemists, biologists, engineers, mathematicians, etc, each bearing 
its own competences, but working in synergy.  
The imaging process allows a spatial and/or temporal distribution of a physical 
quantity be registered in an image. In the optical imaging the image acquired by a detector 
visualizes the spatial distribution of the radiation intensity emitted by an (eventually 
irradiated) object. Particular success has obtained in the last years the application of the 
fluorescence reflectance imaging (FRI) technique in biomedical in vivo imaging on small 
animals. It is a very simple technique where a CCD camera, with entrance filtered to the 
fluorescence emission wavelength, collects the spatial distribution of the fluorescence 
radiation emitted by the object irradiated by light at the fluorescence excitation 
wavelength. What is the object? As it was specified above, it is a small animal, typically a 
mouse of 20 g body weight, where the biomolecular or genetic target of interest has been 
labeled with a fluorescent marker. Depending on the biomedical target of interest, the 
more suitable fluorescence targeting strategy will be selected by using a non specific, 
specific, or targeted, or “smart” fluorescent contrast agent, called also fluorochrome, or 
fluorescent or bioluminescent protein.  
The scope of imaging studies can be of various kind: the understanding the 
biomolecular mechanisms that control the functions of the healthy and diseased cells and 
tissues; or the (possibly) early, diagnosis of oncologic (and some non tumoral) diseases, 
the subsequent analysis of the disease evolution up to the identification of metastases 
formation and dissemination; or efficacy tests of new anticancer drug, by monitoring the 
possible disease regression and/or drug side effects.  
Different reasons justify the choice of the optical modality of imaging: optics is a 
branch of the physics that developed technicologically advanced imaging instrumentation 
and techniques, that are much safer than other imaging modalities, as, for example, 
radioniclide imaging. Indeed, the optical markers are generally non toxic and the optical 
radiation, being non-ionizing, doesn’t damage the biological tissues, so that the optical 
methods are intrinsically non invasive.  Finally imaging optical systems can be designed 
having: i) high sensitivity, so allowing for the use of very low dose of fluorescent marker;. 
ii) high spatial resolution, so they are suitable for the human disease model studies on 
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small animals; iii) structural features, allowing the integration with other imaging systems 
to form a multimodal system, where one technique is complementary to the other.  
As a counterbalance, optical imaging has intrinsic drawbacks that prevent from its 
clinical use. Indeed the interaction optical radiation-tissue is characterized by the 
absorption and the strong scattering by tissues with the consequent loss of the information 
carried by the light. The penetration depth of the light in the tissues depends on the 
wavelength and on the irradiation geometry, besides on tissues optical properties and it 
has a maximum (<10 cm) in the so called optical window, the spectral interval between the 
600 nm and 900 nm, where the absorption and the scattering effects are strongly reduced. 
Here also the fluorescence of biological tissue components, called autofluorescence or 
endogenous fluorescence has a minimum. This limit in the penetration depth affects 
optical planar imaging and it can be exceeded only by the tomographic imaging 
techniques that however we don’t discuss in this thesis. Moreover, in the fluorescence 
imaging, the detected signal is a diffuse light signal whose intensity shows a strong 
dependence on the depth of the investigated target in the tissue, so the quantitative 
determinations are difficult to infer. It is also noteworthy to remark that, since any 
exogenous fluorochrome doesn’t have a 100% affinity with the target, some quantity of 
fluorochrome will be present also in the non-target tissue generating the so called 
background fluorescence. The autofluorescence and fluorescence background signals 
lower the optical contrast of the fluorescence labelled target with respect to the 
surrounding region. Hence, some instrumental and/or data processing procedures are 
required to cancel these contributions and to improve the optical contrast.  
This thesis is an experimental study on the in vivo detection of subcutaneous human 
tumors implanted on small animals by a laser induced FRI technique using a 
hematoporphyrin (HP) compound as an exogenous optical contrast agent. It is widely 
reported in literature that the HP compounds accumulate preferentially in tumor tissues, 
although the uptake mechanisms of HP compounds in tumors are not completely 
understood. The absence of specificity in the targeting is a limit of HP labeling with 
respect to other fluorescent tumor markers with high specificity, since doesn’t allow for 
the monitoring of the molecular and/or genetic pathways of the disease. On the other 
hand, the HP tumor unspecific uptake is an advantage, since it makes HP suitable to target 
efficiently different type of tumors to the diagnostic purposes. In particular, the early 
diagnosis is a basic medical requirement to increase the patient survival probability, 
especially if the tumor has a high degree of malignancy. Indeed, the final aim of our 
investigation is to test the capability of our HP-FRI system to detect tumor in the early 
stage of its growth.   
In the first chapter the principal features of the interaction of the optical radiation 
with biological tissue, which constitutes the basis to understand the physical background 
of the FRI technique, is illustrated.  In the second chapter an overview of the FRI 
techniques is presented, so defining the framework where is collocated this work. In the 
third and fourth chapter the experimental apparatus and procedures are described and the 
obtained results are discussed. In particular, in the third chapter, we report on the 
preliminary tests on the HP-FRI system and on the first HP-FRI measurements, concerning 
the in vivo detection in mice of subcutaneous human thyroid carcinomas of different 
malignancy degree and on the combination of our optical imaging system with a 
radionuclide imaging system in order to exploit the complementarity of the two different 
modality imaging. In the fourth chapter, the HP-FRI measurements acquired with a high 
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sensitivity CCD camera in the spectral region of interest that allowed for in vivo early 
detection in mice of tumors with a high degree of malignancy are described. Finally, the 
appendix at the end of the Chapter 3 is devoted to the CCD technology and characteristics, 
since they are relevant for the performed FRI measurements. 
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Chapter 1 
Interaction radiation - biological tissues  
1.1 Introduction 
 
In this first charter of the thesis will be recalled the fundamentals of tissue optics as 
theoretical background of our experimental work in optical imaging in vivo on small 
animals. Here we will just run over the definition of the optical parameters that 
characterize the interaction between the radiation and the biological medium and their 
feature versus wavelength of the radiation that travels in the tissue. We are not interested 
to illustrate the models of light propagation in tissue, because this is beyond the scopes of 
our thesis, although the study of these models constitutes the prerequisite for quantitative 
determinations in the optical imaging, that are one of the challenge in this research field. 
We want especially outline that the strong scattering and absorption, features that 
dominate the interaction light-tissue, determine the limit of optical imaging in vivo, as will 
be well showed in the next chapter.  
 
1.2 Property of light 
 
Let us recall briefly the general properties of light and molecules before the specific 
tissue-light interactions are described (7). 
Light is dualistic in nature. It can be described as an electromagnetic wave or as a 
package or quantum of energy - a photon. The aspects are equally valid and often one or 
the other is chosen to describe a specific phenomenon. The electromagnetic spectrum 
ranges from radio waves through infrared and visible light to X-rays and gamma 
radiation. The wavelength, λ, or the frequency, ν, are used to describe the radiation when 
the wave nature is considered, and the energy, E, is used when light is regarded as a 
stream of photons. These quantities are easily connected by the speed of light, c, and the 
Planck constant, h. 
 
E = h ⋅ν = h ⋅ c/ λ [ J ] 
c = λ ⋅ν [m/s] 
 
In the experiments described in this thesis, light in the visible and near infrared 
range has been used. In this region, the wavelength, λ, is the most common quantity used 
to represent the light energy.  
The light fluence rate, φ (mW/cm2), the light energy per second passing through the unit 
cross section area, is another important parameter. 
1.2.1 Energy levels in molecules 
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When atoms bond together to form a molecule, the total energy is lower than the 
sum of energy of the constituents. The description of energy levels becomes more 
complicated than for atoms, since energy states due to vibration and rotation motion are 
added to the electronic levels. In Figure 1.1 (7), the schematic picture of electronic levels 
and the addition of vibration and rotation levels is shown. The electronic levels are 
determined by the atomic and electronic configurations of the molecule, whereas the 
vibrational and  rotational levels are determined by the three-dimensional positions of its 
atomic assembly, and the molecule’s quantized vibrational/rotational characteristics 
generated by the movements of the atomic nuclei of the molecules.  
The simplest calculation of vibrational energy levels for a diatomic molecule 
involves the approximation of the potential by a parabola as in a harmonic oscillator. This 
results in a simple expression of vibration frequency and energy  
 
E=(v + ½ )ћν 
 
with ν=√k/µ, where µ is the reduced mass and k is a force constant. Thus, the 
vibrational levels are equidistant and there will always be a non-zero lowest vibrational 
energy. 
 
 
Figure 1.1. Energy states in a molecule.  
 
 
The degree of complexity increases for polyatomic molecules and there can be 
numerous modes of vibration. There are two types of vibrational modes: stretching 
modes, where the distances between the atoms or groups of atoms are altered; and 
bending modes, where the angles between atoms or groups of atoms are altered.  
Molecules in general can rotate around three different axes. For the simple case of a 
diatomic molecule, it rotates around the mass centre and the rotation energy can be 
calculated as 
E = ћ2J(J +1)/2I  
 
with J = 0, 1, 2, ... and I is the moment of inertia with respect to the rotation axis. If 
the bond between the atoms is not completely rigid, the molecular bond will be stretched 
out in higher rotational states and I will increase, leading to a downshift of higher levels. 
In polyatomic molecules the theory becomes much more complex, and also here symmetry 
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aspects are important. In large biomolecules, the rotational structure, in the energy level 
diagram, is often lost and the energy levels are smeared out into a band. 
The configuration of the energy levels of a molecule determines many of the 
properties of that molecule. For instance, the energy separation between the electronic 
states determines the visible wavelengths that can be absorbed and thus the colour of the 
molecule. The transitions between the levels are the origin of many interesting phenomena 
like laser action, phosphorescence and fluorescence. 
The energy separations between close-lying electronic levels often correspond to 
visible wavelengths. Vibration transitions occur in the infrared range, while transitions 
between rotational levels in the same vibrational mode fall in the far infrared range. 
1.2.2 Transitions between levels 
 
Light impinging on a molecule can, if the energy corresponds to the energy 
separation between two levels, be absorbed and an electron is transferred to a higher level. 
The excited state of a molecule can be an electronic, a vibrational or a rotational level, 
where a multitude of vibrational and rotational levels are associated with each electronic 
level. The molecule only remains in this state for a short period of time given by the 
lifetime of that state. There are selection rules set by quantum mechanics for radiative 
transition within vibration and rotational levels. For vibration, ∆v = ±1 must be fulfilled 
and for rotation ∆J = ±1.On the way back to the ground state, none or several intermediate 
levels may be involved.  
 
 
Figure 1.2: Jablonski diagram of a fluorescent molecole. Electronic levels are S singolet states, and T 
triplet states. Vibrational levels are represented by the nonlabeled horizontal bar, contained within the 
electronic levels. Rotational levels are not shown. A denotes the resonant absorption of a photon, S is the 
resonant scattering, and IC internal conversion. All “wavy” arrows denote internal conversion. F is 
fluorescence and P phosforescence. IX represents intersystem crossing and ET energy transfer to another 
molecule.    
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Figure 1.3. Schematic of energy transfer from photosensitive substance (hematoporphyrin) to oxygen 
molecules. The molecule absorbs a photon with a electron jump up excited states empty (S1 e S2). After about  
20 nsec three phenomena can be occur: the first is the radiative decay with fluorescence emission, the second 
is energy conversion in heat; the third is state change of the electron which modifies only the state spin (T1 e 
T2 triplet states). This later event is statistically dominant and produces other events: radiative decay with 
phosphorescence emission and energy transfer to oxygen molecules, that so they produce radicals. 
 
On the one hand, elastic resonant radiation can occur, resulting in a photon being 
emitted at the same wavelength as the incoming one. On the other hand, one of several 
inelastic scattering processes may ensue. In brief, the molecule can return to its ground 
state through one of the following pathways (Figure 1.2)1(7): 
• resonant radiation of identical wavelength, compared to the incoming photon. 
• internal conversion (IC) Due to interaction with other molecules, the electron is 
transferred to the lowest lying  vibrational and rotational state within the excited 
state furnishing energy to molecular motion generating heat. 
• intersystem crossing: Because the transition between a singlet and a triplet state 
including emission of light is forbidden, if an atom, with a singlet ground state, is in 
its lowest lying triplet state, it can only release the excess energy due to other 
interactions, for instance collisions. Such a transition is called inter-system crossing. 
Thus the triplet state is a metastable state with a long lifetime. In a so-called 
Jablonski diagram (Figure 1.2), the transition from state S1 to T1 is shown. In this 
state, the molecule can stay for long times since the transition to the ground state S0 
is forbidden. If it returns to the ground state, the emission is called 
phosphorescence. 
• fluorescence, When the molecule returns to any of the levels in the ground state, 
fluorescence light can be emitted. The wavelength of the fluorescence will always 
be longer than the excitation light. Fluorescence light in solids and liquids is 
broadbanded due to the strong interaction between molecules and due to the large 
number of vibration and rotation levels which involves the re-emission of a photon 
of lower energy, i.e. greater wavelength. 
                                            
1 Finally, another inelastic process can occur, if the photon excites the molecule to a virtual state, followed by 
a rapid radiative de-excitation to the molecule’s electronic ground state, where a slight shift in the 
vibrational level of the molecule is possible. Hence, the emitted photon may be of longer, equal or shorter 
wavelength, referred to as Stokes, Rayleigh and anti-Stokes scattering, respectively. The process itself is 
denoted Raman scattering. 
 E
rr
o
re
. 
Lo
 s
ti
le
 n
o
n
 è
 d
e
fi
n
it
o
. 
• energy transfer to a neighboring molecules, causing a chemical reaction. A 
clinically relevant example is the transfer of energy to oxygen, potentially resulting 
in cytotoxic oxygen species, such as singlet oxygen (1O2), which can react with and 
destroy e.g. lipid bilayer membranes (Figure 1.3).(8) This phenomenon can be 
utilized in selectively destroying tissue, e.g. neoplastic lesions in a process called 
photodynamic therapy (PDT). In PDT, a photosensitizing substance is either 
applied topically, i.v. or i.p. injected or administered orally, followed by 
illumination of the treatment area, using an appropriate wavelength. The desired 
result is tumor necrosis.(9) 
• molecular dissociation after excitation to repulsive states. 
In conclusion, the deexcitation modes non-radiative, collision, internal conversion and 
inter-system crossing, compete with fluorescence emission. 
 
1.3 Fundamentals of tissue optics 
 
The term tissue optics encompasses modelling of the light transport in tissues, 
measurement of tissue optical transport parameters, and development of models which 
can explain the optical properties of tissue and their dependence on the number, size and 
arrangement of the tissue elements. An exact modelling of the inhomogeneous and turbid 
tissue is not presently feasible. The tissue is therefore generally represented as an 
absorbing bulk material with scatterers randomly distributed over the volume. Further, it 
is usually assumed to be homogenous, even though this is not a true representation. 
Hence, absorption and scattering are the two physical phenomena affecting light 
propagation in biological tissue (Figure 1.3). Although both are important, scattering is the 
dominant mechanism (10). Even for sub-millimetre, sections of tissue, injected photons are 
likely to be scattered several times before they reach the boundary. As a consequence a 
coherent, collimated input laser beam will be effectively incoherent and isotropic after 
traversing a few millimetres of tissue.  
Figure 1.3 shows schematically what happens to a light photons beam when they incide 
on the interface between air and biological medium. If the incidence angle is not normal, a 
fraction will be reflected (specular reflectance, see Figure 1.9); a remaining fraction will be 
refracted in the biological medium, where they can be or absorbed by molecules  when the 
light photon energy equals the energy difference between levels of molecular electronic 
states; or backscattered, after they have expedited multiple scattering events that them 
report on the interface (diffuse reflectance); or forward scattered remerging on the 
opposite interface after multiple scattering events that have altered their motion direction 
(diffuse transmittance); or unaltered transmitted without scattering events on their walk 
(ballistic component). 
Therefore, the parameters used to characterize the optical properties of the tissue are: 
• the absorption coefficient µa,  
• single scattering coefficient µs,  
• transport coefficient µt = µa + µs   
• phase function p(es,es´), from which derive the anisotropy parameter g and the 
reduced scattering coefficient µs’ = µs (1 – g). 
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In the next paragraphs we will illustrate in major detail these two fundamentals 
phenomena in the light propagation in tissue, introduce the corresponding parameters 
and discuss the principal characteristic of biological tissue components. 
 
  
 
Figure 1.3: Scattering and absorption of light photon in biological medium. The incident photons 
reflected or refracted on the interface between air and biological medium; the photons refracted are or 
absorbed by molecules, or backscattered returning on the interface  (diffuse reflectance) or forward scattered 
remerging on the opposite interface (diffuse transmittance) or unaltered transmitted (ballistic component). 
 
 
1.3.1 Absorption 
 
The condition when the photon energy of the incident radiation field exactly 
matches the energy difference between the final (excited) and initial state of a molecule is 
called resonance. The photon can be then absorbed by the molecule which changes from the 
initial state to the exited state through a transition. Hence, the probability of absorption is 
strongly wavelength dependent. Molecules that absorb light are called chromophores.  
There are two major types of transition: electronic transitions and vibrational 
transitions (5).  
The former are relatively energetic and hence are associated with absorption of 
ultraviolet, visible and near-infrared wavelengths. Many biological molecules can absorb 
light via electronic transitions. In early biological evolution, the pyrrole molecule was a 
chromophore which could absorb sunlight which enabled subsequent synthetic reactions 
that produced biological polymers and other proto-metabolic products. Combining four 
pyrroles into a tetrapyrrole ring  yielded an efficient chromophore for collecting solar 
photons: porphyrin. Chlorophyll is such a porphyrin. Hemoglobin, vitamin B12, 
cytochrome C are also examples of porphyrins in biology. We outline that the optical 
contrast agent used in optical imaging in our work belongs to the porphyrin family, as we 
will see in the next chapter.  
The latter interests the field of infrared spectroscopy that studies the variety of 
bonds which can resonantly vibrate or twist in response to infrared wavelengths and 
thereby absorb such photons. Perhaps the most dominant chromophore in biology which 
absorbs via vibrational transitions is water (Figure 1.4). In the infrared, the absorption of 
water is the strongest contributor to tissue absorption.  
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Figure 1.4: Schematic of vibrational modes of water molecule and the corresponding frequency and 
wavelength of the transition. 
 
 
1.3.2 Absorption coefficient 
 
The absorption coefficient is the parameter used to describe the effectiveness of 
absorption. To intuitively understand the significance of this parameter, we can recur to a 
schematic, hence incorrect description of the real situation. Idealize a chromophore as a 
sphere with a particular geometrical size; consider that this sphere, absorbing incident 
light, blocks and casts a shadow (Figure 1.5). The size of the absorption shadow is called 
the effective cross-section (σa [cm2]) and can be smaller or larger than the geometrical size 
of the chromophore (A [cm2]), related by the proportionality constant called the absorption 
efficiency Qa [dimensionless]:  
σa = QaA 
If a medium containing many chromophores at a concentration described as a 
volume density a [cm3] is considered, the absorption coefficient µa [cm-1] is the cross-
sectional area per unit volume of medium.  
µa =  ρaσa 
 
Figure 1.5: Schematic description of absorption of light by a chromophore sphere. 
 
Experimentally, the units [cm-1] for µa are inverse length, such that the product µaL 
is dimensionless, where L [cm] is a photon's pathlength of travel through the medium. So, 
the absorption coefficient, µa can be defined as 
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dI = - I dx µa 
where dI is the differential change of the intensity I of a collimated light beam traversing 
an infinitesimal path dx through a homogeneous medium with absorption coefficient µa. 
Integration over a thickness x yields 
I = I0 e- µax 
 
Expressing the absorption coefficient µa in terms of particle density ρ and 
absorption cross section σa  we obtain the Beer-Lambert law 
 
I = I0 e- 
ρσa x 
 
 
 
Figure 1.6. The Lambert-Beer law of exponential decay of light intensity when travel in tissue of 
absorption coefficient  µa(11) 
 
 
The reciprocal, 1/µa, is called the absorption pathlength and equals the mean free 
path a photon travels between consecutive absorption events. The probability of survival 
(or transmission T) of the photon after a pathlength L is:  
 
T=e-µaL 
 
This expression for survival holds true regardless of whether the photon path is a 
straight line or a highly tortuous path due to multiple scattering in an optically turbid 
medium. We recall also the definition of the attenuation, or optical density (OD) of an 
attenuating medium given by 
 
OD= log10(1/T)= -log10(I/I0) 
 
 
1.3.3 Absorption in biological tissues 
 
In biomedical optics, absorption of photons is a very important event. Without 
absorption, there is no energy transfer to the tissue. It is the primary event that allows a 
laser or other light source to cause a potentially therapeutic (or damaging) effect on a 
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tissue. Absorption is used for both spectroscopic and imaging applications: provides a 
diagnostic role such as the spectroscopy of a tissue and a clue as to the chemical 
composition of a tissue, and serve as a mechanism of optical contrast during imaging.  
The absorption coefficient of biological tissues is wavelength dependent. However, 
the overall absorption coefficient of tissue does not display a simple relation to 
wavelength, since multiple tissue components absorb light, each with a unique 
wavelength profile. The most important chromophores in human biological tissue are 
DNA, melanin, water, fat, proteins such as organometallic molecules, e.g. cytochromes, 
myoglobin, and oxygenated (HbO2) and deoxygenated hemoglobin (Hb). 
Let us analyze in major details the absorption spectrum of water, fat and 
hemoglobin. The first (12) is shown in Figure 1.7. Significant transmission through tissue is 
only possible from the UV (about 200 nm) to the near infrared (about 935 nm). The 
absorption drops again beyond 1000 nm, but there are currently no efficient detectors 
available at such long wavelengths.  
 
 
 
Figure 1.7: Absorption spectrum of water. 
 
 
Figure 1.8 represents the absorption spectrum of pork fat (13), which is thought to 
be largely identical to that of human lipids. The absorption coefficient, which is of the 
same order of magnitude as for water, is low at shorter wavelengths (down to about 600 
nm, not shown in spectrum), with a strong peak at about 930 nm.  
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Figure 1.8: Attenuation of pork fat 
 
 
The spectra of oxy- and deoxyhemoglobin, expressed in terms of the specific 
extinction coefficient, can be seen in Figure 1.9 (14).  Hemoglobin molecules within the red 
blood cells (Erythrocytes) carry 97% of the oxygen in the blood, while the remaining 3% is 
dissolved in the plasma. Each hemoglobin molecule consists of four iron-containing heme 
groups as well as the protein globin. It is the iron to which the oxygen atoms easily bind, 
causing the hemoglobin molecule to assume a new three-dimensional shape. In the 
oxygenated state hemoglobin is referred to as oxyhemoglobin (HbO2), and in the reduced 
state it is called deoxyhemoglobin (Hb). Oxyhemoglobin has its main absorption peak, the 
Soret band, at 418 nm, and two smaller absorption peaks, Q bands, at 542 and 577 nm, 
respectively. Upon deoxygenation, the Soret band is shifted slightly up in wavelength, 
whereas the two Q bands of HbO2 instead form a single absorption peak at approximately 
560 nm for Hb, and a new absorption peak appears at about 758 nm. While both absorb 
strongly in the blue and green regions of the visible spectrum, the absorption of 
deoxyhemoglobin is slightly stronger beyond about 690 nm. Hence venous blood appears 
in a darker red than the arterial blood. The concentrations of oxygenated and 
deoxygenated hemoglobin change according to the function and metabolism of the tissue. 
Thus the corresponding changes in absorption can provide clinically useful physiological 
information. 
 
 
   
 
Figure 1.9 Absorption spectra of oxy- and deoxyhaemoglobin in the ranges 450-1000 nm (left), and 
650-1050 nm (right)  
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The Figure 1.10 summarize the primary absorption spectra of biological tissues. 
Also shown are the absorption coefficients at some typical laser wavelengths.  
 
 
 
Figure 1.10: Absorption spectra of biological tissues. Also shown are the absorption coefficients at 
some typical laser wavelengths.  
 
In the ultraviolet (UV) spectral region (λ<400 nm), the main chromophores 
responsible for light absorption are DNA, proteins and water. Because of the high tissue 
concentration of these molecules, light absorption is strong. The key absorbers are the 
organometallic molecules, as well as epidermal melanin, bilirubin, hemosiderin and 
carotenes in fatty tissue (15,16). A ten per cent volume fraction of melanosomes are 
assumed in the epidermis, and a five per cent volume fraction of blood in the dermis (45 % 
hematocrit). The water content is set to 75 % (17). The key features to observe are the 
decrease in melanin absorption and increase in water absorption with increasing 
wavelength. Tissue absorption continues to decrease up to about 1300 nm in the near 
infrared (NIR) region (700-2500 nm), and then it rapidly increases again, mainly as a result 
of light absorption by water. The main constituents of biological tissue which contribute 
towards absorption in the near infrared are water, fat and hemoglobin. The wavelength region 
650-900 nm is called the tissue optical window, since the absorption generally is lower, 
and, hence, light penetration will be deeper. 
 It is not only the chemical composition of the different chromophores that 
determine tissue absorption, but also their concentrations and chemical structural 
configuration (18).Water is the overall dominant absorber in tissue, because, although the 
absorption coefficient of water is rather low in this ‘water transmission window’, its 
concentration is very high in biological tissue, a fact easily understood since cells can 
consist of up to 85 % water.43 Blood is the main absorber in the visible spectrum, but its 
dominance is reduced by the fact that the tissue volume fraction of blood only is about two 
to five per cent.40 Further, in highly absorbing chromophores, such as blood in the UV to 
green/yellow region, a phenomenon called shielding can be observed. Since blood is 
contained in vessels, only the outermost chromophores are apparent to the light. The 
central core of absorbers is, in effect, shielded by the surrounding blood. Thus, a 
homogenous distribution of blood of a certain hematocrit will result in a greater effective 
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light absorption, in the UV to green/yellow spectral region, compared to the case when 
blood is enclosed in vessels (19). The difference is negligible if the absorption length in 
blood ([µa,blood]-1) is large compared to the individual blood vessel radius (19), which is 
more likely to be the case in the red wavelength region, where the light absorption by 
blood is a factor 100 smaller compared to at green/yellow wavelengths, and 1000 times 
smaller than in the UV range. Finally, changes in the molecular configuration of a 
chromophore also have an impact on the absorption coefficient (16). These configurational 
alterations can be induced by temperature and tissue osmotic changes, as well as 
oxygenation of a molecule, which is apparent in the case of hemoglobin.  
 
 
1.3.4 Scattering 
 
Scattering of light occurs in media which contains fluctuations in the refractive 
index n, whether such fluctuations are discrete particles or more continuous variations in 
n. Refractive index mismatches on a macroscopic scale, e.g. between skin and skull, give 
rise to refraction, but are usually so small that they are ignored in most photon transport 
models. The refractive index varies very little on a macroscopic scale and is typically 
around 1.40 for most tissue types (20). The refractive indices of the individual tissue 
constituents vary from 1.33 for water to approximately 1.55 for fat and concentrated 
protein solution (21). However, scattering of light in biological tissue is caused by 
refractive index mismatches at microscopic boundaries such as cell membranes, 
organelles, cell nuclei etc. So, the scattering properties of tissue are related to its 
morphology. Probably, the most appropriate model is to describe a biological scattering 
medium as a continuum of refractive index fluctuations. The main drawback of this 
approach, is its mathematical complexity (15). For this reason, a scattering medium is 
instead often perceived as an ensemble of discrete, randomly distributed scattering 
particles with a refractive index different from that of the surrounding medium. Light 
scattering can occur by non resonant elastic scattering or quasi-elastic scattering. Non 
resonant elastic scattering (Rayleigh scattering) is weak, and is the result of a photon 
coming within interaction distance of an atom (or a molecule) in its ground state, where 
the energy of the incoming photon does not correspond to any of the atom’s stable energy 
levels. The electromagnetic field of the incoming photon may still drive the electron cloud 
of the atom into oscillation, but there is no resulting atomic transition. In effect, an 
oscillating dipole has been created by the vibration of the electron cloud with respect to 
the positive nucleus, thus emitting light at the same frequency as the incoming photon 
(22). After a minimal time delay, about 10-15 seconds, the photon may have changed its 
direction of motion, and polarization, but still has the same energy, i.e. frequency, and the 
atom or molecule remains in its ground state. Quasi-elastic scattering involves a minute 
frequency shift of the incoming light, as a result of interaction with a moving scatterer.  
The elastic scattering process can be further subdivided, based on if the photon is 
refracted/reflected at a boundary between media with different refractive indices, or if it 
interacts with an object. In the former process, the scattering behavior is determined by the 
angle between the incident light and a normal to the boundary/surface, the magnitude of 
the refractive index mismatch, the polarization of the light, and the structure and shape of 
the surface. Snell’s law describes the angle of the refracted light at a boundary: 
 E
rr
o
re
. 
Lo
 s
ti
le
 n
o
n
 è
 d
e
fi
n
it
o
. 
 
n1sinϑ1=n2sinϑ2 
 
where n1 and n2 are the refractive indices of the two respective media, and ϑ1 and ϑ2 are 
the angles between a normal to the boundary and the incident and transmitted light, 
respectively. The fraction of reflected power, or  specular reflectance, R, at a boundary, is 
given by Fresnel’s law, (Figure 1.11) assuming unpolarized light (15): 
 
R= ½[sin2(ϑ1-ϑ2)/sin2(ϑ1+ϑ2) + tan2(ϑ1-ϑ2)/tan2(ϑ1+ϑ2)] 
 
Figure 1.11: A ray of light hitting an interface between two media with different refractive index is 
partially reflected into the new medium. ϑ1 is the angle between the incoming or reflected light beam, and a 
normal to the interface, while ϑ2 is the angle between the refracted ray and a normal to the interface. R is the 
fraction of reflected power, assuming unpolarized light. 
 
 
In the latter process, Mie theory rigorously describes the scattering behavior of 
spherical particles as a function of the parameters x and m, where 
 
x= 2Jα/λ 
 
m= ns/ nm 
 
x is a dimensionless size parameter, α is the radius of the spheres and λ is the wavelength 
of the radiation outside the sphere (23). m is the relative refractive index, defined as the 
ratio of the refractive index of the sphere, ns, and the surrounding medium, nm; thus, in a 
sense, coupling Mie theory to specular reflectance.  
It has been shown by Graaf et al (24) that the scattering efficiency is proportional to 
λ-0.37, for 1 < m < 1.1 and 5 < x < 50, where the range of m probably is relevant for human 
tissue, based on measurements of the refractive index of various tissue types (20).The 
highly anisotropic (i.e. not equal in all directions) character of light scattering in most 
tissue types (25) indicates that the range of x is relevant as well. However, x appears to be 
smaller in e.g. adipose tissue,16 which displays a more isotropic light scattering (25). The 
aforementioned range, 5 < x < 50, would roughly correspond to 0.8λ< α <8λ, or 0.5 µm < α 
< 5 µm at λ= 632.8 nm, the wavelength of the commonly used helium-neon (He-Ne) laser. 
The probability of Mie scattering is dependent on the size of the particle, r, that the 
incoming photon interacts with, and on the wavelength of the incoming photon, λ. In the 
case of a sphere, r corresponds to its diameter, i.e. 2α. If r ~ λ, or r > λ, the probability of 
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scattering is approximately proportional to λ-0.37, as previously mentioned (24). The 
distribution of the scattered photons is highly forward peaked. On the other hand, if r << 
λ, the probability of this elastic scattering process is proportional to λ-4, i.e. it is highly 
wavelength dependent (26). This special case is denoted Mie scattering in the Rayleigh 
limit, or, simply, Rayleigh scattering, which yields a nearly isotropic distribution of the 
scattered photons. In between these two extremes, there is a general trend that the 
wavelength dependence of the scattering probability changes from λ-4 to λ-0.37, as the 
particle size, α, increases from r << λ to r > λ (Figure 1.12). 
 
Figure 1.12: Wavelength dependence of light scattering in spherical particles. Note that the 
scattering probability is monotonously decreasing with increasing wavelength of the light. Increasing radius 
of the light scattering elements, α, reduces the wavelength dependence of scattering, progressing from a λ-4.0 
to a λ-0.37 relationship. 
 
 
1.3.5 Scattering coefficient 
 
Following an analogous schematics used to introduce the absorption coefficient, 
consider a scattering particle idealized as a sphere with a particular geometrical size. 
Assume that scattering is constituted by the process in which this sphere redirects incident 
photons into new directions, so preventing the forward on-axis transmission of photons 
and thereby casting a shadow (Figure 1.13). Again, this description, an oversimplified and 
schematicized version of the real situation, provides a simple concept which captures the 
essence of the scattering coefficient, a parameter analogous to the absorption coefficient 
discussed previously. 
The size of the scattering shadow is called the effective cross-section ( s [cm2]) and 
can be smaller or larger than the geometrical size of the scattering particle (A [cm2]), 
related by the proportionality constant called the scattering efficiency Qs [dimensionless]:  
σs = QsA 
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For a medium containing many scattering particles at a concentration described as a 
volume density ρs [cm3], the scattering coefficient µs [cm-1] is the cross-sectional area per 
unit volume of medium: 
µs =  ρsσs 
 
 
Figure 1.13: Schematic description of scattering of light by a sphere. 
Experimentally, the units [cm-1] for µs are inverse length, such that the product µsL 
is dimensionless, where L [cm] is a photon's pathlength of travel through the medium. In 
the same manner as for absorption, one can define a scattering coefficient, µs, for a 
collimated source, such that 
I = I0 e- µsx 
 
where I the is non-scattered component of light after traversing a non-absorbing sample of 
thickness x.  
 
 
 
Figure 1.14: The optical path length, the path length done by light photon in traveling the tissue, is 
different by the physical path length, the thickness of the medium traveled, because of scattering or 
absorption events in the medium. 
 
 The probability of transmission T of the photon without redirection by scattering 
after a pathlength L is:  
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T=e-µsL 
 
The scattering pathlength, 1/µs, is the average distance a photon travels between 
consecutive scattering events and the quantity µs x is the (dimensionless) optical thickness 
of a sample expressed in terms of scattering pathlengths (Figure 1.14). 
 
 
 
1.3.6 Phase function and anisotropy parameter 
 
When a photon that is incident along a direction described by the unit vector es 
experiences a scattering event, the angular probability of it being scattered into direction 
es´ is given by the normalised phase function p(es,es´). For random, soft tissues it can be 
assumed that the probability distribution is a function of the angle between the incident 
and scattered photon only, and does not depend on the angle of incidence relative to the 
scatterer. Hence the phase function can be conveniently expressed as a function of the 
cosine of the scattering angle es·es´=cos(θ) 
 
p (es, es´) =p (cosθ) 
Consider an experiment in which a laser beam strikes a target such as a cylindrical 
cuvette containing a dilute solution of scattering particles. The scattering pattern p(θ) is 
measured by a detector that is moved in a circle around the target while always facing the 
target. Hence the detector collects light scattered at various deflection angles θ in a 
horizontal plane parallel to the table top on which the apparatus sits. The anisotropy, g 
[dimensionless], is a measure of the amount of forward direction retained after a single 
scattering event. Imagine that a photon is scattered by a particle so that its trajectory is 
deflected by a deflection angle θ, as shown in the Figure 1.15. Then the component of the 
new trajectory which is aligned in the forward direction is shown in red as cos(θ). On 
average, there is an average deflection angle and the mean value of cos(θ) is defined as the 
anisotropy. The proper definition of anisotropy is the expectation value for cos(θ):  
 
It is common to express the definition of anisotropy in an equivalent way:  
 
Note that the function depends on only the deflection angle θ and not on the 
azimuthal angle ψ. Such azimuthally symmetric scattering is a special case, but is usually 
adopted when discussing scattering. However, it is possible to consider scattering which 
does not exhibit azimuthal symmetry. The p(θ) has historically been also called the 
scattering phase function. A theory developed by (27) enables analytical solutions of the 
 E
rr
o
re
. 
Lo
 s
ti
le
 n
o
n
 è
 d
e
fi
n
it
o
. 
phase function to be derived for the scattering of a plane electromagnetic wave by 
isotropic spherical particles of any size. Note that in the limit where the size of the 
scatterer is much less than the wavelength of the incident photon, Mie theory can be 
approximated by Rayleigh’s theory of scattering (28). This, however, is of limited 
significance for scattering in biological tissues. The limiting cases are g=0 for perfectly 
isotropic scattering, and g=1 for complete forward scattering of the incident wave. 
Biological tissues in the NIR wavelength range are strongly forward scattering with 
anisotropy factors typically in the range 0.69<g<0.99  (10).  
 
 
 
 
Figure 1.15: A scattering event causes a deflection at angle θ from the original forward trajectory. 
There is also  an azimuthal angle of scattering, ψ. But it is the deflection angle θ which affects the amount of 
forward direction, cos(θ), retained by the photon. 
  
In terms of phase function, the scattering can be described in two ways (Figure 1.16): 
plotting p(θ) or p(θ)2pisinθ. In the first case, the plot indicates how photons will scatter as a 
function of θ in a single plane of observation (source-scatterer-observer plane). This 
pattern is similar to the type of goniometric scattering experiments commonly conducted. 
In the second case, the plot indicates how photons will scatter as a function of the 
deflection angle θregardless of the azimuthal angle ψ, in other words integrating over all 
possible ψ in an azimuthal ring of width dθ and perimeter 2pisinθ at some given θ. The 
p(θ)2pisinθ goes to zero at 0° because the azimuthal ring becomes vanishingly small at 0°. 
This plot is related to the total energy scattered at a given deflection angle and hence is 
more pertinent to the value of anisotropy.  
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Figure 1.16: a typical forward-directed scattering pattern p(θ) corresponding to an experimental 
goniometric measurement in a single source-scatterer-observer plane, and p(θ)2pisinθ which integrates over 
all possible azimuthal angles ψ. 
An isotropic scattering function would scatter light with equal efficiency into all 
possible directions. Such a scattering function would have the form:  
 
 
 
 
1.3.7 Reduced scattering coefficient 
 
The reduced scattering coefficient is a lumped property incorporating the scattering 
coefficient µs and the anisotropy g:  
µs' = µs(1 - g) [cm-1] 
The purpose of µs' is to describe the diffusion of photons in a random walk of step 
size of 1/µs' [cm] where each step involves isotropic scattering. Such a description is 
equivalent to description of photon movement using many small steps 1/µs that each 
involve only a partial deflection angle if there are many scattering events before an 
absorption event, i.e., µa << µs'. This situation of scattering-dominated light transport is 
called the diffusion regime and µs' is useful in the diffusion regime which is commonly 
encountered when treating how visible and near-infrared light propagates through 
biological tissues. This point is illustrated in Figures 1.17. 
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Figure 1.17: The figure shows the equivalence of taking 10 smaller steps of "mean free path" mfp = 
1/µs with anisotropic deflection angles and one big step with a "reduced mean free path" mfp' = 1/µs' (left) 
and how many such big steps involving isotropic scattering are equivalent to many small anisotropic steps 
(right). 
 
Combining absorption and scattering, one can define a transport attenuation 
coefficient µtr = µa + µs’ where δtr = µtr-1 is commonly referred to as the mean free path 
between either a scattering or absorption event or optical penetration depth, that is 
estimated to be less than 100 µm in soft, noncolored tissue. In the visible range (400 - 700 
nm), light penetration in terms of δtr increases to about 200 to 1000 µm. (Figure 1.18) 
 
 
Figura 1.18  Light penetration depth: (left) values in human skin at different laser wavelenght; 
(right) schematic versus radiation wavelength where is increasing from UV range to visible range, 
decreasing correspondently absorption and scattering, maximum in red-NIR range, where both absorption 
and scattering are minimum, decreasing again in the IR range, principally for the increased absorption of 
water. 
 
1.3.8 Scattering in biological tissues 
In biomedical optics, scattering of photons is an important event. Scattering 
provides feedback during therapy. For example, during laser coagulation of tissues, the 
onset of scattering is an observable endpoint that correlates with a desired therapeutic 
goal. Scattering also strongly affects the dosimetry of light during therapeutic procedures 
that depend on absorption. The scattering affects "where" the absorption will occur. 
Scattering has diagnostic value. Scattering depends on the ultrastructure of a tissue, eg., 
the density of lipid membranes in the cells, the size of nuclei, the presence of collagen 
fibers, the status of hydration in the tissue, etc. Whether one measures the wavelength 
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dependence of scattering, the polarization dependence of scattering, the angular 
dependence of scattering, the scattering of coherent light, scattering measurements are an 
important diagnostic tool. Scattering is used for both spectroscopic and imaging 
applications.   
The light scattered by a tissue has interacted with the ultrastructure of the tissue. 
Tissue ultrastructure extends from membranes to membrane aggregates to collagen fibers 
to nuclei to cells.  
 
 
Figure 1.19: schematic of principal scatterers in the tissue: the scatterers linear dimensions are 
associated with the corresponding scattering events type for visible and infrared light. 
 
Summarizing the precedent theoretical considerations, photons are most strongly 
scattered by those structures whose size matches the photon wavelength. Scattering of 
light by structures on the same size scale as the photon wavelength is described by Mie 
theory. Scattering of light by structures much smaller than the photon wavelength is called 
the Rayleigh limit of Mie scattering, or simply Rayleigh scattering.  
The Figure 1.19 designates the size range of tissue ultrastructure which affects 
visible and infrared light by Mie and Rayleigh scattering. Mitochondria are intracellular 
organelles about 1 µm in length (variable) which are composed of many folded internal 
lipid membranes called cristae. The basic lipid bilayer membrane is about 9 nm in width. 
The refractive index mismatch between lipid and the surrounding aqueous medium 
causes strong scattering of light. Folding of lipid membranes presents larger size lipid 
structures which affect longer wavelengths of light. The density of lipid/water interfaces 
within the mitochondria makes them especially strong scatterers of light. Collagen fibers 
(about 2-3 µm in diameter) are composed of bundles of smaller collagen fibrils about 0.3 
µm in diameter (variable). Mie scattering from collagen fibers dominates scattering in the 
infrared wavelength range. On the ultrastructural level, fibrils are composed of entwined 
tropocollagen molecules. The fibrils present a banded pattern of striations with 70-nm 
periodicity due to the staggered alignment of the tropocollagen molecules which each 
have an electron-dense head group that appears dark in the electron micrograph. The 
periodic fluctuations in refractive index on this ultrastructureal level appear to contribute 
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a Rayleigh scattering component that dominates the visible and ultraviolet wavelength 
ranges.  
The extracellular fluid has an effective refractive index between 1.348 and 1.351, 
influenced by concentrations of e.g. electrolytes, alcohols, glucose and fructose (16, 29). 
Refractive indices of the cytoplasm have been determined to be 1.3703 to 1.38 (30, 31) and 
of the nucleus of Chinese hamster cells 1.392 (31). Components of higher index of 
refraction, such as lipids (1.46) and proteins (1.51), are also present in tissue (33, 34). 
Membranes in the cell, e.g., consist of phospholipid layers with proteins, and the refractive 
indices have been found to be in the range 1.43 - 1.51 (30). Since the fraction of components 
of higher refractive index is fairly low (about 5 %) (30), the effective cellular refractive 
index can be estimated to approximately 1.40.35 Scattering is thus expected to occur from 
cell membranes, organelles and proteins (30), or entire cells. For instance, the main 
scatterer in blood is the entire red blood cell (RBC) (16).Based on the numbers above, the 
relative refractive index, m, between cytoplasm or extracellular fluid and phospholipid 
bilayer membranes would be in the range 1.03 - 1.10. The size of the scattering centers is 
expected to range from proteins, with sizes measured in Angstroms, to cells with 
diameters of up to 20 µm. A few examples of diameters include the hemoglobin molecule, 
64 Å, nucleoli and chromatin, 1 µm, mitochondria and nuclei, 1-5 µm, and mammalian 
cells, 3 to 20 µm. Corresponding size parameters, x, at λ= 632.8 nm, if these scattering 
centers were spherical, would be between 0.06 and 198.6. Both the structural arrangement 
and configuration of cells, organelles and macromolecules, as well as the cellular content 
of various organelles, strongly influence the scattering properties. It has, for example, been 
seen that immature and thin (compared to the wavelength of the incident light) collagen 
fibers yield isotropic scattering, whereas enlargement of the fibers, as seen in the 
maturation process, increases the anisotropy (34). On a cellular level, both the cell 
membrane and the nucleus have high refractive indices, whereas the mitochondria have 
low refractive indices (30). However, parameters such as structure, size and concentration 
of the scattering objects must also be taken into account, in considering what part(s) of the 
cell or tissue will mainly contribute to their respective scattering properties. As an 
example, tissues of high mitochondrial content, e.g. liver, exhibit a high µs’ (35). This is 
most likely mainly because of the large volume fraction of mitochondria in hepatocytes 
(about 20 %) (35). On the other hand, a low correlation has been found between µs’ and 
the tissue DNA content (33), in spite of the high refractive index of the nucleus. A likely 
explanation for this, is the low volume fraction of nuclear membrane structures (0.2 - 0.7 
%) (30). Finally, lipid droplets inside adipocytes have been shown to contribute strongly to 
cellular scattering, both because of their high index of refraction, and high volume fraction 
in the adipose tissue cells (35). The scattering coefficients of various tissue types are 
wavelength dependent, and decrease monotonically with increasing wavelength (15). As 
can be understood from the discussion above, the various tissue constituents causing light 
scattering have a wide size distribution, indicating that they have different scattering 
efficiencies, and cause different degrees of anisotropy. It has been shown, that the 
compound scattering coefficient of dermis, as a function of wavelength, can be described 
by combining the highly wavelength dependent, and nearly isotropic, Rayleigh scattering 
with the more forward peaked Mie scattering distribution, in this case cylindrical Mie 
theory with a λ-1.5 dependence. 
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Figure 1.20: Scattering and absorption factors within the tissue optical window. 
 
 
1.4 Conclusions  
 
Up to this point, we have focalized two fundamentals features about the interaction light 
and biological tissue. First, the dominant phenomena in light propagation in tissue are 
scattering and absorption, being the scattering dominant with respect the absorption. 
Second, both are wavelength dependent: the scattering is decreasing with wavelength, 
while the absorption presents a dependence more complicated from wavelength, but such 
that it is possible identify a spectral range, called optical windows, comprised between 650 
and 900 nm, in which the penetration depth in tissue is maximum, being there minimum 
both scattering and absorption (Figure 1.20). 
Hence, the photons light travel in the biological medium doesn’t impair the tissues, but 
yields a lock of information carried out by light photons. So, if the optical methods in 
biomedical applications (diagnosis and therapy) are ideal candidates as intrinsically non 
invasive, their analysis power is limited to superficial phenomena. We have so furnished 
the principal prerequisite to understand the drawbacks and the advantages of the optical 
imaging technique reported in the successive chapters. 
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Chapter 2 
Planar Fluorescence Imaging 
2.1 Introduction  
In this chapter we will focalize on the fluorescence reflectance imaging (FRI) technique 
as research tool in the field of the biomedical optical imaging performed in vivo on small 
animals to study mice models of human, in particular oncological, diseases. First, we recall 
the principia of the fluorescence as physical event and we discuss how the tissue 
fluorescence emission depends by environmental factors, how the interaction tissue-
fluorescent photons affect the fluorescence detected and how the tissue endogenous 
components fluorescence can be a diagnostic tool. After explaining the new role of in vivo 
on small animals optical imaging for the diseases studies in proteomic and genetic terms, 
the fundamentals of FRI technique relatively to the experimental apparatus and methods 
will are considered. Then, we will offer an overview of the different FRI techniques 
relatively to the fluorescence labelling strategy of the biological target of interest, 
distinguishing non specific, targeted and activatable fluorochrome, beyond fluorescent 
protein and bioluminescence. In particular, we also refer on the properties of the 
porphyrin compound family to which belongs our fluorescent marker, hematoporphyrin 
(HP) dychlorohydrate. The advantages and drawbacks of the FRI techniques, in general, 
can be illustrated so in the next chapters we can put our HP mediated FRI in comparison 
with the other FRI techniques that have been developed in the more recent years.  
2.2 Biomolecules fluorescence  
2.2.1 A brief history 
 
In 1852 Stokes described the phenomenon of fluorescence observed in fluorite (36), 
which, irradiated by UV source, gave off radiation at a longer wavelength. In 1911 Stübel 
reported that most animal tissues were fluorescent upon UV illumination (37). 
Fluorescence was detected by the naked, un-aided eye, and classified according to 
apparent color:  light green fluorescence from rabbit fat, and dark brown, or slightly 
greenish fluorescence from rabbit cardiac muscle (37) Thirteen years later, Policard 
discovered red fluorescence in animal tumors, exposed to a Wood’s lamp (38) and 
suggested that this fluorescence was due to accumulation of endogenous porphyrins. So 
he performed an important first step towards realizing both the potential of fluorescence 
as a biomedical diagnostic tool, and the importance of the porphyrins as possible tumor 
markers.  
Then, the fluorescent molecules, or fluorophores, responsible for the endogenous tissue 
fluorescence, called autofluorescence, have been extensively investigated, (39-50) and 
many diagnostic applications have been found that are based merely on the 
autofluorescence (51) Further, multiple exogenous fluorophores have been studied, 
enhancing the diagnostic potential of fluorescence considerably (52). Biomedically, 
fluorescence has been used in fluorescence microscopy, flow cytometry and cell sorting for 
some time. In addition, in vivo fluorometry applications are becoming established, 
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including tissue metabolic studies, cardiovascular diagnosis, and applications in 
ophthalmology and oncology (52). The latter application interests most of the fluorescence 
imaging and spectroscopy studies in vivo: the final goal is the detection of neoplasia, 
possibly at an early stage, probing tissue with light. So an “optical biopsy” is realized that 
in real time yields a histological, chemical and metabolic diagnosis, instead of the invasive, 
time consuming and costly procedure of removing tissue biopsies surgically for later 
microscopic analysis (52-59). 
 
 
2.2.2 Fluorescence 
 
As was briefly mentioned in the previous chapter, fluorescence is one of the 
possible results of resonant absorption of a photon in a molecule. The molecule is 
normally in its electronic ground state, which in most cases is the singlet state with the 
lowest energy, S0 (see the Jablonski diagram in Figure 2.1). One notable exception is the O2 
molecule, which has a triplet ground state. These electronic levels are characterized by the 
resulting spin vector of the electrons in the molecule: singlet states exhibit a zero sum of 
the electron spin quantum numbers, whereas the spin of one electron has changed sign in 
the triplet states. The electronic levels of a molecule correspond to the energy levels of an 
atom, and are determined by the atomic and electron configuration of the molecule. A 
typical separation in energy between electronic levels is a few eV, corresponding to 
photons with a wavelength of 100 to 1000 nm; i.e. encompassing the range of visible light. 
The electronic levels are further subdivided into several vibrational levels that are further 
subdivided into rotational levels. The latter two are determined by the movements of the 
atomic nuclei of the molecule. The lower-lying vibrational levels are typically separated by 
fractions of eV (about 0.1 eV), which corresponds to EM radiation of about 10 µm. Finally, 
the separation between rotational levels is about 0.001 eV, or roughly EM radiation of 
about 1 mm. For large molecules, the intervals between the different levels are very small, 
and may sometimes overlap due to molecular interactions (7, 59-61). 
The vibrational structure of an electronic transition, e.g. from S0 to S1, is explained 
by the Franck-Condon principle, which states that an electronic motions takes place 
considerably faster than those nuclei, since the nuclei are much more massive than the 
electrons. An electronic transition that occurs without change of nuclear geometry is called 
a vertical transition (Figure 2.1). Electron density is rapidly built up in new regions of the 
molecule, and removed from others, as a result of the electronic transition; thus, the nuclei 
suddenly experience a new force field, and will start to vibrate (in classical terms, the 
nuclei are considered initially stationary). The equilibrium bond lengths of an excited 
electronic state are usually shifted to greater internuclear separations compared to the 
electronic ground state, since the excited state has more antibonding character. Hence, the 
initial internuclear separation (where the molecule is in the lowest vibrational state of the 
electronic ground state) will be one of the two stationary turning points (the one with the 
shortest internuclear separation) in the vibrational motion of the excited electronic state. 
This is the explanation why the excited molecule is more likely to end up in a higher 
vibrational level than the lowest one, in its excited electronic state. Molecules are not long-
lived in their excited states, and a rapid relaxation (picoseconds), through non-radiative 
kinetic interactions with surrounding molecules, internal conversion (IC), to the lowest 
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rotational-vibrational state of S1 will ensue, generating heat. The rapid relaxation is a result 
of the high density of rotational-vibrational levels (7,60) 
From the lowest rotational-vibrational level of S1, the molecule can either relax back to S0 
through spontaneous emission of a photon of longer wavelength than the incident photon, 
since some energy has been lost to IC in the excited singlet state, and since the molecule 
may return to any of the many rotational-vibrational levels in S0. This process is called 
fluorescence. The shift in wavelength from the absorbed photon exciting the molecule, to 
the fluorescent photon, is denoted the Stokes shift. The distribution of energies of the 
fluorescence photons, i.e. the fluorescence spectrum of the molecule, will reflect the 
probability of transitions to the rotational-vibrational levels contained in S0, in accordance 
with the Franck-Condon principle. In a gaseous sample, the complex electronic spectra of 
a molecule, with a multitude of rotational-vibrational levels, may be resolved. However, in 
a liquid or solid phase, the molecules are interacting more closely, and the rotational and 
vibrational lines of the electronic levels usually merge together, resulting in broad, almost 
featureless absorption and fluorescence bands. Typically, the lifetime of fluorescence 
emission is on the order of nanoseconds. Finally, the molecule will return to its ground 
state, the lowest rotational-vibrational level of S0, once again through internal conversion. 
Consequently, the fluorescence process is reversible, which is an advantage in a diagnostic 
setting (7, 59, 61).  
 
 
 
 
 Figure 2.1 Molecular energy level diagram illustrating the Franck-Condon principle. The transition 
from the lowest vibrational state of S0 to the vibrational state in S1 lying vertically above it (vertical 
transition) is illustrated by an arrow. S1 is in this case displaced to greater equilibrium bond lengths 
compared to S0. In classical terms, the initial separation (corresponding to the sink of S0) becomes a 
stationary turning point in the final electronic state. In the quantum mechanical version of the Franck-
Condon principle, the transition is from the lowest vibrational state of S0, as illustrated in the figure. 
 
2.2.3 Biomolecules fluorescence features  
 
Fluorescent molecules have one structural feature in common – an unbroken chain 
of conjugated double bonds. Hence, the molecular structure of porphyrins (essentially four 
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pyrrole rings linked by methane bridges) is a good example of a fluorophore, as will be 
showed in a next paragraph (59,61).  
The surrounding environment affects the molecules fluorescence. If the fluorophore 
is in a solution, both pH and polarity of the solution will affect the fluorescence properties. 
Polar solutions, such as H2O, can dramatically increase the Stokes shifts of fluorophores, 
compared to the situation in non-polar solutions (59). Another important factor is 
quenching of fluorescence, which will affect both fluorescence quantum yield, i.e. the 
fraction of the decay that proceeds through a fluorescence pathway (62), and fluorescence 
lifetime, the average time a molecule stays in S1. Quenching can be caused by coupling of 
the fluorophore to certain molecules, and is temperature dependent. Quenching can also 
occur if a solvent is composed of molecules with widely spaced vibrational levels (such as 
water), that can accept large quanta of electronic energy from the solute (fluorophore) (60). 
It is to be pointed out that tissue structure, i.e. histology, the biochemical and metabolic 
states affect both light scattering and absorption2. Tissue fluorescence detected will be 
influenced both directly by the metabolic state and structural alterations of tissue in the 
emission fluorescence phase; and indirectly, because the emitted fluorescence photons will 
also be scattered and absorbed in tissue, before they can be detected and, hence, all 
parameters of tissue pathology will affect the detected fluorescence. Hence, both excitation 
and fluorescence light is subject to absorption and scattering in the tissue, but differently 
because of the Stokes shift and the wavelength dependence of the tissue optical properties 
(Figure 2.2).  So, Monte Carlo simulations have shown that 35-40% of the fluorescence 
photons are remitted in the forward direction, away from the tissue surface (63); thus, 
resulting in a greater probing depth than would be expected based on the optical 
properties at the excitation wavelength, since the light attenuation is less pronounced for 
the Stokes shifted light. 
As regard the absorption effects on fluorescence detected, one of the main chromophores 
is the hemoglobin. First, the Soret band of HbO2 at 418 nm often interferes with the 
excitation process, since many fluorophores have their main absorption peak in this 
region. Most porphyrins, e.g. have their main excitation peak (Soret band) close to 405 nm, 
with a characteristic dual peaked fluorescence in the red at about 630 and 690-700 nm 
(Figure 3.2)(53). Second, the endogenous fluorescence of a biological tissue usually peaks 
in the blue-green region, e.g. at about 490 - 500 nm after 425 nm excitation (58).Thus, the 
Q-bands of hemoglobin have the potential of creating re-absorption dips in the 
fluorescence spectrum. This interaction both reduces the “true” fluorescence signal, and 
creates artificial peaks in the fluorescence spectrum. Obviously, other tissue chromophores 
may also influence the propagation of fluorescence photons.  
In addition, the high and varying wavelength dependent scattering coefficients of 
tissue (53) can cause apparent changes in the spectral shape of the detected fluorescence 
(52). Similar discrepancies arise if one tries to compare fluorescence measurements using 
various optical configurations, e.g. varying source detector separations, both due to 
different sampling depths and light attenuation.  
 
 
 
                                            
2 Hence, a method designed to monitor these alterations could be used in detecting e.g. neoplasia, which is 
discussed in a review article by Bigio and Mourant (52). 
 E
rr
o
re
. 
Lo
 s
ti
le
 n
o
n
 è
 d
e
fi
n
it
o
. 
 
Figure 2.2 The scattering and absorption phenomenon affects both excitation light moving from 
interface to fluorescent target and fluorescent light emitted from fluorescent target moving from it to the 
interface, with the difference that the fluorescent light suffers minor attenuation than excitation light being of 
wavelength longer. 
 
 
2.2.4 Autofluorescence  
 
Besides absorption and scattering, tissues are inherently characterized by 
autofluorescence since all tissues contain low amounts of fluorophores which absorb light 
and subsequently emit light at a higher wavelength. Andersson-Engels et al have reported 
on the fluorescence of some fluorophores suspected to be of relevant importance (51). 
Thus, using an excitation wavelength of 337 nm, tryptophan and collagen display 
fluorescence peaks at about 390 nm, elastin at 410 nm, NADH at 470 nm and carotene at 
520 nm. All peaks are broad with FWHM on the order of 100 nm. These values are given 
for the purified compounds in solution. Endogenous porphyrins are excited using light 
slightly above 400 nm, yielding red fluorescence. Further, oxidized forms of riboflavin, 
flavin mononucleotide and dinucleotide, emit a strong fluorescence at around 515-520 nm, 
after excitation at 450 nm (64). 
Because a general goal in diagnostics is to inflict no harm, and to be non-invasive,  it 
would be advantageous if fluorescence diagnostics could be based merely on endogenous 
fluorophores: thus, reducing the risks of the diagnostic procedure to that of the ultraviolet 
radiation used in excitation of the fluorophores, especially for internal organs (52). Indeed, 
as normal tissue becomes dysplastic, there is a change in the spectroscopic properties of 
the tissue based likely on changes in the concentration of these components (65). Laser-
induced autofluorescence spectroscopy (LIAFS) was first employed in the early 1980s to 
differentiate normal from timorous tissues (66). This technique is based on fluorescence 
intensity spectra, which are acquired at excitation with different wavelengths. It has been 
shown, for instance, that bladder tumors exhibit a significantly lower fluorescence 
compared with normal tissue when examined with LIAFS (67). Bigio and Mourant (57) 
have presented a summary of clinical studies using autofluorescence and various metrics 
to discriminate adenomas, dysplasia and malignancies from normal surrounding tissue, in 
various organs in vivo (52) .Results are impressive, with sensitivities and specificities in 
most cases in excess of 90 %, e.g. in uterine cervix, colon and esophagus. In the case of skin 
malignancies, results are more ambivalent. Some studies have claimed it to be possible to 
Detect
or 
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distinguish non-dysplastic naevi from melanoma and dysplastic naevi, merely using 
autofluorescence with 365 nm excitation. Multiple studies have shown that the overall 
intensity of the autofluorescence is decreased in neoplastic tissue, compared to 
surrounding non-transformed tissue (55-58,64).  Consequently, it has been suggested that 
an enhanced tumor demarcation can be achieved by incorporating the reduced 
autofluorescence in a diagnostic criterion, e.g. by normalizing the fluorescence signal from 
an administered tumor localizing exogenous fluorophore with the endogenous 
fluorescence.  
A particular case is the protoporphyrins IX, a class of porphyrins that have been 
shown to accumulate in pre-malignant tissue and that exhibit favorable fluorescence 
properties with an excitation peak at 450 nm and a significant Stoke’s shift (emission in the 
NIR at 620 nm). An endogenous precursor of these protoporphyrins (5-aminolevulinic 
acid, ALA) can be applied systemically in order to increase endogenous autofluorescence 
of malignant tissue. This technique has been successfully applied for the detection of 
dysplasia in Barrett’s esophagus and colitis in endoscopic imaging (68). Whereas this 
approach focuses on enhancing the inherent autofluorescence of the tissue, specific or 
rather molecular events cannot be targeted using the autofluorescence detection.  
Through several molecules are responsible for the autofluorescence of various 
tissues, however, the problem with autofluorescence techniques is that the 
autofluorescence emission spectrum will vary from tissue to tissue, and is dependent on 
excitation wavelength. Further, the SNR for early-stage diseases is low, due to low 
amounts of fluorophores and the relatively high background (e.g., scattering, reflection), 
which limits the applicability of these optical signatures for early cancer detection (66). 
The Figure 2.3 shows an autofluorescence excitation-emission matrix (EEM), a 
matrix which contains the autofluorescence intensity as a function of excitation and 
emission wavelength, obtained in vivo at different excitation wavelengths (69). The 
excitation range, denoted as λx, is from 337 to 610 nm, and the emission range (λm) is from 
360 to 750 nm. It is noteworthy that the much lower tissue autofluorescence at longer 
wavelengths again justifies the preferential use of fluorochrome with excitation and 
emission wavelength shifted in the red-NIR spectral region, hence in the optical window 
where also absorption and scattering events are minimal.   
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Figure 2.3 Autofluorescence excitation emission spectrum. The autofluorescence intensity decreases 
with increasing of both excitation λx and emission λm wavelength, becoming almost constant in the red-NIR 
region. 
 
 
2.3 Optical imaging in vivo on small animals 
 
What is optical imaging? It could be defined as a visualization in space and/or time of 
normal as well as abnormal cellular processes involved in tissues of biomedical interest, at 
molecular or genetic level, by using the optical radiation as an analysis instrument.  
Tissue observation with light is probably the most common imaging practice in 
medicine and biomedical research ranging from the simple visual inspection of a patient 
to advanced in vivo and in vitro spectroscopic and microscopy techniques (70). While 
intrinsic tissue absorption and scattering yields significant information on functional and 
anatomical tissue characteristics, significant attention has also been given to fluorescence 
investigations of tissue since many biochemical markers can be retrieved due to 
fluorescence contrast, and many more can be targeted using appropriate fluorescent 
markers (71,72). Numerous different optical imaging approaches can be used for imaging 
fluorescence in vivo. Traditionally, optical methods have been used to look at surface and 
subsurface fluorescent events using confocal imaging (73-75), multiphoton imaging (76-79) 
microscopic imaging by intravital microscopy (80,81) or total internal reflection 
fluorescence microscopy (82). Recently however, light has been used for in vivo 
interrogations deeper into tissue using photographic systems with continuous light (83-86) 
or with intensity-modulated light (87) and tomographic systems (88-89). Potentially, 
phased-array detection (90) can also be applied. This recent focus in macroscopic 
observations of fluorescence in tissues has evolved due to the potential of transferring this 
technology to imaging through animals and humans (71).  
The considerable increased interest in the use of optical methods for medical 
imaging, diagnosis and therapy1 is motivated by various and different factors. First, the 
considerable potential of the optical approaches has now become feasible because of the 
technological development of the component of the experimental apparatus, essentially 
monochromatic light sources (lasers) with higher but nevertheless safely delivered power 
per wavelength compared with white-light illuminators, and highly sensitive detectors 
with the associated data acquisition and analysis software. Second, different optical 
techniques have already been developed and used for many years in the molecular 
biology community to probe tissue samples or cells (such as, for example, the use of 
fluorescent proteins and fluorescently labelled antibodies). These techniques can be 
adapted and modified for in vivo applications. Further, since the techniques are of very 
sensitivity, where the autofluorescence of tissues is very low, a high SNR can be achieved 
even when low amounts of fluorescent reporter are present at the target.  Then, this 
technology has become feasible mainly due to the development of fluorescence probes 
emitting in the near-infrared spectrum where tissue offers low absorption and minor 
scattering, whereas also the autofluorescence is minimum. A further catalyst has been the 
erosion of traditional boundaries that separated physicists, engineers, mathematicians, 
computer scientists, chemists, cell and molecular biologists and physicians  and the 
establishment, at many leading institutions, of interdisciplinary programmes where the 
imaging sciences and biology are seamlessly integrated. Finally, different functional 
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paradigms can be applied for optical contrast agents, such as fluorescence energy transfer 
or bioluminescence, in order to detect specific target interactions in vivo such as enzyme 
activity.  
From a some point of view, fluorescence imaging is nothing new: fluorescently 
labelled contrast agents that bind to specific proteins, particularly cell-surface receptors, 
have been employed for decades in cell culture. These techniques have since migrated to 
the in vivo environment. What has changed over the last several years, acting as a catalyst 
for the explosive growth and popularity of optical (and not only) imaging, is the 
extraordinary avalanche of information regarding the specific genes and proteins involved 
in disease mechanisms, the sequencing of the human genome (and more recently, the 
mouse genome) and the advent of combinatorial chemistry and mass screening techniques 
that produce large numbers of candidate molecules that can interact with a particular 
biological target of interest. In addition, the imaging field has embraced this opportunity 
by discovering and developing a range of novel approaches for generating protein and 
gene specific contrast in an image, and through stunning improvements in the imaging 
technologies themselves, particularly at the level of in vivo small-animal imaging. This is 
important, because as the genomic era provides us with better animal models of cancer 
and more specific therapeutics, better methods are needed to monitor tumour 
development in animals. The goal of molecular imaging is to image specific proteins, 
genes or the biochemical and molecular pathways they are involved in, within intact 
living subjects. The ultimate goal is to know where specific proteins or genes are expressed 
in the body, the level at which they are expressed and how that distribution and level 
changes over time or following an intervention.  
 
 
2.4 Fluorescence Reflectance Imaging:  FRI 
 
Specifically, we focus on reflectance fluorescence imaging, which is the most 
common approach currently used for imaging in vivo fluorescent probes in  tissues.  
 
2.4.1 Technology  
 
Reflectance imaging is a simple “photographic methods”, in which the light source and 
the detector reside on the same side of the object imaged. Fluorescence reflectance imaging 
(FRI) is currently the typical method for accessing the distribution of fluorescent probes in 
vivo, but the method can be applied more generally to imaging fluorescent proteins or 
even bioluminescence even if in the latter case no excitation light is used (91). FRI operates 
a source of light whose wavelength falls in the excitation band of the fluorescent molecule 
used as optical contrast agent or molecular probe. The fluorescence signal can be resolved 
with an emission filter and captured by a high-sensitivity CCD camera. A typical 
reflectance imaging system is shown in Figure 2.4.  
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Figure 2.4 Typical fluorescence reflectance imaging (FRI) system for in-vivo animal investigations. The 
illumination source and CCD camera are on the same side of the animal imaged. The components shown are 
usually enclosed into a light-tight box. 
 
 
The two key light sources for fluorescence detection systems are lamps and lasers. 
Lamps are usually inexpensive and can yield high output powers, but are more difficult to 
efficiently couple to optical fibers in endoscopic applications, and may require multiple 
filters to select the appropriate wavelength. Lasers, on the other hand, have the advantage 
of high output power within a narrow wavelength band (temporal coherence), and a high 
spatial coherence, simplifying the coupling to optical fibers. Further, both continuous and 
pulsed lasers exist, allowing e.g. the introduction of gated detection, triggered by the light 
pulses. Fixed-frequency lasers operating at a certain wavelength, determined by the lasing 
medium, can be used to pump tunable lasers; thus, yielding light at another wavelength, 
depending on the lasing medium used in the tunable laser. The laser beam is expanded on 
the animal surface with an optical system of lenses (not shown). Narrow wavelength 
selection is important, especially in the NIR, whereas the excitation and emission spectra 
overlap and it is likely that excitation photons can propagate into the fluorescent images.  
The CCD camera is usually a high-sensitivity camera since fluorescent signals are of 
low strength, while CCD chip resolution and dynamic range are not crucial factors in 
these types of systems since the targeted measurement is a diffuse-light measurement, 
emanating from a virtually flat surface. In the fluorescence measurements the detection 
sensitivity limit is set by the background tissue fluorescence (background probe 
distribution and auto-fluorescence); therefore, fluorescence strength can be adjusted above 
the camera noise floor by optimizing illumination strength and acquisition times, so that 
the noise requirements of a CCD camera for fluorescence imaging are not as stringent. 
Instead, in the bioluminescence measurements the detection sensitivity is usually set by 
the CCD camera noise floor. 3 
Typically, the fluorescence image acquired is accompanied by a second image 
measured without the fluorescence filter. The animal “photograph” obtained for 
registration purposes at the excitation wavelength also serves as a calibration 
measurement since it records the exact spatial distribution of the excitation light strength 
for later correction of excitation field inhomogeneities. It is noteworthy that the 
                                            
3 Detection systems that scan a single spot over a field of view and detect light using photo-multiplier tube 
detectors have also been reported (92). Such systems may offer greater dynamic range than CCD-based 
systems but compromise resolution, acquisition frame rate, and overall noise characteristics, and are not 
widely used in in vivo fluorescence reflectance measurements. 
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fluorescence (or luminescence) image, recording fluorescence signals emanating from 
under the surface and using mainly the diffuse component of light, is by nature a low-
resolution image, while the intrinsic light image records the structure on the animal 
surface and can yield high-resolution images after appropriate focusing. The side-by-side 
comparison or the superposition of the two images into a single image yields a good 
visual effect since high resolution is retained. 
The fluorescence imaging measurements in vivo on small animals are sometimes 
accomplished by fluorescence spectroscopic measurements on histological sections of 
healthy/diseased mice tissue to obtain a control measurement of the imaging results. 
 
2.4.2 Targeting strategies 
 
In order to obtain molecular information from an intact organism, several 
fundamentals have to be fulfilled. First of all, it is essential to define a target, which is 
highly relevant for the pathology to be imaged. Secondly, the target needs to be 
sufficiently characterized so that optical sensors with a high selectivity and affinity for the 
target can be developed. Thirdly, since imaging should ultimately be performed in vivo, a 
drug delivery paradigm has to be applied, which allows for sufficient delivery of the 
molecular probe to the target. Finally, if possible, signal amplification strategies should be 
applied in order to improve the signal-to-noise ratio (SNR) for molecular structure 
detection (93-94).  
 
 
Figure. 2.5 A–C Design of different optical contrast agents. A Whereas non-specific fluorochromes, such as 
indocyanine green or porphyrins, show simple perfusion and/or permeability properties of the tissue, B 
targeted probes bind via specific ligands to protein structures on the cell surface. Targeting of tumor-
associated receptors, such as the somatostatin receptor, allows for specific detection of cancerous lesions. C 
“Smart” probes are activated by enzymatic conversion. Whereas these probes are virtually non-fluorescent 
in their native state (C, left) due to fluorescence energy transfer, they become brightly fluorescent once the 
fluorochromes are released from the backbone (C, right).  
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Various strategies can be pursued to obtain optical information from the tissue ranging 
from endogenous tissue contrast4 to non-specific, targeted, or “smart” optical probes 
(Figure 2. 5) (104). The choice of the targeting modality depends on the study objective. In 
general, if the scope is disease (tumor) diagnosis, then the non specific fluorochrome is a 
useful choice. If, instead, it is necessary to determinate the molecular and/or genetic 
pathway of the disease, then a more specific fluorochrome must be used.    
 
 
 
 
 Figure 2.6. The emission range of several common fluorochromes and luciferases used for imaging 
on the tissue absorption coefficient graph calculated assuming normally oxygenated tissue (saturation of 
70%), a hemoglobin concentration of 50 mM, and a composition of 50% water and 15% lipids.  
 
 
 In general, fluorochromes for optical imaging should ideally fulfill some criteria in 
order to be suitable for in vivo diagnostic imaging: 
1. Excitation and emission maxima in the red-NIR range (600–950 nm) (Figure 2.6)(4)  
2. High extinction coefficient 
3. High quantum yield (i.e., strong fluorescence signal) 
4. No photo-bleaching 
5. No photo-sensitizing effects 
6. Hydrophilicity 
7. Low toxicity 
 
                                            
4 Photons interact with tissue by absorption, scattering, and reflection. Generally speaking, absorption of 
light in the NIR is due mainly to the hemo- and myoglobin content within a given volume and thus 
dependent on vascularization and/or perfusion in the tissue. Scattering, however, is determined by 
refraction leaps, which are dependent on tissue architecture and intracellular composition such as density of 
organelles (e.g., mitochondria) (95,96). Classic diaphanic/transillumination imaging thus depicts a 
combination of absorption and scattering processes in the tissue. In the early years, optical mammography, 
for instance, tried to apply this principle to medical practice. Whereas a few studies in the 1980s reported 
favorable results for optical mammography compared with radiological screening (97-99), other studies 
discouraged the use of light for breast cancer diagnostics mainly due to poor sensitivity and specificity (100-
102). More recently, multi-spectral imaging measuring the spectral dependence of tissue absorption and 
scattering provide additional information concerning tissue contents (water, lipids, oxy- and deoxy-
hemoglobin) which may be useful in managing breast disease (103).  
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2.4.2.a Non specific fluorochromes  
 
Two principal non specific fluorochromes family will be considered: cyanine dyes 
and porphyrins. 
 
Cyanine dyes 
 Cyanine dyes (CD) represent one of the most prominent classes of optical contrast 
agents with ideal properties for in vivo imaging. The chromophore’s optical properties are 
adjustable offering high extinction coefficients with the desired absorption and emission 
ranges throughout the visible to the near-infrared range (66). At the same time, CD can be 
conjugated to specific ligands, which can impart molecular specificity within the optical 
probes (see next paragraph). 
 Indocyanine green (ICG, cardiogreen) is one example for a non-specific 
fluorochrome, which has been used clinically for many years for hepatic function testing, 
cardiac physiology tests, and ophthalmological fluorescence angiography (105-107). It is a 
safe imaging agent, having been used in tens of thousands of patients with a reported side 
effect rate of <0.15%, an extremely favorable index as compared with other reporter 
agents46. In addition, it has been used in at least one clinical study as an absorber (not a 
fluorochrome) for enhanced tumor detection31. Experimental studies have proven the 
feasibility of tumor detection using nonspecific CD fluorochromes (108-110). Moreover, in 
a clinical study on patients with various breast lesions, ICG proved to be an efficient tool 
for lesion detection (88).  
 Near-infrared fluorochromes with improved biophysical properties (solubility, 
quantum yield, stability, synthetic yield, conjugatability) have recently been developed47–
49 and open new avenues for high efficiency labeling of affinity molecules. Before they can 
enter routine clinical use, however, these fluorochromes will need to undergo testing and 
receive approval from the US Food and Drug Administration. 
Porphyrins 
Chemical properties 
Pyrrole, or pyrrol, is a heterocyclic aromatic organic compound, a five-membered 
ring with the formula C4H5N (Figure 2.7). Pyrroles are components of larger aromatic 
rings, including the porphyrins of heme, the chlorins and bacteriochlorins of chlorophyll, 
and the corrin ring of vitamin B12. 
 
 
Figure 2.7 Pyrrole structure 
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A porphyrin is a heterocyclic macrocycle made from 4 pyrrole subunits linked on 
opposite sides (α position) through 4 methine bridges (=CH-) (Figure 2.8). The macrocycle, 
therefore, is more aromatic than the related corrins, chlorins (2,3-dihydroporphyrin) and 
bacteriochlorins (2,3,12,13-tetrahydroporphyrin). The extensive conjugated system makes 
the compound chromatic, hence the name porphyrin, from a Greek word for purple. The 
macrocycle has 22 pi electrons, 18 of which are active in the conjugated system. Porphyrins 
combine readily with metals, coordinating with them in the central cavity. Iron- (heme), 
magnesium- (chlorophyll), zinc-, copper-, nickel-, and cobalt- containing porphyrins are 
known, and many other metals can be inserted. A porphyrin in which no metal is inserted 
in its cavity is called a free base. Some iron-containing porphyrins are called hemes; and 
heme-containing proteins, or hemoproteins, are found extensively in biochemistry, e.g., 
hemoglobin. Hemoglobin iron is the actual transfer site for oxygen and can be 
preferentially bound up with carbon monoxide, thus poisoning by asphyxiation can occur. 
Some shellfish with green-colored blood have a copper-centered porphyrin. If one of the 
four pyrrole subunits is reduced to pyrroline, a chlorin is produced, the ring structure 
found in chlorophyll.  
The number of double bonds in a row gives a rough estimate of the Q-band 
absorption wavelength. In the case of porphyrins, the number of double bonds is fairly 
large; hence, the Q-bands are located in the red region of the light spectrum. 
 
 Figure 2.8 Porphyrin structure 
 
Porphyrin for diagnostic purposes 
 
An overview of the main available diagnostic fluorophores is given by Andersson-
Engels et al, (52) starting with the development of the first clinically significant 
photosensitizer and diagnostic fluorophore, hematoporphyrin (Hp) and a derivative 
thereof, hematoporphyrin derivative (HpD). Many of these substances have originally 
been developed for PDT purposes, and therefore carry potential side effects, such as skin 
photosensitization. However, reduction of dosage has been one way of minimizing the 
side effects. A multitude of studies, both experimental and clinical, have been published 
on the tumor marking properties of Hp and HpD,(53,111,112) showing tumor-to-normal 
substance related fluorescence intensity ratios of about 2-3:1, depending on the type of 
malignancy. However, if administered in therapeutic doses, general cutaneous 
photosensitivity may persist for several weeks (113). This fact combined with the 
heterogeneous chemical composition of HpD, and the presence of non-fluorescent 
aggregated material triggered the development of new sensitizers. 
Several fluorophores have been developed and tested in tumor models, e.g. 
phthalocyanines (114), various chlorins (mono-aspartyl chlorin e6 (MACE) (115) and 
meso-tetra hydroxyphenyl chlorin (mTHPC) (116) and benzoporphyrin derivative (54). 
They all exhibit a strong fluorescence, but also have strong photosensitizing  capabilities, 
which may be a drawback for diagnostic purposes. The tumor selectivity of the substance 
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uptake is not much better than that of HpD. However, Nelson et al did show that MACE 
does not induce any cutaneous photosensitivity because of a fast clearance rate. More 
recently, -amino levulinic acid (ALA) has been introduced as an attractive alternative for 
PDT (117). It is metabolized to protoporphyrin IX (PpIX) in the endogenous heme cycle 
(61), but PpIX has photophysical properties similar to those of HpD (52). Some research 
has been focused on finding exogenous fluorophores without any phototoxicity; i.e. these 
compounds could only be used for diagnostic purposes, and not PDT. 
Carotenoporphyrins have been found to demarcate MS-2 fibrosarcoma well in mice, with 
a tumor to peritumoral muscle concentration ratio of up to 30 (118). Takemura et al (119) 
have developed a chlorine derivative that is very tumor selective in a pancreatic cancer in 
hamsters, and without phototoxicity, but no numbers are given regarding the tumor 
selectivity.  
 
Porphyrins tumor selectivity mechanisms 
Many different theories have been presented as to the mechanisms behind the 
relatively selective accumulation of porphyrins in neoplastic tissue. The tumor selectivity 
varies between different tumor models, and is not the same in vitro and in vivo. In some 
cases, there is no selectivity, possibly because of a poor vascular supply in fast growing 
malignancies. It has been proposed that the structure of the neoplastic tissue is more 
important for the selectivity, than the properties of the transformed individual cells. 
Evensen et al have pointed out that the large interstitial space of many malignant tumors, 
occupying about 50 % of the total tumor volume, or twice the fraction compared to normal 
tissue, may be important in this context (110). Porphyrins bind to plasma proteins after i.v. 
injection, (118,121) and will accumulate in the interstitial space, due to the increased 
endothelial permeability of neoplastic lesions. Once in the interstitium, these 
proteinporphyrin complexes bind to collagen, elastin and fibrin (122,123) .Thus, a tumor to 
normal ratio of 2:1 may be expected, merely based on this mechanism. Indeed, this is the 
approximate ratio displayed for uptake of Hp, e.g. in an experimental colon 
adenocarcinoma in rats (53). In fact, tritiated water has shown the same uptake in a Lewis 
lung carcinoma in mice (124). 
On a cellular level, it has been suggested that hydrophobic fractions of HpD traverse 
the plasma membrane of neoplastic cells, and by some mechanism are converted to highly 
fluorescent hydrophilic monomers inside the cell (125).  Consequently, these monomers 
will in effect be trapped inside the cell. Porphyrin aggregates have also been suggested to 
enter cells through diffusion and pinocytosis (124). Another mechanism for retention of  
porphyrins in tumors, has been proposed to be due to the reduction of one half to one unit 
in pH in neoplastic tumors (126).The shift in pH will change the equilibrium towards more 
neutral, and less charged species of Hp. Since the neutral species are less soluble, they may 
be retained for a longer period of time in a malignant tumor. Further porphyrins bind to 
various plasma proteins, such as albumin and lipoproteins (118,121). Since the number of 
low density lipoprotein (LDL) receptors is increased on fast growing cells, especially 
malignant tumors, it has been suggested that porphyrin-LDL complexes will enter 
malignant cells preferentially (127). The uptake in this case would be through receptor-
mediated endocytosis (128). However, there are also reports claiming that LDL inhibits the 
uptake of porphyrins into cells (129). In vitro experiments have shown that there is no 
difference between porphyrin uptake in normal and malignant cells in culture (130); 
hence, possibly supporting the aforementioned hypothesis, that the determining factor for 
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selective uptake of porphyrins in tumors, is the structure of the neoplastic tissue, and not 
so much the properties of the individual cells, even if the in vitro situation cannot be 
directly translated to the in vivo setting. 
 
2.4.2.b Targeted fluorochromes 
 
The two most common types of targets currently exploited in molecular imaging 
studies are enzymes and cell-surface receptors. Figure 2.10 (1) shows schematically how 
such a protein target could be imaged using the simple accumulation of a contrast agent. 
In this case the contrast agent molecules are designed to bind tightly to a cell-surface 
receptor protein found only on cancer cells. The contrast agent is also designed such that 
unbound contrast agent is cleared fairly rapidly by the body, either through the 
urogenitary or hepatobiliary systems. After the contrast agent is administered (usually by 
intravenous injection), it distributes rapidly throughout the body, accessing all the cells of 
the body. An image taken at this early time reveals little or no specific signal (Figure 2.10 
(left)). But after waiting for some time, most of the unbound contrast agent has been 
cleared away, and the signal comes primarily from contrast agent molecules that are 
specifically bound to the receptors. Therefore, the image intensity reflects the distribution 
and density of these receptors (Figure 2.10 (right)). There is always some background due 
to contrast agent molecules that bind to other proteins in the body (no contrast agent is 
100% specific), any contrast agent remaining in the circulation, routes of excretion of the 
contrast agent from the body and contrast agent that has been chemically modified so that 
it no longer recognizes the intended target. Minimizing this background is a key goal of 
contrast agent development. The timing of the imaging with respect to contrast agent 
administration depends on the type of contrast agent, and the time taken for distribution 
and clearance. For small molecule contrast agents, this process may only take a few 
minutes, while for larger biomolecules such as antibodies, it may take several days. 
 
 
  
 Figure 2.10 Schematic diagram showing imaging of a cell-surface receptor found on cancer cells 
using a contrast agent designed to bind tightly and specifically to that receptor. At early times (left) after 
contrast agent administration, the agent is distributed throughout the tissues and there is no specific 
binding. At later times (right), the contrast agent has found and become bound to the receptor, and most of 
the unbound contrast agent has been cleared from the tissues and the circulation. The signal seen at this time 
comes predominantly from contrast agent that is specifically bound to the target receptors. There is also 
some signal from contrast agent that is nonspecifically bound to other proteins, and from remaining 
unbound contrast agent that is still in the circulation. In this figure, the ‘target-to-background’ ratio for the 
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contrast agent is 4:1 (12 contrast agent molecules are bound to the targeted receptor, 3 other molecules are 
present but not bound to the receptor). 
 
  
Conjugating specific ligands to a cyanine dye is one way to obtain tissue-specific or 
molecular information with an optical contrast agent. Since many cancers overexpress 
various receptors, specific ligands can act as a vehicle for selective tumor visualization 
(66). In this context targeting of extracellular angiogenesis related matrix proteins 
(oncofetal fibronectin) using dye-labelled single-chain antibodies has been described (131). 
Other studies have exploited the folate receptor for cancer- specific targeting of 
fluorochromes (132). More recently, a peptide-dye conjugate consisting of a cyanine dye 
and the somatostatin (SST) analog octreotate (indotricarbocyanine-octreotate) was 
synthesized serving as a contrast agent for optical tumor imaging (133,134) The probe 
showed an accumulation in mouse xenografts detected by an in vivo near infrared (NIRF)- 
reflectance imager with a threefold higher tumor fluorescence compared with non-
diseased tissue (133). The targeting conjugate was also specifically internalized by primary 
human neuroendocrine tumor cells (133). Figure 2.11 depicts fluorescence reflectance 
images using a conjugate of tricarbocyanine dye and an octapeptide (c.f. Fig. 11a) for 
targeting the somatostatin receptor in CA20948 tumor-bearing rats (135,136). The tumor 
cells were implanted subcutaneously in the left flank of the rat demonstrating a marked 
fluorescence increase compared with surrounding tissues (Fig. 11b, c).  
 
 
 Figure 2.11  a Molecular structure of cytate, a conjugate of tricarbocyanine dye for near-infrared 
imaging and an octapeptide for targeting somatostatin receptor which is up-regulated in neuroendocrine 
tumors. b Fluorescence intensity imaging of a CA20948 tumor-bearing rat 27 h post administration of cytate 
via the tail vein. Tumor cells were implanted subcutaneously in the left flank of the rat. c Fluorescence-
intensity image of selected organ parts excised 24 h post injection of cytate. The somatostatin receptor-
positive tumor, CA20948, preferentially retains cytate. (Adapted from 135 and 136) 
 
Similar observations were performed in a separate study (133) that showed significant 
fluorescence increase from tumor sites compared with normal tissues using the 
somatostatin analog octreotate coupled to indocarbocyanine dyes. Specifically, the 
fluorescence detected before the injection of the dye-peptide conjugate administered in a 
tumor-bearing mouse (RIN38 pancreatic tumor expressing the somatostatin receptor 
subtype 2) and a control mouse are shown in Figure 2.12a and b, respectively. Figure 2.12c 
and d show the fluorescence images obtained from the same animals 6 h after probe 
injection. The administered probe dose was 0.02 µmol/kg body weight. The receptor-
binding indotricarbocyanineoctreotate conjugate leads to a significantly elevated tumor 
signal (Figure 2.12c), whereas a control conjugate with no receptor affinity does not 
generate contrast (Figure 2.12d).  
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 Figure 2.12 In vivo fluorescence images of tumor-bearing mice (RIN38 pancreatic tumor expressing 
the somatostatin receptor subtype 2) a, b before and c, d 6 h after injection of dye-peptide conjugate at a dose 
of 0.02 µmol/kg body weight. c The receptor-binding indotricarbocyanine–octreotate conjugate leads to a 
significantly elevated tumor signal,  whereas d a control conjugate with no receptor affinity does not 
generate contrast.  
 
   
 A different strategy for specification of optical contrast has recently been described 
by Zaheer and coworkers. They synthesized a fluorescent bisphosphonate derivate (Pam 
78) that exhibits rapid and specific binding to hxdroxylapaptite (HA) in vivo. After 
intravenous injection, the agent allowed for detection of osteoblastic activity in vivo using 
a NIRF-reflectance imager (137). This imaging approach might be useful to assess 
osteoblastic activity in metastatic disease or to study the skeletal development in vivo 
(137). Using the described receptor or binding affinity approach, high target specificity can 
be achieved using low amounts of fluorochromes. Nevertheless, this approach operates 
with a relatively low signal-to-background ratio, since non-bound probes are fully 
fluorescent and thus contribute to background noise.  
 
 
Nanoparticles 
Organic fluorophores have been used in NIR applications for many years. They are 
typically 1200 or less Daltons in size, varying in toxicity, with widely different 
biodistibution and pharmacokinetics, and are cleared from the circulation by renal 
filtration in minutes (138). However, they suffer from problems with controlling their 
excitation and emission wavelengths, hydrophobia, molecular stability, low quantum 
yields (efficiency of emission) and are susceptible to photobleaching (loss of fluorescence) 
which limits their sensitivity to detection (138). Quantum dots have recently been 
introduced to the field of NIR and have the potential to solve many of the problems 
associated with organic fluorophores. Quantum dots comprise an inorganic core and shell 
of metal and an outer organic coating (Figure 2.13). The inorganic core and shell enables 
tuning of fluorescence with a narrow bandwidth (25–35 nm), thus enabling multi-coloured 
quantum dots for multiplexed detection of molecular targets (139). In addition, quantum 
dots are resistant to photobleaching, with an emission time constant (one-half) of 
approximately 16 min (140), and they have a high quantum yield of close to 90% (141). 
However, quantum dots are typically large structures of 3–20 nm hydrodynamic diameter, 
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and hence are difficult to clear from circulation by renal filtration, which results in a high 
background signal. Also, the issue of in vivo toxicity is as yet unknown, and needs to be 
addressed (140). 
 
 
 
 
 
 
 
 Figure 2.13  Schematic illustration of biconjugated QDs for in vivo cancer targeting and imaging.(top) 
Structure of a multifunctional QD probe, showing the capping ligand TOPO, an encapsulating copolymer 
layer, tumor-targeting ligands (such as peptides, antibodies or small molecule inhibitors) and polyethylene 
glycol (PEG). (bottom) Permeation and retention of QD probes via leaky tumor vasculatures (passive 
targeting) and high affinity binding of QD-antibody conjugates to tumor antigens (active targeting). 
 
 
 Under in vivo conditions, QD probes can be delivered to tumors by both passive 
and active targeting mechanisms (see Figure 2.13, bottom). In the passive mode, 
macromolecules and nanometer-sized particles accumulate preferentially at tumor sites 
through an enhanced permeability and retention effect (142-144). This effect is believed to 
arise from two factors: (i)angiogenic tumors produce vascular endothelial growth factors 
that hyperpermeabilize the tumor-associated neovasculatures and cause leakage of 
circulating macromolecules and small particles; and (ii) tumors lack an effective lymphatic 
drainage system, which leads to macromolecule or nanoparticle accumulation. For active 
tumor targeting, are used antibody-conjugated QDs to target a prostate-specific membrane 
antigen (PSMA). Previous research has identified PSMA as a cell surface marker for both 
prostate epithelial cells and neovascular endothelial cells (145). PSMA has been selected as 
an attractive target for both imaging and therapeutic intervention of prostate cancer (146).  
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 Figure 2.14 In vivo fluorescence images of tumor-bearing mice using QD probes with three different 
surface modifications: carboxylic acid groups (left), PEG groups (middle) and PEG-PSMA Ab conjugates 
(right). For each surface modification, a color image (top), two fluorescence spectra from QD and animal skin 
(middle) and a spectrally resolved image (bottom) were obtained from the live mouse models bearing C4-2 
human prostate tumors of similar sizes (0.5–1.0 cm in diameter). The amounts of injected QDs and the 
lengths of circulation were: 6 nmol and 6 h for the COOH probe; 6 nmol and 24 h for the PEG probe; and 0.4 
nmol and 2 h for the PSMA probe. The site of QD injection was observed as a red spot on the mouse tail. The 
spectral feature at 700 nm (red curve, middle panel) was an artifact caused by mathematical fitting of the 
original QD spectrum, which has little or no effect on background removal. 
 
 
 Figure 2.14 (147) compares the in vivo imaging results from three types of surface 
modifications: COOH groups, PEG groups and PEG plus PSMA Ab. In agreement with 
histological examinations, no tumor signals were detected with the COOH probe, only 
weak tumor signals were observed with the PEG probe (passive targeting) and intense 
signals were detected in the PEGPSMA Ab conjugated probe (active targeting). This 
comparison provides further evidence for the conclusion that active tumor targeting by 
using a tumor-specific ligand is much faster and more efficient than passive targeting 
based on tumor permeation, uptake and retention. 
 
 
2.4.2.c Activatable fluorochromes 
 
A different means to impart molecular specificity into optical contrast agents is to 
design activatable probes (148), appropriately engineered fluorochromes that, in the non-
activated state, are loaded in closed proximity onto a graft copolymer consisting of a poly-
lysine (PL) backbone through appropriate peptides and undergo mutual energy transfer; 
thus, they exist in a quenched state. At the presence of the targeted enzyme, cleavage of 
the peptide link releases the fluorochromes (dequenching) which results in a bright 
fluorescence signal, up to several hundredfold increase, which can be detected in vivo 
(Figure 2.15) (1).  
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  Multiple enzymes, especially proteases5, are involved in a whole variety of 
pathologies ranging from carcinogenesis to immune diseases (149). In 1999 an 
autoquenched fluorescent probe was developed, which is converted from a non-
fluorescence to fluorescence state by proteolytic activation (148). The first generation of 
this type of molecular contrast agent consisted of a long circulating macromolecular 
carrier molecule (poly-lysine backbone) shielded by multiple methoxy-polythylene-glycol 
sidechains (PLL-MPEG). Multiple cyanine dyes (Cy 5.5; excitation maximum: 675 nm; 
emission maximum: 694 nm) are loaded onto this carrier molecule resulting in a 
fluorescence signal quench due to fluorescence resonance energy transfer (FRET) among 
the fluorochromes (overlapping excitation and emission spectra) (148). This first 
generation of protease-sensing optical probes is activated by lysosomal cystein or serin 
proteases such as cathepsin-B (148). By linking the fluorochromes via a peptide spacer to 
the carrier molecule (second-generation probe) the probe selectivity can be tailored to 
other enzymes such as matrix-metalloproteinase- 2, cathepsin-D, or thrombin (148-154). 
 
 
 
Figure 2.15 Example of an activatable optical contrast agent. The contrast agent is built on a backbone 
and consists of a linker that can be cleaved by a specific enzyme of interest and a fluorophore and quencher 
molecule that are on either side of the linker and in close proximity with one another. When the linker is 
intact (a), and the fluorophore is excited by an external laser, the energy is efficiently transferred to the 
quencher molecule and very little is emitted as light. If the contrast agent molecule encounters the enzyme of 
interest (b) and that enzyme cleaves the linker (c), the quenching molecule moves away from the fluorophore 
and now the excitation of the fluorophore leads to the emission of light. The signal is therefore switched on 
by the presence of the specific enzyme. 
 
  
 Cathepsin B is a lysosomal cysteine protease involved in cellular protein turnover 
and degradation (155, 156). It is overexpressed in many tumors as well as overexpressed 
by host cells associated with tumors. It has been implicated in tumor progression: both 
metastases formation (157,158) and in vitro growth (159-161) decrease in the presence of 
cathepsin B inhibitors. Several studies (162-165) have demonstrated that high levels of 
cathepsin B expression correlate with aggressive tumor behavior. High levels of cathepsin 
B expression also correlate inversely with patient survival (164-167). Given cathepsin B’s 
close relationship with early cancers and metastasis with resultant host response, the first 
optical probes constructed for targeting protease activity were specific for cathepsin B 
                                            
5 Proteases: enzymes that catalyze the proteins hydrolysis. 
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(168-169). Figure 2.16 shows how a breast cancer implanted in a nude mouse is revealed 
with cathepsin B imaging (163). The time for imaging after probe administration may be as 
short as 2 h, depending upon the location of the enzyme being imaged (170); optimal 
timing after injection depends as well upon the disease imaged (171, 172). Image 
acquisition times on newer systems are in the subsecond time frame, allowing real-time 
visualization of fluorescent anatomical detail. The bright fluorescence, as this example 
shows, helps locate this micrometastasis-sized tumor, based upon its cathepsin B activity.  
 
 
 
 Figure 2.16 Aggressiveness of breast cancer revealed with cathepsin B imaging. An aggressive (left) 
and well-differentiated (right) breast tumor implanted in a nude mouse have different fluorescent signal 
intensities correlating with their invasive and metastatic potential (from Ref. 25).  
 
 A probe specific for cathepsin D has also been synthesized and tested in mouse 
models (56-57). The main function of cathepsin D is in protein catabolism; however, a 2–
50-fold increase in enzyme levels has been reported in breast cancers (173-174), and 
overexpression has been associated with higher metastatic potential (175). Imaging of 
cathepsin D was analogous to cathepsin B imaging in Figure 2.17. However, these studies 
additionally demonstrated that it was possible to selectively image tumors based on a 
difference of a single gene expression. 
 
 
 
 
 Figure 2.17 Representative optical images of the lower abdomen of a nude mouse 
implanted with a CaD1 (red arrow) and CaD2 (blue arrow) tumor. a, white light image 24 h after i.v. 
injection of the reporter probe. b, identical imaging set-up as in a, except that NIRF fluorescence is 
shown at 700 nm. Note that the CaD1 tumor emits fluorescence, whereas the CaD2 tumor has a 
significantly lower signal. The dotted green line represents the line for the density slice profile shown 
at the bottom. c, superimposed images from a and b, with CaD information shown as a 
thresholded false color map. 
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Imaging MMP-2 and Its Inhibition 
 MMPs (176) similar to the cathepsins detailed above, are proteases overexpressed in 
many cancers. The level of MMP expression has been shown to be related to tumor stage 
(177) and metastasis (178). Among the subtypes, MMP-2 (gelatinase) has been identified as 
one of the key MMPs. Numerous clinical studies show a clear correlation between MMP-2 
expression and poor outcome of disease (179-182). A number of MMP inhibitors, some of 
which advanced to Phase III clinical trials, have been developed (183-185). A characteristic 
example of this technology applied to elucidate different expression levels of tumor MMP-
2 activity is shown in Figure 2.18 using an MMP-2-positive human HT1080 fibrosarcoma 
and an MMP-2-negative BT20 mammary adenocarcinoma (153).  
 
 
 
 Figure 2.18 . NIRF imaging of a nude mouse implanted with both an MMP-2–positive human 
HT1080 fibrosarcoma and an MMP-2–negative BT20 mammary adenocarcinoma. Top: Both tumors 
measured approximately 2 3 3 mm. Bottom: Raw NIRF image shows that the fibrosarcoma generated strong 
fluorescent signal intensity 2 hours after intravenous injection of the MMP-2–sensitive probe, but the signal 
intensity of the BT20 tumor was only slightly higher compared with the background fluorescence of the skin. 
Quantitative analysis revealed a significant difference between the fluorescent signal intensity in BT20 tumor 
and that in HT1080 tumor. 
 
 Given its importance in tumor pathology, a MMP-2-selective probe was 
constructed. Imaging of MMP-2 activity was demonstrated, starting 2 h after probe 
administration (171, 153). Most importantly, a series of experiments showed in parallel 
cohorts of mice that fluorescent signal intensity after MMP-2 probe administration 
significantly decreased in tumors from animals that were pretreated with a MMP-2 
inhibitor compared with controls. Thus, essentially realtime protease inhibition may be 
imaged noninvasively, instead of waiting several months to evaluate anatomical response, 
as is traditionally done in individual patients, as well as in in vivo animal trials of inhibitor 
therapy. Such imaging has implications for faster, more accurate titration of inhibitor 
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dosing in human drug trials, as well as potentially routine care in the future for individual 
patients. 
2.4.2.d Fluorescent protein 
 
Green fluorescent proteins are native to a few marine organisms, but can be 
introduced into the cells of other organisms by gene transfer. These transferred GFPs act 
as a chemical fluorescent contrast agent for protein activity inside the cell 186. Unlike NIR 
fluorescent imaging, GFP imaging does not use exogenous fluorochromes. The original 
GFP was cloned from the bioluminescent Aequorea victoria jelly fish6 187, and had an 
absorption and excitation wavelengths in the green part of the spectrum from 489 to 508 
nm, respectively. FP expression is based on emission of visible photons at specific 
wavelengths based on energy-dependent reactions catalyzed by luciferases, whose gene 
have been cloned from a large number of organisms, including bacteria, firefly (Photinus 
pyralis), coral (Renilla), jellyfish (Aequorea), and dinoflagellates (Gonyaulax). Sensitive 
imaging systems have been built to detect quantitatively a small number of cells or 
organisms expressing luciferase as a transgene (188). 
 Fluorescent proteins offer another possibility for extracting molecular information 
in small animals but have a less defined role in clinical applications. A drawback of GFP is 
its low emission wavelength (510 nm), which overlaps with the autofluorescence of 
many tissues. This is one of the reasons that mutants of GFP with redshifted emission have 
been engineered. A new red fluorescent protein (DsRed) that emits fluorescence at 583 nm 
has been isolated from tropical Discosoma corals (189).Another red fluorescent protein that 
is potentially even more suitable for in vivo imaging is HcRed, generated by site-directed 
and random mutagenesis of a nonfluorescent chromoprotein isolated from the reef coral 
Heteractis crispa, which emits light at 618 nm (190,191). Unlike bioluminescent proteins 
(discussed below), fluorescent proteins do not require cofactors or chemical staining 
before in vivo imaging. The ability to quantify fluorescence accurately and repeatedly will 
be essential in different biological applications. Currently one of the main imaging 
applications of fluorescent proteins is in monitoring tumor growth (192,193) (Figure 2.19) 
and metastasis formation (194,195) (Figure 2.20) as  well as occasionally gene expression 
(196) (Figure 2.21). Fluorescent proteins have also been used as reporters to image gene 
promoter activity (197). Because hemoglobin is an efficient light absorber, GFP-expressing 
tumors have been used to image angiogenesis, as vessels are contrasted against fluorescent 
tumor background (198) (Figure 2.22). 
 
                                            
6 The green fluorescent protein is found in the jellyfish, Aequora Victoria, that contains a bioluminescent 
protein -aequorin- that emits blue light. The green fluorescent protein converts this light to green light, 
which is what we actually see when the jellyfish lights up.  
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Figure 2.19 Whole-body image of orthotopically growing HCT 116-RFP human colon cancer in GFP nude 
mouse. Image was acquired in a fluorescence light box with a CCD camera 10 weeks after orthotopic 
implantation ofHCT116-RFP cells.  
 
 Figure2.20 External images of B16F0-GFP colonizing the liver. Ametastatic lesion of B16F0-GFP in 
the liver growing at a depth of 0.8 mm after portal vein injection was externally imaged through the 
abdominal wall of the intact nude mouse. (A) An external image of multilobe liver metastases of the B16F0-
GFP cells (large arrows). (B) An external image of small liver metastatic lesions of approximately 1.5 mm in 
diameter (small arrows) and other larger metastatic lesions (large arrows).  
 
 Figure 2.21 External whole-body image of vAd-GFP gene expression in the brain. An external image 
of vAd-GFP gene expression in the brain acquired from a nude mouse in the light box 24 h after gene 
delivery. Clear image of transgene expression in the brain can be visualized through the scalp and skull.  
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 Figure 2.22 : Time course of whole-body fluorescence imaging of MDA-MB-435-GFP human breast 
cancer angiogenesis in orthotopic primary tumor. The GFP expressing human tumor was transplanted by 
SOI in the fat pad of nude mice and whole-body imaged. (A) Week 1. (B) Week 4. (C) Week 8. (D) Week 20. 
(E) Quantitative graph of microvessel density as a function of time. 
2.4.2.e Bioluminescence 
 
Bioluminescence imaging is used to detect the photons that emanate from cells that 
have been genetically engineered to express luciferases. Luciferases comprise a family of 
photoproteins, isolated from a variety of species, which modify their substrate, called 
luciferin, causing the release of a photon. Firefly luciferin (a benzothiazole) and P. pyralis 
luciferase are the most commonly used substrate-enzyme pairs for in vivo imaging (199-
202) because of their high wavelength and quantum yield. In the firefly, luciferasi utilizes 
energy from ATP to convert its substrate luciferina to oxyluciferin, with the emission of a 
detectable photon. The names ‘luciferin’ and ‘luciferase’ are generic terms for the active 
agents (substrate and enzyme, respectively) in bioluminescent organisms. Numerous 
examples of bioluminescence exist in nature, most notably the flashes of light emitted by 
the male firefly (Photinus pyralis). Other examples include light emission by various marine 
organisms such as sponges, corals, jellyfish, clams and a few types of fish. More recently, 
imaging using Renilla reniformis luciferin and coelenterazine in mice has also been reported 
(203). Firefly luciferin normally produces light at 562 nm, although a number of 
genetically engineered luciferases from the firefly have been created, resulting in spectral 
shifts of released light photons. Luciferase can be transgenically expressed in mammalian 
cells, and when exposed to substrate, releases photons that can be detected and quantified 
using lowlight photon-counting cameras. Using sensitive filters, these mutants can be used 
to track more than one protein, similar to what has been done with blue- and red-shifted 
GFP.  
Bioluminescence imaging has emerged as a useful and complementary 
experimental imaging technique for small animals.  Because of its simplicity and ease of 
generating luc/lux cells, its primary uses have been for tracking tumor cells, stem cells, 
immune cells and bacteria as well as for imaging gene expression. In contrast to 
fluorescence techniques, there is no inherent background with bioluminescence, which 
makes this technique highly sensitive. The main limitation has been that the method 
currently does not allow absolute quantification of target signal. Rather, its primary uses 
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are either in binary mode (yes/no luc expression) or as an imaging tool to follow the same 
animal under identical conditions, including positioning. The imaging signal also depends 
on ATP, O2, depth and the presence of excess substrate, which is administered 
exogenously. Typical doses of luciferin are in large excess (120 mg/kg i.p.) and are injected 
immediately before data acquisition with photon-counting cameras. Image acquisition 
times are on the order of minutes, depending on expression levels, depth and photon flux. 
One of the principal uses of luciferase imaging has been to track cells, in particular 
dividing cells such as tumor cells (199,204), progenitor and stem cells (Figure 2.23), 
immune  cells (205) and bacterial cells (206). Thus, for example, luc-expressing stem cells 
can be seen crossing the cerebral hemispheres in a tumor model (Figure 2.23a), and 
peritoneal proliferation of ovarian cancers can be monitored over time (Figure 2.23b). 
Estimates from subcutaneous implantations indicate that between 103 and 104 luc cells can 
be detected at this location. Another important application has been to use luc as a 
transgene in experimental gene transfer studies (207-209), as a screening tool for rapid 
identification of transgenic founder mice (210) or to visualize activation of specific 
pathways in cancer formation (211). Most recently, engineered luciferases have been used 
to image specific cellular processes. In one study, the estrogen receptor domain was fused 
through a caspase-3-cleavable site to both ends of luciferase to image apoptosis in vivo (B. 
Ross, personal communication). In experimental studies, bioluminescence has been used 
to image protein–protein interactions (212) and NF-κB degradation (213). It is likely that 
the imaging applications of luciferase will continue to expand rapidly with the use of 
engineered luciferases, activatable luciferins and bioluminescence resonance energy 
transfer (BRET) strategies.  
 
 
 
 
 Figure 2.23 Bioluminescence imaging. Two examples of imaging with bioluminescence. a, Migration 
of luc-labeled neural progenitor cells (C17.2, obtained from E. Snyder) across the brain midline attracted by a 
contralaterally implanted glioma. b, Luc-labeled OVCAR-8 ovarian cancer cells implanted into the peritoneal 
cavity at different densities. Note that there is a faint focus of signal even with 5 103 implanted cells.  
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2.4.3 Advantages and drawbacks 
 
Encouraging results have already been obtained for use of optical techniques for in 
situ monitoring of tissue parameters, discrimination of diseased tissue from normal, 
mammography, and several therapeutic applications. Despite advances in medical 
imaging technologies over the past two decades, we are currently still limited in our 
ability to detect tumors or other diseases in their earliest stage of formation, phenotype 
tumors during complex cycles of growth, invasion and metastases, to use imaging 
techniques to speed up drug testing, and to use imaging as an objective endpoint for 
tailoring therapies in a given individual.  
Reflectance imaging is an ideal tool for high-throughput imaging and screening of 
surface fluorescent events in vivo or in excised tissues. It offers simplicity of operation and 
high sensitivity for molecular events that are close to the surface. Typical acquisition times 
range from a few seconds to a few minutes. For laboratory settings, multiple animals can 
be simultaneously imaged. Hardware development and implementation is also 
straightforward and relatively inexpensive. Reflectance systems do not use ionizing 
radiation, employ safe laser powers, can be made portable and attain small space 
requirements to be ideal for the laboratory bench.  These features can allow easy 
laboratory and bench-top use and enable monitoring of molecular events repeatedly and 
over time. The combination of molecular beacons and optical imaging technologies is 
expected to play a fundamental role in biomedicine in the next decade and continued 
developments in probe design and imaging technologies will undoubtedly further expand 
current capabilities. 
On the other hand, reflectance imaging has fundamental limitations both as a research 
or clinical tool. Firstly, the technique attains only small penetration depths (a few 
millimeters). This is because the appearance of deeper lesions is significantly blurred and 
the signal detected from them is significantly attenuated as a function of lesion depth 
while the background noise remains constant in reflectance mode since it consists of 
fluorescence signals from superficial layers and intrinsic light contaminating the 
fluorescence measurement due to imperfect filtering. This is in contrast to tomographic 
methods where both signal and noise reduces so that signal to noise remains significant 
for lesions that are much deeper than a few millimeters. Secondly, reflectance imaging is 
not capable of quantification: a small structure of high fluorochrome concentration that is 
deeper into tissue could yield the same appearance on the surface as a larger structure of 
low fluorochrome concentration that is closer to the surface. This is due to the nature of 
propagation of diffuse photon density waves into tissue. The photon count reading at a 
surface of an animal due to a lesion on or under the surface depends on the lesion depth, 
the lesion volume and the optical properties of both the lesion and the surrounding tissue; 
therefore, images from different animals, or from the same animal at different time points, 
are generally insufficient for yielding quantitative insights. Further, one of the major rate-
limiting steps is the development of well designed and carefully validated contrast agents 
that are selective for major molecular pathways implicated in disease. Attracting talented 
chemists and creating appropriate training programs to increase the pool of available 
chemists that are interested in developing imaging agents should also be a priority. 
Finally, notwithstanding the tremendous promise of these techniques, the translation of 
molecular imaging methodology into the clinic, and its role in the diagnosis and staging of 
disease, and the monitoring of therapy, is yet to be defined and demonstrated. There is a 
 E
rr
o
re
. 
Lo
 s
ti
le
 n
o
n
 è
 d
e
fi
n
it
o
. 
need to improve imaging performance, either increasing spatial or temporal resolution, 
sensitivity, or commonly both. The ability to accurately quantify molecular imaging 
studies is of great importance when these tools are used to track disease and the effects of 
interventions. There also has been little characterization of the quantitative accuracy or 
reproducibility of imaging methods, nor a careful statistical analysis of to what degree 
longitudinal molecular imaging studies provide an advantage over generally more 
accurate, but usually much more invasive, methods and techniques. In all these areas, and 
many more, there are opportunities for biomedical physicists to make significant and 
important contributions which will help build the solid foundation required for the future 
anticipated growth of molecular imaging science. 
 
 
2.5 Conclusions 
The fluorescence is the third fundamental phenomenon, after absorption and scattering, 
that interests the interaction light-biological tissue. Hence, it is naturally born a family of 
fluorescence imaging techniques, FRI, different relatively to the fluorescence labelling 
strategy, but about identical relatively to the experimental implementation. The FRI 
technique, as well as optical, is non invasive and the fluorescent marker are generally not 
toxic. The experimental apparatus is simple, inexpensive, generally compact and easy to 
use. Set the experimental apparatus, it is possible study different biological target 
exploiting the most adapt strategy labelling: tumor diagnosis can be performed by a non 
specific fluorophore, as cyanine or porphyrin, while molecular pathway studies use 
fluorophores of high specificity, targeted or “smart”, or fluorescent protein expressed by 
only the cells transfetted with the FP gene. The FRI technique allows for monitoring in 
vivo tumor growth, detection of metastasis formation and dissemination, gene expression, 
apoptosis, angiogenesis, inflammatory diseases. However, the analysis in vivo is limited to 
penetration depth of few centimetres in the range spectral of NIR, so that the applicability 
to clinic of FRI techniques is a challenge. The absence of quantitative determinations is 
another important limit. So the FRI principal applications are the studies in vivo on small 
animals, that represent today a research field rich and very important because of the 
possibility of study in mice human diseases and transfer these knowledges to humans.  
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Chapter 3 
HP-FRI in vivo on small animals: preliminary 
measurements 
 
3.1 Introduction 
In this chapter and in the successive it will be showed the way of our experimental work 
to obtain the final aim: detection of subcutaneous solid in early stage tumors in vivo on 
small animals through HP mediated FRI. Hence, the biological target is the early detection: 
it is crucial, indeed, in the tumor diagnostic to be able to detect the tumor formation, since 
earlier diagnosis greater the patient survival probability, especially if the tumor is highly 
invasive.  
Before we reach this research stage, it is been necessary to carry out a preliminary work 
studying the HP water solution fluorescence spectrum at different concentration; 
evaluating the more efficient HP injection modality in mouse by FRI and 
spectrofluorimetric measurements; verifying the resistance of HP compound to 
photobleaching; estimating the HP accumulation in different tissue types both tumor and 
healthy by spectrofluorimetric measurements on histological sections of mice tissue.  
Then, in a first part of the work, the in vivo FRI measurements were performed 
combining the in vivo fluorescence image of the tumor region on the mouse with a 
fluorescence image of a healthy region on the same mouse to perform a digital subtraction 
of the last image from the first. This simple operation, reducing the autofluorescence and 
the HP background fluorescence contribute, enhances the contrast of the tumor region. It 
was so possible to reveal an increased fluorescence emission in tumor region with respect 
to healthy region with different tumor types and to correlate this feature to the tumor 
malignancy degree.   
Furthermore, we present the results obtained by imaging in vivo mice surface solid 
tumor bearing with simultaneous acquisitions in two modalities: our HP-FRI and a 
radionuclide imaging based on a semiconductor pixel detector of the Medipix family at 
high spatial resolution. With this combined system we investigated the detectability of 
two different types of tumor, having different malignancy degree.  
In a second part of the work it is been employed a new CCD camera with high 
sensitivity and low noise that, combining with the HP features, allows for a new imaging 
modality and more advanced results, as just early tumor detection. This last part is 
deferred to the next chapter.   
 
3.2 Experimental set-up.  
3.2.1 HP-FRI measurements 
In the preliminary and first part of the work the experimental apparatus (Figure 3.1) for 
FRI measurements was composed by: 
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• Excitation source, a frequency doubled mode-locked active-passive Nd:YAG 
laser (λ = 532 nm, beam diameter = 7 mm, energy/pulse = 30 mJ, pulse 
width = 50 ps, repetition rate = 10 Hz); 
• Optics for the collection of the excitation radiation on the sample (neutral 
filter, reducing the excitation intensity to avoid that intensity too high 
reaches the CCD camera in the excitation image registration, collimation 
lens, matching the excitation beam section to the tumour area, and mirror, 
reflecting the laser beam onto the mouse; 
• sample, a tumor bearing or healthy anesthetized mouse; 
• emission filter, a cut-on long wave pass filter (Andover 600FH90-25, cut-on 
wavelength: 600 nm). This filter allows HP fluorescence radiation (whose 
spectrum extends beyond 600 nm) to be recorded and backscattered 
radiation at 532 nm to be rejected. 
• an analogue CCD camera (Hamamatsu C3077-71S, 560x575 pixels, sensitivity 
= 0.3 lux) equipped with a Computar objective of 16 mm focal length;  
• image acquisition (average of 32 single frame consecutive acquisitions) and 
analysis board, Hamamatsu Lepas 11 system (10 bit ADC).  
 
During the FRI measurements, the whole apparatus was closed by dark panels to 
avoid the penetration of spurious light in the CCD camera. 
 
 
 
 
Figure 3.1 View of the experimental setup used in the preliminary measurements and in the first part of the 
FRI measurements. From left to right: (a) the laser head; (b) the neutral filter; (c) the collimation lens; (d) the 
mirror; (e) the CCD camera with cut-on filter. Also drawn is the optical ray path from the source to the 
camera, when the animal is placed on the table top.  
 
Moreover, was used also a spectrofluorometer (Perkin Elmer LS50) computer 
controlled to obtain fluorescence spectra of histological sections of mice tissues. 
We observe explicitly that, although the main absorption band of HP compound is 
localized in the UV region, at about 405 nm (Figure 3.2), nevertheless we prefer exploit a 
secondary absorption band centred at about 530 nm exciting it with the Nd:YAG second 
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harmonic light at 532 nm, since, as explained in the Chapter 1, the penetration depth is 
higher and the autofluorescence emission is lower at higher excitation (and fluorescence 
emission) wavelength.  
 
 
 
Figure 3.2 A typical Hp compound absorption and fluorescence emission spectra. The maximum 
absorption band is centered at about 405 nm, while a secondary absorption band is at about 530 nm. The 
typical fluorescence peaks at 620 nm and 680 nm are also showed.  
 
The analog CCD camera operates at 25 frames per second with internal trigger and is 
inactive only for 10 µs (blanking time) per frame. Then, the CCD image acquisition is not 
triggered by the trigger signal available at each laser shot, and some camera frames may 
correspond to a no-irradiation period and are not useful for analysis. Anyway, given the 
laser repetition frequency and the rapid fluorescence decay of the fluorophore (10–20 ns 
half-life), we consider that by grabbing 32 consecutive camera frames the number of useful 
frames included is always the same. Then, the final image is the accumulation of those 32 
single frame consecutive acquisitions. 
In the Appendix at the end of this chapter is presented a brief overview of the features of 
the CCD camera, because of the key role played by this instrument in FRI measurements. 
 
 
3.2.2 FRI/Gamma combined imaging 
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Figure 3.3 Schematic view of the experimental combined (fluorescence, radionuclide) imaging 
system. 
 
 
The experimental setup for combined fluorescence and radionuclide imaging is 
shown in Figure 3.3. The radionuclide imaging set-up, combined with our FRI set up 
described in the previous paragraph, uses as gamma radiation detector two hybrid 
detectors based on the Medipix2 read-out circuit (214), which features 256x256 pixels with 
55-µm pitch, for a total sensitive area of 14x14 mm2. The Medipix2 chip is interfaced 
serially (215) to a PC, running the Medisoft 4 software (216). One hybrid detector is 
obtained by bump-bonding Medipix2 to a 300-µm thick silicon pixel detector, the second 
one by bump-bonding Medipix2 to a 1-mm thick CdTe pixel detector (217). The silicon 
detector was reverse biased at 80 V, the CdTe detector was biased at 100 V. At 140 keV, the 
silicon detector has only about 1% quantum efficiency, while the 1-mm CdTe detector has 
quantum efficiency greater than 30%. For gamma-ray imaging, we have used 90 knife-
edge pinhole collimators made of pure tungsten with 0.78-mm diameter (7-mm thick) or 
1.0-mm diameter (4-mm thick), respectively.  
 
3.3 Materials and methods.  
In the next paragraphs we describe the steps that have preceded the FRI measurements 
in vivo. 
 
a. HP solutions fluorescence spectroscopy 
 
The HP solution for fluorescence tumor labeling in mice in vivo was obtained by 
dissolving 4.448 mg of powder of hematoporphyrin dichlorohydrate (Vit-porphyrin II, 
Teofarma, Italy), corresponding to 4 mg HP, in 2 ml distilled water. HP dichlorohydrate 
water solutions emission fluorescence spectra at higher dilution with respect to the 
solution injected in mice (1:2, 1:4, 1:8, 1:16, 1:32) were measured with spectrofluorometer. 
In these measurements the excitation wavelength was 532 nm, the scanning velocity 120 
nm/min and the spectral resolution 5 nm. The wavelength scanning range is 550–800 nm 
and the scan step is 0.5 nm. Moreover, we also checked the stability of the spectra of the 
solutions, repeating the spectroscopic measurements on HP water solutions 24 h after they 
have been kept at room temperature. Finally, in order to check the HP photobleaching 
resistance, we exposed to the same laser light dose administered to mice during the 
fluorescence measurements Petri dishes containing the HP solutions at different 
concentrations and we recorded the emission spectra of the solutions before and after 
irradiation. 
 
 
 
b. HP injection modality in mice  
 
In all the measurements in vivo we used six-week-old Crl:CD-1 athymic nude mice 
(Charles River Laboratories, Calco, Italy) of about 20 g of body weight. These studies were 
conducted in accordance with the Italian regulation for experimentation on animals. All in 
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vivo experiments were carried out with ethical committee approval and met the standards 
required by the United Kingdom Co-ordinating Committee on Cancer Research 
(UKCCCR) guidelines (available at www.ctu.mrc.ac.uk). No mice showed signs of wasting 
or other signs of toxicity. 
Healthy mice were injected subcutaneously (sc) (two mice), or  intraperitoneally (ip) 
(two mice), or intramuscularly (im) (one mouse), with 200 µl of the above solution, 
corresponding to a dose of approximately 7 mg HP/kg mouse body weight. A not injected 
mouse was used as a control. Fluorescence measurements on healthy sc and ip injected 
mice were performed, respectively, 3, 6, and 24 h after HP administration and after 3 h 
only for im injected mice. Ten minutes before the measurements the mice were 
anesthetized by the injection of 100-110 µl of a solution of chloral hydrate 10 mg/ml in 
NaC1 0.9%. 
 
 
c. HP-FRI in vivo  
 
In the first HP-FRI measurement, the tumor cells are the ARO tumor cell line, 
derived from anaplastic human thyroid carcinoma cells. This is a tumor poorly 
differentiated and, therefore, with high degree of malignancy. Tumor in mouse was 
obtained by injecting 5x106 ARO cells in the mouse back and the fluorescence 
measurements were performed 6 and 24 h after HP administration. Mouse was injected in 
a leg muscle with HP solution at the same dose as the healthy ones (7 mg HP/kg mouse 
body weight). This mouse will be called mouse #0. 
In the successive FRI-HP measurements, tumor cells are derived by two human 
thyroid tumors with different degree of malignancy. Besides the ARO cell line, was 
considered also the NPA tumor cell line, derived from papillary human thyroid carcinoma 
cells. The ARO cells are much more malignant with respect to the NPA cells. Cells were 
cultured in DMEM culture medium supplemented with 10% fetal calf serum, penicillin (50 
U/ml) and streptomycin (50 µg/ml).  
ARO or NPA cells (~3.5x106 cells/mouse) were inoculated into the right dorsal 
portion or paw of mice. Measurements on tumor bearing mice are performed 
approximately ten days after cell inoculation, when the tumor mass achieved the volume 
of about 50 mm3 (NPA tumors) and 400 mm3 (ARO tumors) and 6 h after HP 
administration.  
We have imaged 10 ARO tumor bearing mice and 9 NPA tumor bearing mice. 
These mice will be called numbering them from 1 to 10 for those ARO tumor bearing and 
from 1 to 9 for those NPA tumor bearing. 
Furthermore, an ARO tumor histological section (mouse #9) was imaged by FRI to 
analyze the HP spatial distribution in all the points of the tumor region and in the region 
surrounding the tumor. 
In our HP-FRI measurement protocol the following sequence of optical images was 
acquired: 
• image of laser beam 2-D profile at 532 nm (with neutral filter on the laser way); 
• black and white (b/w) image of the mouse acquired under white light illumination 
and without emission filter; 
• fluorescence image of the mouse. 
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The average image of the 2-D laser beam profile was integrated to supply a 
reference value to take into account possible intensity fluctuations of the laser beam in 
different sets of measurements. The average fluorescence image was divided by the mean 
beam intensity during each set of measurements. 
 
 
d. Fluorescence spectroscopy 
At the end of the fluorescence imaging measurements, some healthy and tumor 
bearing mice were sacrificed and tissue biopsies were taken and kept at low temperature 
(20 0C) to study their fluorescence spectra. The examined samples were: 
• frozen skin samples for control and im injected healthy mouse; 
• frozen skin samples for sc and ip injected healthy mouse; 
• frozen histological sections (thickness 30 µm) of mouse muscle for control and im 
injected healthy mouse; 
• frozen samples of ARO tumor and healthy tissues of the tumor bearing mouse #0; 
• histological sections from the healthy muscle and tumor tissues of three of the ten 
ARO-bearing and three of the nine NPA-bearing mice, sacrificed immediately after 
the fluorescence imaging measurements. 
In these measurements the excitation wavelength was 532 nm, the scanning velocity 120 
nm/min and the spectral resolution 5 nm. The wavelength scanning range is 550–850 nm 
and the scan step is 0.5 nm. Measurements of frozen tissue samples were performed so 
quickly that they did remain frozen. After measurements the frozen samples were added 
with one or two drops of a solution of PBS and glycerol (1 : 10) and then saved at 4 0C. The 
stability of the spectra following sample fixation with formalin and saving at 4 0C was also 
investigated. Since the addition of glycerol may change significantly their optical 
properties, these samples were not anymore used for spectroscopic measurements. 
 
e. Combined imaging 
 
The mice imaged with combined system were an ARO tumor bearing mouse and a 
NPA tumor bearing mouse. Once anaesthetized (like explained in paragraph 3.3 c), the 
mice were put horizontally in the imaging field (Figure 3.3). The fluorescence image 
provides a top view of the HP injected 6 h before concentration in the subcutaneous tumor 
area, and the bottom view taken with the hybrid pixel detector gives the scintigraphic 
image of the tumor area using 99mTc MIBI injected (74 MBq) about 2 h beforehand. 
  To obtain a control measurement for radionuclide emission, immediately after the 
combined imaging the mice were imaged by a commercial gamma camera. Finally, tissue 
autoradiography was performed on fresh tumor tissue histological sections. 
 
3.4 Results and their discussion  
a. Preliminary tests  
Figure 3.4 shows fluorescence spectra of water solution of HP for different concentration 
values. These spectra exhibit the well known emission peaks around 610 and at 680 nm. 
Both peaks decrease in intensity with increasing HP concentration, the peak at 610 nm 
decreasing more rapidly than that one at 680 nm, so that they have the same height at a 
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dilution ratio 1 : 8. The HP concentration dependence leading to the disappearance of the 
peak at 610 nm can be ascribed to the aggregation state of the HP molecules, which 
strongly affects both their fluorescence quantum yield and lifetime (218). We recall that the 
HP compounds shows also a secondary absorption band centered at about 630 nm (Figure 
3.2), that at least partially reabsorb the fluorescence emission of the peak at 610 nm, 
especially in the tissue, where the emission peaks are shifted toward longer wavelengths 
(Figure 3.7).    
 
 
 
Figure 3.4. Fluorescence spectra of water solution of HP for different values of dilution. The starting 
solution is that one we injected in mice (HP concentration  = 0.7 mg/ml). 
 
These spectra do not change both upon long lasting exposure to light at 532 nm or 
after sample keeping at room temperature: the HP chemical stability is high and 
photobleaching is negligible.  
 
 
 
Figure 3.5 For each treatment condition (A-F) the anesthetized mouse, contained in the metal holder, 
is imaged optically (left column images) and correspondingly via its fluorescence emission (right column 
images, showing the iso-intensity contour plot and the mouse silhouette). A: untreated (control) mouse; B: 
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HP injected subcutaneously, fluorescence image taken at 24 h after injection; C: HP injected 
intraperitoneally, fluorescence image after 6 h; D: HP injected intraperitoneally, fluorescence image after 24 
h; E: HP injected in the left leg muscle, fluorescence image after 3 h, laser beam hitting the mouse in a region 
that includes the injection site; F: as in (E), but in this case the laser beam hits the mouse in a region that does 
not include the injection site. The grayscale indicates fluorescence intensity (CCD pixel value) in arbitrary 
units. 
 
Figure 3.5 shows the optical (left) and corresponding fluorescence (right) images of 
the tests performed on a healthy control mouse and on healthy mice injected with the HP 
fluorophore with different modalities. These tests were performed in order to determine 
good experimental conditions as for type and site of injection and imaging exposure. The 
comparison of b/w images, those taken at 532 nm and fluorescence images, allows the 
basic check that excitation light impinges really on the region under investigation and that 
it spatially corresponds to fluorescence emission images. Fluorescence levels in the images 
obtained with the filter with wavelength cut-on at 600 nm are higher than the same images 
obtained with a filter with the cut-on at 650 nm. This is in agreement with the 
spectroscopic measurements on water HP solutions which show the presence of an 
emission peak located between 600 and 650 nm. Therefore, we decided to consider the 
images obtained with the filter with the lower cut-on wavelength. The comparison (Figure 
3.5) of fluorescence images of the injected mice (normalized to the mean intensity of the 
laser beam during the measurement) with the control one (Figure 3.5A) shows that the 
increase of fluorescence due to HP administration is detectable 24 h after sc injection, 6 h 
after ip injection and 3 h only after im injection. In this last case the fluorescence is diffused 
in a body region well outside the injection site. Therefore, since these measurements 
showed that the im administration gives a higher and quicker HP uptake in tumors with 
respect to the sc and ip injection, all the successive HP injections in mice were of this type.   
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Figure 3.6 Gray level contour plots of the tumor fluorescence (second row) and of the difference 
between healthy tissue and the tumor fluorescence (third row) superimposed to the mouse silhouette, 6 h 
(left column) and 24 h (right column) after HP administration, respectively. Note that the tumor contrast in 
the difference image is enhanced with respect to the fluorescence image. The tumor (<10 mm diameter) is 
visible on the mouse leg in the images in the first row. The grayscale on the bottom fourth row indicates 
fluorescence intensity levels expressed in arbitrary units. 
 
Figure 3.6 shows (from the top to the bottom row):  
• b/w image of the tumor bearing mouse; 
• fluorescence image of the tumor, where the area of the laser beam, i. e. of the region 
irradiated by excitation laser light, is slightly greater than the tumor region; 
• difference image obtained subtracting the fluorescence area of a healthy region 
fluorescence image of the same mouse by the fluorescence area imaged in the 
previous item. 
The left and right column images in Figure 3.6 refer to measurements performed 6 h 
and 24 h after HP administration, respectively. The contrast between the tumor region and 
the neighboring healthy tissue is noteworthy increased in the image obtained as the 
difference of the fluorescence image of a healthy and the tumor region of the same mouse. 
In fact, by defining the contrast in terms of minimum, Imin, and maximum, Imax, intensity 
levels as the ratio Imax/Imin, we found that the raw fluorescence image contrast is of the 
order of 2, while for the digitally subtracted image is approximately 90. 
We used a very simple approach, in which background digital subtraction is 
performed between optically filtered fluorescence image of tumor region and filtered 
fluorescence image of a healthy region of the same laboratory animal, taken in the same 
conditions. The use of the fluorescence of a healthy region of the mouse as a background 
fluorescence is based on our spectral measurements on the explanted tumor, reported 
below (see Figure 3.7 e), showing that its emission can be interpreted as a superposition of 
a strong tumor-associated fluorescence (peaked at approximately 700 nm) and a faint 
background fluorescence. The first one can be ascribed to the strong HP uptake by the 
tumor, the second one to the endogenous fluorescence and, possibly, to the low HP 
concentration fluorescence by healthy tissues. This is in agreement with the finding of 
Profio et al. (219) for an human carcinoma in situ. A reliable evaluation of this last 
fluorescence can be obtained by measuring the fluorescence of a healthy region of the 
mouse far enough away from the tumor region. By measuring the fluorescence of different 
healthy regions of the same mouse, we found relative fluctuations of the average 
fluorescence intensity in the order of few percent, as it can be expected if we consider that 
the laser beam impinges on a large fraction of the mouse surface. 
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Figure 3.7: Fluorescence spectra of frozen sample of a) muscle control mouse and im injected mouse 
histological section; b) skin control mouse and im injected mouse tissue; c) skin control mouse and sc injected 
mouse tissue; d) skin control mouse and ip injected mouse tissue; e) mice healthy/tumor tissue.  
 
From the spectroscopic measurements of the various tissue samples it was found 
the following results: 
• Fixation with formalin and sample keeping at 4 0C significantly affect their spectra. 
freezing could change indeed the optical properties of tissues, depending on the 
type of biological sample. Prahl (220) states that the evidence for changes of the 
optical properties of tissues exists for muscle tissue, while aorta and dermis seem 
e) 
a) b) 
c) 
d) 
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not susceptible to freezing artifacts. This last statement seems to be confirmed by a 
similar finding for optical properties of porcine skin dermis at IR wavelengths (221). 
In some cases, the freezing is a beneficial technique: at liquid nitrogen temperature, 
fluorescence spectroscopy of rapidly-freezed trapped tissue blocks was shown to 
recognize pathological human cervical tissues (222). In any case the freezing is 
necessary to obtain very thin sections and to perform, without a severe damage of 
the sample, spectroscopic measurement with a standard spectrofluorimeter. 
• The fluorescence peaks are shifted toward longer wavelengths, being located at 635 
nm and 710 nm for ip injected mouse skin (Figure 3.7d) and for tumor tissue (Figure 
3.7e). The other spectra (Figures 3.7a, b, c) show a weak correlation with the 
emission spectrum illustrated in Figure 3.4. In addition, the peak at 710 nm has, in 
any case, height and width greater than that at 600 nm. The preferential attenuation 
of light to shorter wavelengths could explain these differences. 
• Three h after HP inoculation, the muscle tissue of im injected mouse shows (Figure 
3.7a) a fluorescence slightly higher than the control in the 700 nm band, while the 
skin sample shows an intensity decrease in this same band (Figure 3.7b). This 
finding could be due to the wavelength-dependent differences in absorption of the 
fluorescence, or to the change of the optical properties of the samples produced by 
the freezing. 
• The fluorescence peak at 700 nm of the skin tissue (measured 24 h after HP 
inoculation), with respect to the control, is lower for sc injected mouse and higher 
for ip injected mouse (Figure 3.7 c and d, respectively). We remark that the 
differences of fluorescence intensity could also be due to a different thickness of the 
sample. Fluorescence spectra of tissue samples of the tumor bearing mouse 24 h 
after HP administration clearly show that the fluorescence of tumor tissue increases 
by a factor up to approximately 100 with respect to healthy tissue in the wavelength 
band at longer wavelengths (Figure 3.7 e).  
 
b. HP_FRI in vivo 
 
 
   
 
Figure 3.8: Images of an ARO tumor bearing mouse: left side: white light image; right side: 
fluorescence image after digital background subtraction, superimposed to the mouse silhouette. The grey 
scale of the fluorescence isointensity regions is also reported. 
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Figure 3.9: Image of an NPA tumor bearing mouse: left side, white light image, right side, 
fluorescence image after digital background subtraction, superimposed to the mouse silhouette. The grey 
scale of the fluorescence isointensity regions is also reported. 
 
                                 
 
Figure 3.10: Left side: fluorescence spectra of histological sections of an ARO tumor tissue (solid line) 
and a healthy muscle tissue (dashed line) for the mouse imaged in Fig. 2. Both fluorescence spectra are the 
mean of the fluorescence spectra of several histological sections of the same tissue. Right side: difference 
between the fluorescence spectrum of sections of ARO tumor and healthy tissue in comparison with the 
fluorescence of HP water solution diluted 1:8. 
 
 
                           
 
Figure 3.11: Left side: fluorescence spectra of histological sections of an NPA tumor tissue (solid line) 
and a healthy muscle tissue (dashed line) for the mouse imaged in Fig. 3. Both fluorescence spectra are the 
mean of the fluorescence spectra of several histological sections of the same tissue. Right side: difference 
between the fluorescence spectrum of sections of NPA tumor and healthy tissue in comparison with the 
fluorescence of HP water solution diluted 1:16. 
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Figure 3.12: Fluorescence image of a histological section of ARO tumor tissue. On the right side the 
grey scale of fluorescence isointensity regions is reported. The fluorescence emission is higher in the skin 
tissue near the tumor and in those regions that appear non necrotic from the histological analysis. 
 
 
The HP-FRI images, after the digital background subtraction, superimposed on the 
mouse silhouette of the ARO tumor bearing mouse #2 and NPA tumor bearing mouse #2, 
reported in right side of Figures 3.8 and 3.9 respectively, show that a fluorescence intensity 
enhancement is present in the region where the tumor is visually recognizable, according 
to the preferential accumulation of the HP fluorescent marker in the tumor region with 
respect to the healthy region. In the fluorescence images, the fluorescence emission of 
ARO tumors, more malignant with respect to NPA tumors appears higher than the 
fluorescence emitted by NPA tumor. This observation is confirmed by the quantitative 
analysis performed on the fluorescence images by means of the fluorescence emissivity 
ratio, a parameter used to characterize the fluorescence properties of the two different 
types of investigated tumors. It was calculated by integrating the fluorescence image 
(normalized to the laser beam intensity, but not background subtracted) and by dividing it 
by the area of the irradiated region of the mouse, which coincides with very good 
approximation with the tumor area. The ratios between these emissivity values for unit 
area for the tumor region and those for a healthy region of a same mouse were calculated 
for each analyzed mouse. It was found that the value of this parameter for the ARO tumor 
tissue is generally greater than that for the NPA tumor tissue, the mean value of the 
fluorescence emissivity ratio for ARO tumor being about two times that for the NPA 
tumor (Table 1). This seems to indicate that higher fluorescence emissivity is associated to 
higher malignancy degree.  
 
 
Table 1 Fluorescence emissivity ratio values for the examined NPA and ARO tumors. The 
corresponding mean values and standard deviations (SD) are listed in the last two columns. 
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In Figure 3.10 the fluorescence spectrum of histological sections of tumor tissue is 
compared with that of the healthy tissue for the ARO tumor imaged in Figure 3.8 (left 
side). In the right side of the same figure, the difference between the fluorescence spectra 
of histological sections of tumor and healthy tissue is compared with the fluorescence 
spectrum of HP water solution at a suitable dilution factor. Figure 3.11 shows the same 
quantities in Figure 3.10 for the NPA tumor imaged in Figure 3.9. The right side spectra in 
Figures 3.10 and 3.11 show also a red shift of the HP spectrum in cells with respect to the 
spectrum obtained for HP water solution. 
The spectroscopic results confirm those of the HP-FRI. In fact, in the wavelength 
region 550 - 800 nm, that is the spectral band contributing to the fluorescence imaging, the 
spectral intensity of the tumor tissue, both ARO and NPA, is higher than that of the 
healthy tissue (left side plot of Figures 3.10 and 3.11). The difference in the fluorescence 
emission we have found for the two types of tumors can be explained in terms of different 
HP uptake by tumors. The plots in the right side of Figures 3.10 and 3.11 show that the 
difference between the fluorescence spectrum of sections of tumor and healthy tissue, i.e. 
the net emission of HP accumulated in the tumor, is consistent with the spectrum of water 
solution of HP at the dilution factor 1:8 for the ARO tumor and 1:16 for the NPA tumor. 
A series of findings can be found in the literature according to this result. Gupta et 
al.(223) found that the oral squamous carcinoma cells accumulated significantly higher 
amounts of HpD (a mixture of ether and esther linked porphyrins, that in a partially 
purified form takes the commercial name of Photofrin II) than glioma cells. They conclude 
that this difference could be imputed to the variations of the frequency and affinity of 
HpD binding sites as well as the aggregation and ionic states of intracellular HpD. 
Similarly it was found that Photofrin II uptake is slightly higher for leukaemic T cell 
lymphoblast Jurkat cells than for breast adenocarcinoma MCF 7 cells (224). This result is 
explained by a different membrane composition and LDL receptor presentation. HpD 
level in glioma was correlated to the grade of evolution and malignancy of the tumor, 
highest levels of photosensitizers being present in glioblastoma, lower levels in 
intermediate-grade anaplastic astrocytoma and low-grade astrocytoma (225). This last 
result agree qualitatively with our finding that poorly differentiated highly malignant 
ARO cells show a greater HP uptake than highly differentiated less malignant NPA cells. 
In the above referenced paper (224) it is also reported a red-shift of the fluorescence 
spectra of Photofrin II in both tumor cell lines with respect to the spectrum of the same 
compound dissolved in PBS (hydrophilic) solution. From the observation that a red shift 
of 20 nm is obtained when the photosensitizer is dissolved in PBS solution and in 
lipophilic environment (PC liposome) the authors argue that this spectral change of 
Photofrin II is due to its incorporation in cell membrane. 
Finally, Figure 3.12 shows the fluorescence image of the histological section of an ARO 
tumor (mouse # 9): clearly the fluorescence is higher in the skin around the tumor and in 
the region where tumor cells are viable, while it is very low in the tumor regions 
appearing necrotic from the histological analysis. This suggests that the HP retention is 
concentrated in the peritumor region and it is absent in the necrotic region. 
 
c. Combined imaging 
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In the following, we present two combined images (white light, isointensity 
fluorescence contour plot superimposed on the mouse silhouette, commercial pinhole 
gamma camera, hybrid pixel detector Medipix2) generated after different test sessions. 
The comparison of the images taken in the different modalities is presently carried out 
offline and visually using an image processing software, by rotating, mirroring and scaling 
the images in order to have a rough visual match of the structures. 
Figure 3.13 shows the combined images of the NPA tumor-bearing mouse. The 
gamma detector is the Medipix2 Si pixel hybrid detector. The acquisition time for the 
optical system was less than half minute and 25 minutes with the radionuclide imaging 
system with a total 80000 counts. The resolution in gamma-ray imaging is about 2 mm 
(with a 0.78-mm pinhole diameter) and the FOV is 16x35 mm2. The system spatial 
resolution was calculated by summing in quadrature the intrinsic detector resolution (as 
twice the detector pixel pitch) and the knife-edge pinhole geometric resolution due to its 
140-keV effective diameter, taking into account the system magnification M=0:4. The 
fluorescence emissivity ratio is about 2. The quality of the inefficient silicon detector is 
very poor due to its low count statistics (a bare 3200 cpm). We show it mainly for 
comparison with the following CdTe detector image and to indicate the progress in the 
development of our project. However, this figure indicates that the NPA tumor was 
clearly observed only in the fluorescence image, since the area of accumulated counts 
showed in the Medipix2 image was found to correspond to the injection site, after the 
comparison with the image from the gamma camera. 
 
 
 
Figure 3.13 Combined images of an NPA tumor-bearing mouse. In this case, the tumor (circled area) 
is visible only in the fluorescence image, while the gamma camera and Medipix2 systems show an 
accumulation of counts only in a region corresponding to the radionuclide injection site. The Medipix2 
 E
rr
o
re
. 
Lo
 s
ti
le
 n
o
n
 è
 d
e
fi
n
it
o
. 
silicon detector image has a FOV = 16 x 35 mm2 and contains 80 000 counts in total (25 min acquisition time). 
The pinhole magnification in this Medipix2 image is M = 0:4. Injected activity = 74 MBq( 99mTc). 
 
 
 
  
Figure 3.14 Images of an ARO tumor-bearing mouse. a) Optical. b) Fluorescence. c) Clinical pinhole 
gamma camera. d) Medipix2 CdTe pixel detector (1-mm pinhole) (5 min acquisition time, low-pass filtered 
image). e) Count profile along the line indicated in d). The surface tumor area (7–8 mm in diameter) is 
circled. The arrow indicates the injection site. The count rate of the gamma camera image is 200 000 cpm. The 
Medipix2 image (pinhole magnification = 0:45) has an area of 256x322 pixels (about 32x40mm2), a count rate 
of 40 000 cpm and it has been obtained by the composition of two partially overlapped images; the white bar 
corresponds to 4 mm. Injected activity = 74 MBq( Tc). The images have been matched visually. In the 
fluorescence and radionuclide images the circle delineates the area of maximum signal intensity. 
 
Figure 3.14 shows the combined images of the ARO tumor-bearing mouse. The 
gamma detector is now the Medipix2 CdTe pixel hybrid detector. With the radionuclide 
imaging system the acquisition time is 5 minutes with a total of 200000 counts, the spatial 
resolution, calculated as above, is about 3 mm (with a 1 mm pinhole diameter, 
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magnification M=0:45), the FOV= 32mm2. The short acquisition time permitted by the 
CdTe hybrid pixel detector has made possible a longitudinal scan of the mouse body in 
steps of 10 mm (adjacent images have a field of view (FOV) partially overlapping). With 
the composition of two such images, we have thus obtained a rectangular FOV of 32 x 40 
mm2. The line profile across the tumor area shows an increased activity (by a factor of 
roughly 3:1 in the tumor area with respect to the background). We notice that in our 
experimental conditions, the CdTe based system produced 9 cps/MBq as against 0.7 
cps/MBq for the Si based system (i.e., just a factor 12 higher, as against a factor greater 
than 30 in the quantum efficiencies of our CdTe and Si detectors), while the mouse 
imaging with the scintillator based clinical gamma camera was performed with 45 
cps/MBq. We also notice that, from the analysis of tissue autoradiographies (data not 
shown), both the ARO and NPA tissue sections appear radioactive in the tumor area. 
Different imaging modalities may supply different information for in vivo imaging, 
that could determine improvements on oncological investigations (226) and tumor 
diagnosis. For example, in Figure 3.13 (NPA-type tumor) the tumor area was detected only 
by the fluorescence technique (although with a low fluorescence signal), while the gamma 
camera and the Medipx2 hybrid pixel detector were unable to detect it. This different 
behavior could be ascribed to different mechanism of accumulation of 99mTc-MIBI and HP 
in tumor cells. HP is reported to enter in vivo cells following its binding with serum 
lipoproteins and albumin, to diffuse in the cytoplasm and to localize in mitochondria 
(227). 99mTc -MIBI diffuse across cell membrane via passive diffusion and is largely 
sequestered in mitochondria (228). Washout of 99mTc -MIBI is related to transmembrane 
transporter proteins whose concentration in different cell types determines the tracer 
uptake (229-231). 
However 99mTc -MIBI uptake was found strongly dependent on the viability of the thyroid 
tissue (232). To the purpose of assembling a compact gamma-ray imaging system with 
semiconductor detectors, the Medipix2 system offers some advantages. Though its 
sensitive area is just 2 cm2, the use of a pinhole collimator in demagnification allows 
reaching a FOV useful for imaging the entire tumor area, while exploiting the high 
intrinsic spatial resolution of this hybrid pixel detector. 
Previous studies (233,234) using a Medipix1 silicon detector had already revealed the 
feasibility of designing a compact gamma camera with such hybrid pixel detectors, with 
high intrinsic spatial resolution. As for its sensitivity, the 1-mm thick CdTe detector with a 
1-mm pinhole collimator produced 9 cps/MBq; a thicker and more efficient CdTe detector 
(e.g., 2 mm or higher) is expected to improve the detection efficiency and hence the system 
sensitivity.  
 
3.5 Conclusions 
 
From the preliminary and first HP-FRI measurements we wish outline that: 
a) The fluorescence spectra of water solution of HP for different concentration values 
exhibit the well known emission peaks around 610 nm and at 680 nm.  
b) The fluorescence spectra of water solution of HP don’t change in the range of time 
durations, temperatures and light doses typical of our experiments. 
c) The optimal injection site is the muscle, the ip and sc injection leading to a lower 
fluorescence emission in the tumor tissue. 
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d) The optimal delay between the time of the HP injection and the FRI measurements 
is between 6 and 24 h. 
e) The well known selective uptake by tumors of HP compound is confirmed also for 
our HP dichlorohydrate by the FRI in vivo measurements.  
f) The results of HP-FRI imaging in vivo in mice are consistent with spectroscopic 
results on samples excised by tumor and healthy tissues of the mice and by 
fluorescence imaging of histological sections of tumor tissues.  
g) In the case studied of mice bearing two different types of tumors, by the combined 
imaging in vivo we were able to discriminate the different uptake of the 
gamma/fluorescent marker in the tumor (235).  
The detection of HP mediated fluorescence is characterized from the use of a non 
specific fluorochrome and it could not be classified as a quantitative technique for tumor 
imaging, since it is very difficult to control the number of parameters determining the 
cellular fluorescence response (236-238). This type of compounds has been largely studied 
in the past years because of their tumor selective uptake, which has been exploited 
especially for photodynamic purposes. In the photodynamic therapy (PDT) the interest for 
porphyrin compounds is increased in the years producing a large number a new 
photosensitizes, the so called “second generation porphyrins”, in the attempt of 
decreasing the photosensibilitation effects and allowing for a better therapeutic effect. 
Although the PDT is the main application of the porphyrin compounds, they have been 
applied also in the photodiagnosis (6). Nevertheless, the HP-FRI techniques has many 
advantages: short measurement times, high spatial resolution, large field of view, wide 
applicability to a large variety of surface tumors. It is able to reveal tumor in vivo through 
the increased optical contrast of the tumor region with respect to the surrounding healthy 
tissue and also to distinguish tumor of different malignancy degree being higher the 
fluorescence emissivity higher is the malignancy degree of the tumor. We limited our 
attention to surface tumors of macroscopic dimension (<2 cm), that are relatively simple to 
be revealed with FRI.  
 
3.6 Appendix: an overview on CCD technology(239) 
 
CCD detectors are made of silicon crystals sliced into thin sheets for fabrication into 
integrated circuits using similar technologies to those used in making computer silicon 
chips. One of the properties of silicon-based detectors is their high sensitivity to light. 
Figure A.1 (240) represents a schematic illustration of a CCD chip. Electrical potential 
wells, known as picture elements (pixels) are created, during manufacture, as a 
rectangular array on the surface of the silicon. When the CCD image sensor is exposed to 
photons (light), which are able to penetrate into the silicon layer, the energy breaks the 
bonds that bind the 
electrons to the silicon lattice, releasing an electron per photon of light absorbed. Applied 
voltages create electrical potentials on the pixels preventing transfer of charge between 
adjacent wells. The charge can then be transferred to adjacent pixels by altering their 
relative potentials. In this way, a charge pattern, corresponding to the intensity of 
incoming photons, is read out of the CCD into an output register and amplifier at the edge 
of the CCD for digitization. This process of converting incoming photons to electrons and 
capturing them in discreet wells is extremely linear, meaning that as the exposure time on 
 E
rr
o
re
. 
Lo
 s
ti
le
 n
o
n
 è
 d
e
fi
n
it
o
. 
a sample is increased, the output signal increases in exact proportion until the well is full 
and saturation has occurred. This feature is extremely useful for quantification in 
fluorescence imaging. The digitized image can then be transferred via a dedicated data 
link to a fast PC for storage and subsequent analysis.  
In summary, there are many different types of CCD chip available whose features are 
suited for particular applications. Some of the features that define the differences between 
CCD types, such as pixel size, chip geometry, quantum efficiency and readout rate have 
been briefly discussed in this Appendix.  
 
 
Figure A.1.  Schematic cross-section of a CCD. 
 
 
Scientific Camera Types 
Scientific Digital cameras come in 4 primary types based on the sensor technology 
they use. The principal forms of high performance digital camera include: 
• The popular Charge-Coupled Device (CCD) Camera 
• The Electron Multiplying Charge Coupled Device (EMCCD) Camera 
• The Complementary-Metal-Oxide-Semiconductor (CMOS) detector camera 
• The Image Intensified CCD Camera (ICCD) 
In the first three detectors, a silicon diode photosensor (pixel) is coupled to a charge 
storage region that is, in turn, connected to an amplifier that reads out the quantity of 
accumulated charge. Incident photons generate electronic charges, which are stored in the 
charge storage region. If the incident photons have sufficient energy and they are absorbed 
in the depletion region, they liberate an electron which can be detected as a charge. Then, 
the transmission and absorption properties of the silicon define the spectral response of 
the detector and this is explained further as QE in a later section. 
In a CCD, there is typically only one amplifier at the corner of the entire array and 
the stored charge is sequentially transferred through the parallel registers to a linear serial 
register, then to an output node adjacent to the read-out amplifier (Figure A.2). CCD 
sensors were first developed in the late 60’s and the technology is relatively mature now. 
CCD performance has pushed the boundaries in the efficiency of light detection and in 
reducing the noise from either dark signal or amplifier readout. One weakness of a CCD is 
the fact that the CCD is essentially a serial readout device and low noise performance is 
only achieved at the expense of slow readout speeds. CMOS cameras can achieve high 
frame rates with moderate sensitivity. 
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Figure A.2 Typical CCD structure 
 
 
 
Figure A.3 CMOS structure 
 
In CMOS detectors, each photosensor or, more typically, each column of 
photosensors has an amplifier associated with it (Figure A.3). A row of pixels can be 
readout in parallel with the row selected by an addressing register or an individual pixel 
can be selected by column multiplexer. A CMOS device is essentially a parallel readout 
device and therefore can achieve higher readout speeds particularly required by imaging 
applications. CMOS detector technology however still needs considerable development to 
compete against CCD for performance in scientific applications. To achieve the parallel 
readout the CMOS amplifier uses multiple amplifiers, each with its own gain, linearity 
and noise performance variation. Compensating for the variations in the current state of 
the art CMOS devices is difficult over a wide range of illumination levels and to the 
accuracy required by scientific applications. High speed readout with high sensitivity can 
be achieved by EMCCD cameras.  
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Figure A.4 EMCCD structure 
 
The EMCCD has essentially the same structure as a CCD with the addition of a very 
important feature (Figure A.4). The stored charge is transferred through the parallel 
registers to a linear register as before but now prior to being readout at the output node 
the charge is shifted through an additional register, the multiplication register in which 
the charge is amplified. A signal can therefore be amplified above the readout noise of the 
amplifier and hence an EMCCD can have a higher sensitivity than a CCD. EMCCDS use 
similar structures to CCD’s and are similarly restrained in the minimum exposure time 
they can achieve.  
 
 
Figure A.5 ICCD structure 
 
Intensified CCD Cameras can achieve ultra short exposure times. In the Image 
Intensifier a photosensitive surface (Photocathode) captures incident photons and 
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generates electronic charges that are sensed and amplified (Figure A.5). The photocathode 
is similar in nature to the photosensitive region of a Photomultiplier tubes (PMTs) that are 
widely used in confocal microscopes and spectrometers. When photons fall on a 
photocathode they utilize the energy of the incident photons to release electrons. The 
liberated electrons are then accelerated toward an electron multiplier composed of a series 
of angled tubes known as the Micro-Channel Plate. Under the accelerating potential of a 
high voltage, the incident electrons gain sufficient energy to knock off additional electrons 
and hence amplify the original signal. This signal can then be detected in several ways, 
either by direct detection using a CCD (also called an EBCCD Electron Bombardment 
Charge Coupled Device) or indirectly by using a phosphor and CCD. The ICCD can 
achieve short exposure times by using a pulsed gate voltage between the photocathode 
and MCP. By applying a small positive voltage, electrons liberated by the photocathode 
can be suppressed and hence not detected. By switching the voltage to a negative voltage, 
electrons from the photocathode are accelerated across the gap to the MCP where they can 
be amplified and detected. By applying a suitable short voltage pulse the intensifier can 
therefore be effectively turned on and off in sub nanosecond intervals.  
ICCD cameras find uses in applications where short exposure times or gating is 
required such as LIBs or combustion research.  
CCD cameras are the camera of choice for most scientific applications which require 
sensitivity or dynamic range. The sheer range of CCD sensor options offers the prospect to 
select a sensor of the best overall characteristics for applications ranging from astronomy 
to spectroscopy. CCD technology is relatively mature while CMOS technology still needs 
major development to compete with CCD’s in scientific applications. 
An EMCCD camera works best in applications when a high sensitivity needs to be 
coupled with high speed such as fluorescent microscopy or ultra fast spectroscopy. 
EMCCD is relatively new technology and there is still a relatively limited range of sensor 
formats currently available. In coming years these sensors are expected to get faster with 
increasing numbers of formats becoming available. 
Hybrid sensors which combine CCD and CMOS technologies can potentially 
deliver performance superior to either CCD or CMOS bulk detectors. They look the better 
long term option but there is still a considerable amount of development required before 
they can be commercially viable. In particular to overcome the issues associated with 
compensating for the variation of the multiple amplifiers. Many of the principals that 
apply to CCD’s also apply to other camera formats. In the following section we will cover 
the characteristics of the CCD and then cover in more detail EMCCD’s and ICCD’s in later 
sections and highlight how their characteristics differ. 
 
 
CCD Sensor Formats 
The most common scientific camera, the Charge Coupled Device camera (CCD), 
comes with three fundamental architectures and these are Full Frame, Frame Transfer and 
Interline format.  
 
 E
rr
o
re
. 
Lo
 s
ti
le
 n
o
n
 è
 d
e
fi
n
it
o
. 
 
Figure A.6 Typical full-frame CCD sensor format 
 
The full frame CCD is the simplest form of sensor in which incoming photons fall 
on the full light sensitive sensor array (Figure A.6). To readout the sensor the accumulated 
charge must then be shifted vertically row by row into the serial output register and for 
each row the readout register must be shifted horizontally to readout each individual 
pixel. This is known as "Progressive Scan" readout. A disadvantage of full frame is charge 
smearing caused by light falling on the sensor whilst accumulated charge signal is being 
transferred to the readout register. To avoid this, devices sometimes utilize a mechanical 
shutter to cover the sensor during the readout process. However, mechanical shutters 
have lifetime issues and are relatively slow. Shutters are not needed however in 
spectrographic operations or when a pulsed light source is used. Full frame CCD’s are 
typically the most sensitive CCD’s available and can work efficiently in many different 
illumination situations.  
 
 
Figure A. 7 Typical frame-transfer CCD sensor format 
 E
rr
o
re
. 
Lo
 s
ti
le
 n
o
n
 è
 d
e
fi
n
it
o
. 
 
The frame-transfer CCD uses a two-part sensor in which one half of the parallel 
array is used as a storage region and is protected from light by a light-tight mask Figure 
A.7). Incoming photons are allowed to fall on the uncovered portion of the array and the 
accumulated charge is then rapidly shifted (in the order of milliseconds) into the masked 
storage region for charge transfer to the serial output register. While the signal is being 
integrated on the light-sensitive portion of the sensor, the stored charge is read out. Frame 
transfer devices have typically faster frame rates than full frames devices and have the 
advantage of a high duty cycle i.e. the sensor is always collecting light. A disadvantage of 
this architecture is the charge smearing during the transfer from the light-sensitive to the 
masked regions of the CCD, although they are significantly better than full frame devices. 
The frame transfer CCD has the sensitivity of the full frame device but are typically more 
expensive due to the larger sensor size needed to accommodate the frame storage region.  
 
 
Figure A.8 Typical interline transfer CCD sensor format 
 
The interline-transfer CCD incorporates charge transfer channels called Interline 
Masks (see Figure A.8). These are immediately adjacent to each photodiode so that the 
accumulated charge can be rapidly shifted into the channels after image acquisition has 
been completed. The very rapid image acquisition virtually eliminates image smear. 
Altering the voltages at the photodiode so that the generated charges are injected into the 
substrate, rather than shifted to the transfer channels, can electronically shutter interline-
transfer CCDs. Interline devices have the disadvantage that the interline mask effectively 
reduces the light sensitive area of the sensor. This can be partially compensated by the use 
of microlens arrays to increase the photodiode fill factor. The compensation usually works 
best for parallel light illumination but for some applications which need wide angle 
illumination (small F/# number) the sensitivity is significantly compromised. 
 
 
Spectral Response 
The spectral response of a camera refers to the detected signal response as a 
function of the wavelength of light. This parameter is often expressed in terms of the 
Quantum Efficiency (QE), a measure of the detector's ability to produce an electronic 
charge as a percentage of the total number of incident photons that are detected. 
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The spectral response (or QE) of the CCD is governed by the ability of the photons to be 
absorbed in the depletion region of the detector. It is only in the depletion region that 
photons are converted into electronic charges and subsequently can be held by the electric 
fields which form the pixel. The charge held in the depletion region is then transferred and 
measured. To highlight the spectral response effects lets examine the cross section of a 
typical CCD detector shown in Figure A.9. 
 
 
Figure A.9 CCD cross section showing depletion region 
 
Photons falling on the CCD must first transverse the region dominated by the gate 
electrodes by which the applied clocking voltages create the electric fields that form the 
boundary of the depletion region and shift charge through the CCD. The gate structures 
can absorb or reflect all wavelengths to some extent and as a result reduce the spectral 
response below the theoretical maximum of 1 electron charge generated per one photon 
(in the case of visible light). The shorter wavelengths (blue light) are particularly absorbing 
and below ~350nm they absorb all the photons before they can be detected in the depleted 
region. Photons with longer wavelengths (i.e. red photons) have a low probability of 
absorption by the silicon and can pass through the depletion region without being 
detected and hence reduce the red sensitivity of the device. Photons with wavelengths 
greater than 1.1µm do not have enough energy to create a free electron charge and so they 
cannot be detected with Silicon CCD's. The various absorption effects combine to define 
the spectral sensitivity of the CCD. The spectral sensitivity is typically expressed as a QE 
Curve, in which the probability to detect a photon of a particular wavelength is expressed 
as a percentage. So for example if one in every 10 photons is detected this is expressed as a 
QE of 10%.  
The losses due to the gate electrode structure can be completely eliminated in the 
Back-Illuminated CCD. In this design, light falls onto the back of the CCD in a region 
where the bulk of the silicon has been thinned by etching until it is transparent (a 
thickness corresponding to about 10-15 microns). Back-thinning results in a delicate, 
relatively expensive sensor that has only been employed in high-end scientificgrade CCD 
cameras.  
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Camera Sensitivity & Noise 
The sensitivity of a camera is typically expressed in either the number of photons or 
in a measure of photon flux which can be related to human observations, called the lux. A 
lux is a measure of illumination which has a value of 1 lumen per square meter. The lumen 
is a photometric equivalent of a Watt which is weighted to match the eye response of the 
"standard observer". 
The sensitivity of the human eye varies at different wavelengths and this has an 
implication of the number of photons equivalent to a given photometric quantity. The 
conversion to photons in the table above assumes the light is monochromatic yellowish 
green light with a wavelength of 555nm which is at the peak of the sensitivity of the 
human eye. For a given minimum sensitivity in lumens the number of photons varies 
(Figure A.10 ).  
 
 
Figure A.10 
 
If a given light signal induces a signal on the camera below the readout noise of the 
camera, it cannot be detected so the total noise of the camera is a useful way to define the 
sensitivity of the camera. 
The noise measured by a digital camera comes from a number of sources which will 
be covered in detail in a later section. Here we will concentrate predominately on the three 
main sources and they are: 
• Sensor readout noise 
• Thermal noise 
• The noise from the signal itself: photon noise 
The total camera noise is the sum in quadrature calculated as: 
 
∂total=√(∂signal2+∂dark2+∂readout2) 
 
The readout noise is an inherent property of the sensor and is usually the limit on 
sensitivity for most cameras. The readout noise is a combination of noise sources, which 
originate from the process of amplifying and converting the photoelectrons created into a 
voltage. Over the years readout noise has improved but fundamentally the faster the 
readout of the camera, the higher the noise due to the increasing bandwidth required. Low 
noise CCD’s in the past have typically employed very low readout speeds and hence they 
are often known as Slow Scan CCD's.  
The second source of noise is the dark noise that arises from thermally generated 
charges in the silicon sensor. Recent improvements in CCD design have greatly 
diminished dark noise to negligible levels and reduced their contribution to total read-out 
noise to less than 10 electrons per pixel at room temperatures. For the ultimate sensitivity 
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cooling the CCD to temperatures ~-100°C is still required. Some room temperature 
cameras may have such a low dark signal that it can be ignored for integration periods of a 
second or less. Cooling further reduces the dark signal and permits much longer 
integration periods, up to several hours, without significant dark charge accumulation. 
The noise arising from the dark charge is given by Poisson statistics as the square root of 
the charge arising form the thermal effects, i.e.: 
 
∂dark=√Ndark 
 
The incoming photons have an inherent noise ∂signal known as photon Shot noise. 
If we consider the effects of a number of photons P which would generate in a pixel with 
QE DQE a signal of Ne electrons, they will have a noise as defined by Poisson statistics 
shown here:  
 
∂signal=√ DQEP 
 
 
Dynamic Range 
The dynamic range of a CCD is typically defined as the full-well capacity divided 
by the camera noise and relates to the ability of a camera to record simultaneously very 
low light signals alongside bright signals. The ratio is often expressed in decibels which is 
calculated as 20log (full well capacity/read noise) or in the equivalent number of A/D 
units required to digitize the signal. 
The full well capacity is the largest charge a pixel can hold before saturation which 
results in degradation of the signal. When the charge in a pixel exceeds the saturation 
level, the charge starts to fill adjacent pixels a process known as blooming (see below). The 
camera also starts to deviate from a linear response and hence compromises the 
quantitative performance of the camera. Larger pixels have lower spatial resolution but 
their greater well capacity offers higher dynamic range which can be important for some 
applications.  
 
Blooming & Anti-blooming 
Blooming occurs when the charge in a pixel exceeds the saturation level and the 
charge starts to fill adjacent pixels. Typically CCD sensors are designed to allow easy 
vertical shifting of the charge but potential barriers are created to reduce flow into 
horizontal pixels. Hence the excess charge will preferentially flow into the nearest vertical 
neighbours. Blooming therefore produces a characteristic vertical streak, e.g. see Figure 
A.11. 
 
 
Figure A. 11 
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Blooming can be a nuisance when a strong signal can obscure data from a weak 
signal of interest especially on an image with a high dynamic range. Some sensors are 
designed with structures built into them which limit blooming, anti-blooming structures. 
Anti-blooming structures bleed off any excess charge before they can overflow the pixel 
and thereby stop blooming. Anti-blooming structures can reduce the effective quantum 
efficiency and introduce non linearity into the sensor. Therefore anti-blooming sensors are 
not recommended for applications requiring very low light or high accuracy 
measurements. As an alternative to using anti-blooming sensors an image can be acquired 
using accumulation mode. Accumulation mode allows successive scans of shorter 
exposures to be summed to achieve effectively an exposure which is longer by the number 
of accumulations acquired. If each of the accumulations has light just below the saturation 
point to be summed the dynamic range of the accumulated signal is also increased by the 
number of accumulations. 
 
Smear 
When a interline-transfer-CCD image sensor is readout the generated charge 
carriers are transferred from the light sensitive part (photodiode) of a pixel to the shift 
register. This is located next to the photodiodes and acts like a potential bucket. As there is 
weak light sensitivity on these shift registers, they are shaded to prevent the additional 
generation of charge carriers. When the charge transfer to the shift register is complete, 
they are vertically shifted, row-by-row, to the horizontal readout line, which is then read 
out serially. This row-by-row vertical shifting is comparable to an endless conveyor belt. 
With every shift step, all registers are shifted by one register location, including those 
register rows that were previously drained from the image. 
If an intense light source is imaged onto the CCD image sensor, this can generate 
unwanted charge carriers in the shielded shift registers (mainly due to the scattering of 
light on the CCD chip) in every line or row that is shifted below the spot. This results in 
additional unwanted light signals called “smear” (Figure A.12 ).   
 
 
Figure A.12 
 
 Smear can be recognized as bright vertical bands below and/or above the bright 
image spot (interline or frame transfer architecture). Smear is dependent on the high 
intensity, therefore short exposure time, high intensity, more smear, while long exposure 
time, low intensity, less smear. Depends also on the image sensor read out time or speed, 
so slow readout, more time for smear, while fast readout, less time for smear  
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Signal/Noise Ratio 
A related measurement to sensitivity and noise is the signal to noise ratio. It is 
defined as the ratio of the light signal to the sum of noise signals and it is expressed as a 
ratio or factor in units of decibels [dB]: ratio[dB] = 20 log[ratio].  Let’s consider the 
theoretical prediction of signal to noise for a typical camera. If we assume we have a 
number of photons P falling on a camera pixel with a Quantum Efficiency DQE this will 
generate a signal of Ne electrons as below: 
 
Ne= DQEP 
 
The incoming photons have an inherent noise ∂signal known as photon shot noise 
and, as the photons follow Poisson statistics, this is the given below: 
 
∂signal=√ DQEP 
 
The other noise sources are: ∂readout is the readout noise, ∂dark is the noise resulting 
from thermally generated electrons (so called dark signal), and ∂signal is the noise generated 
by the photon signal. Putting these terms together we can then generate an expression for 
the signal to noise ratio for a typical camera. 
 
S/N= DQEP/√(∂signal2+∂dark2+∂readout2) 
 
Substituting for the expressions for noise we can see the equation for signal to noise 
is as follows: 
 
S/N= DQEP/√( DQEP +Ndark+∂readout2) 
 
The thermal noise component Ndark is a function of temperature and exposure time 
and in the limit where the exposure time is very short and the CCD is cooled to a low 
temperature this term is negligible.  
It can be seen by manipulation of the equation that the signal to noise ratio 
approaches that of an ideal detector in the situation when light signal is high so that the 
shot noise is predominant with respect to readout noise and dark noise: 
 
DQEP ≥ ∂readout2+ Ndark 
 
which can be rearranged thus: 
 
P ≥ (∂readout2+ Ndark )/DQE 
 
Expressing the photon number impinging on CCD as 
 
P= Φ t A/hν 
 
where  Φ is the light power [W/m2], hν the photon energy [Ws], t the time exposure [s] 
and A the pixel area [m2], we see that to achieve a good SNR high QE, large pixel area, 
small readout and dark noise are all desirable. 
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Spatial Resolution 
The resolution of a CCD is a function of the number of pixels and their size relative 
to the projected image. CCD arrays of over 1,000 x 1,000 sensors (1 Mega-pixel) are now 
commonplace in scientific-grade cameras. The trend in cameras is for the sensor size to 
decrease, and cameras with pixels as small as 4 x 4 microns are currently available in the 
consumer market. Before we consider the most appropriate pixel size of a particular 
application, it is important to consider the relative size of projected image to the pixel size 
to obtain a satisfactory reproduction of the image. 
Consider a projected image of a circular object that has a diameter smaller than a 
pixel (Figure A.13). If the image falls directly in the centre of a pixel then the camera will 
reproduce the object as a square of 1 pixel. Even if the object is imaged onto the vertices of 
4 pixels the object will still be reproduced as a square, only dimmer – not a faithful 
reproduction. If the diameter of the projected image is equivalent to one or even two pixel 
diagonals the image reproduction is still not a faithful reproduction of the object and 
critically varies on whether the centre of the image projection falls on either the centre of a 
pixel or at the vertex of pixels. It is only when the object image covers three pixels do we 
start to obtain an image that is more faithfully reproduced, and clearly represents a 
circular object. The quality of the image is also now independent of where the object image 
is centered, at a pixel center or at the vertex of pixels.  
 
 
Figure A.13 CCD output patterns 
 
In addition to the discrete pixels, other factors such as the quality of the imaging 
system and camera noise all limit the accurate reproduction of an object. The resolution 
and performance of a camera within an optical system can be characterized by a quantity 
known as the modulation transfer function (MTF), which is a measurement of the camera 
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and optical system’s ability to transfer contrast from the specimen to the intermediate 
image plane at a specific resolution. Computation of the MTF is a mechanism that is often 
utilized by optical manufacturers to incorporate resolution and contrast data into a single 
specification. This concept is derived from standard conventions utilized in electrical 
engineering that relate the degree of modulation of an output signal to a function of the 
signal frequency (Figure A.14). 
 
 
Figure A.14 Measurements of MTF 
 
Adequate resolution of an object can only be achieved if at least two samples are 
made for each resolvable unit (many investigators prefer three samples per resolvable unit 
to ensure sufficient sampling). In the case of the epi-fluorescence microscope, the 
resolvable unit from the Abbe diffraction limit at a wavelength of 550 nanometers using a 
1.25 numerical aperture lens is 0.27 microns. If a 100x objective is employed, the projected 
size of a diffraction-limited spot on the face of the CCD would be 27 microns. A sensor size 
of 13 x 13 micron pixels would just allow the optical and electronic resolution to be 
matched, with a 9 x 9 micron pixel preferred. Although small sensors in a CCD improve 
spatial resolution, they also limit the dynamic range of the device. 
 
Frame Rate  
The frame rate of a camera is the fastest rate at which an image or spectra can be 
continuously recorded and saved. Frame rates are governed principally by the number of 
pixels and the pixel readout rate but other factors such as whether a sub array is used, 
whether there is binning and at which vertical shift clock speeds are also factors. Digital 
cameras can readout sub sections of the image or bin pixels together to achieve faster 
readout rates, therefore typically two frame rates are defined, i.e. one is a full frame 
readout rate and the other is the fastest possible readout rate. 
 
Binning 
CCD’s are very versatile devices and their readout pattern can be manipulated to 
achieve various effects. One of the most common effects is binning. Binning allows charges 
from adjacent pixels to be combined and this can offer benefits in faster readout speeds 
and improved signal to noise ratios, albeit at the expense of reduced spatial resolution. 
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To understand the process, lets us compare the process of single pixel readout 
versus 2 x 2 binning shown in the successive Figures A.15, when on the left side is showed 
a single pixel case and in the right side the binned case. If we consider a spot of light 
evenly illuminates the four pixels of our miniature CCD. The CCD has a light sensitive 
region of just four pixels and a readout register depicted in blue at the bottom of the CCD. 
The light signal induces a charge of 20 electrons in each of the four pixels as shown by 
their shading and the numbers in the bottom right hand corner of the pixel. The light falls 
evenly on the four pixels and creates a charge of 20e in each of the four pixels. 
 
 
Figure A.15.1 
 
The first operation is to shift the charge down one row. The charge from the lowest 
pixels gets shifted into the readout register. 
 
 
Figure A.15.2 
 
For single pixel readout, the charge in the readout register is shifted to the right and 
into the readout amplifier. In the binning operation the charge is shifted down again and 
the charge from the second row is added to the first row in the readout register. 
 
 
Figure A.15.3 
 
For single pixel readout, the first pixel is readout while the readout register is 
shifted again to shift the charge in the second pixel into the readout amplifier. In the 
binning operation the summed charge from the two right pixels is shifted into the readout 
amplifier. 
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Figure A.15.4 
 
In the single pixel readout, the next row is shifted vertically into the readout 
register. In the binning operation the readout register is shifted again to sum the charge 
from the 4 pixels in the readout amplifier before being readout. 
 
 
Figure A.15.5 
 
In the single pixel readout mode, the readout register is shifted to the right again to 
readout the next pixel. Binned operation is now complete. 
 
 
Figure A.15.6 
 
In the single pixel readout the readout register is shifted to the right again to 
readout the final pixel. 
 
 
Figure A.15.7 
 
It is important to highlight the main differences in the two readout schemes. In the 
first we achieve the full spatial resolution the sensor offers. In the binned example we have 
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reduced the 4 pixel pattern to a single pixel and hence lost spatial resolution. However the 
binned operation takes less steps to readout the sensor and hence is faster. Typically 
binning 2x2 is twice as fast; this is achieved by having to shift the readout register only 
every 2 vertical shifts. If we were binning 3x 3 or 4x4 on a CCD then the readout would be 
respectively 3 and 4 times faster.  
The binned example also highlights how binning improves signal to noise ratio. If 
we assume our CCD has a readout noise of 10e then in the single pixel example each pixel 
is readout with a noise of 10e hence we achieve a signal to noise ratio of 2:1 (20e/10e). 
Even if we subsequently sum the four pixels in a computer after readout, the signal-to-
noise ratio becomes 4:1. In adding the four pixels we sum the signal (4 times 20e i.e. 80e) 
and the noise is added in quadrature i.e. square root of the sum of the noises squared 
(square root of 4 times 10 squared i.e. 20e). In the binned example there is no noise until 
the signal is readout by the amplifier so the signal to noise ratio is 8:1(80e/10e) i.e. twice as 
good as the single pixel readout mode. 
It is noteworthy that the binning reduces the detectable amount of light per pixel; 
however, in the majority of existing CCD image sensors, the serial shift and summation 
point register before the A/D conversion have enough capacity to accumulate charge 
carriers that are twice as large, compared to the full-well capacities of each pixel. 
Binning is primarily used for low light level applications and for configured CCD 
image sensors where the readout noise (mainly in cooled CCD image sensors) id 
dominant, since other noise contributions such as dark current accumulate with binning.  
 
Blemishes & Non-uniformities 
All cameras to some degree exhibit blemishes which impair the faithful 
reproduction of the light signal. The primary source of the blemishes is the sensor itself 
and here are some of the blemishes that occur. 
Black Pixels 
Black pixels are regions of the sensor, typically pixels or small clusters of 
pixels, which have significantly lower response than their neighbors (less than 75% 
the response of the average pixel). They are typically formed due to contamination 
on the sensor surface or embedded in the sensor. The effect of black pixels can be 
removed by taking a flat fielding reference or by post processing interpolation to 
mitigate their effects. Black pixels are rarely a major issue unless they extend to 
many pixels. 
Hot Pixels 
Hot pixels have a much higher dark current than their neighbors (50 times 
higher than specification). They typically have a different temperature response 
than the bulk of the sensor and so can appear to differing amounts at different 
temperatures. 
They are usually due to contamination embedded in the sensor. 
The effect of hot pixels, unless they are particularly large, can usually be removed 
by taking a background. 
Column Defects 
A combination of blemishes may adversely affect a column. A column defect 
may due to some of the following: 
• A total of more than 30 black pixels or hot pixels 
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• Hot Column: a column which has a dark current greater than 2 times 
specification 
• Black Column: a column which has saturation less than 90% of the average 
column 
• A trap: see next section 
Traps 
Traps are peculiar to CCD’s, they usually only occur in a single pixel and 
they can be caused by contaminants getting into the CCD during the production 
process or by the effects of radiation on the CCD structure. They act by becoming 
temporary holders of charge. As charge is shifted though a trap, the trap holds onto 
a portion of the charge (the trap size); while the trap is filled subsequent charge 
transfers are unaffected. The charge in the trap slowly dissipates until it is refilled 
by new charge created by illumination or by new charge being shifted through the 
pixel. Traps can be any size even down to a single electron charge trap but they are 
usually only noticeable when their size is greater than 200 electrons. Traps are 
identified by analyzing their impact on an illuminated CCD at a mixture of high 
and low light levels. The dynamic nature of the traps is difficult to model and 
therefore they are difficult to compensate for. Severe traps can be overcome by 
providing an initial light illumination to fill the traps before the proper exposure is 
required, but this adversely affects the signal to noise ratio. 
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Chapter 4 
 
HP-FRI in vivo on small animals: early 
tumor detection 
 
 
4.1   Introduction 
 
In this chapter we present the procedures and the results relative to HP-FRI 
measurements in vivo on small animals performed in the second part of our work. They 
contain the most important results both for implementation technical of the FRI system 
and the obtainment of the biomedical target of interest.   
The second part of our work starts with the acquisition of a new CCD camera, 
Hamamatsu ORCA 285, an instrument of low noise, high sensibility, spatial resolution, 
dynamic range and quantum efficiency in the spectral region of our interest. As mentioned 
above, especially the CCD camera high sensibility is of fundamental importance in the FRI 
measurements. First, we calculated the spatial resolution of our FRI system with ORCA 
camera. Then we image different types of tumor (mammary, thyroid anaplastic and 
papillary), using also different collection geometry of fluorescent light (simple lenses 
system or stereomicroscope).  
Exploiting the high sensibility feature of the ORCA camera, the submillimetric spatial 
resolution of our FRI system and the HP uptake selective in the tumor tissues, we have set 
as biomedical target the early detection of high malignancy tumor, i. e. the detection of 
tumor in vivo on mice in an early stage of its development. It is noteworthy that in the 
previous tumor detection by HP-FRI measurements, the dimensions of the studied tumors 
were about 50-400 mm3, so that the tumor masses were visible to the naked eye and 
palpable. Instead, it is crucial in the tumor diagnostic to be able to detect the tumor 
formation: earlier diagnosis greater the patient survival probability, especially if the tumor 
is highly invasive, as it is the ARO tumor. So, after a positive preliminary HP-FRI 
measurement on one mouse 6 h after HP injection and five days after ARO tumor cells 
inoculation, we performed HP –FRI measurements daily for 5 day on a set of 10 mice from 
the third day after ARO tumor cells inoculation and 6 h after HP injection; we repeat this 
series of HP-FRI measurements after a second HP injection the eighth day from tumor 
cells inoculation. 
 
4.2  Experimental set-up 
 
In the second part of the work the experimental apparatus for FRI measurements (Figure 
4.1) was so composed: 
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• Excitation source, a frequency doubled mode-locked active-passive Nd:YAG 
laser (λ = 532 nm, beam diameter = 7 mm, energy/pulse = 30 mJ, pulse 
width = 50 ps, repetition rate = 10 Hz), or tungsten lamp with fiberoptic 
illuminator; 
• optics for the collection of the excitation radiation on the sample: an iris 
diaphragm, a beam enlarging  lens, a flat mirror directing the beam on the 
mouse surface; 
• sample, a tumor bearing anesthetized mouse; 
• optics for the collection of the fluorescence emission radiation in two 
alternative modalities: a) relay positive lenses and by the CCD camera 
equipped with a 16 mm lens (field of view (FOV) ≈ 5×4 cm2 or 13×10 cm2 on 
the animal body) (not shown in Figure 4.1)); b) a stereomicroscope at 1.3X 
(FOV≈1.1×0.9 cm2, resolution≈120 pixel/mm) (Figure 4.1).  
• cut-on long wave pass filter (Andover 600FH90-25, cut-on wavelength: 600 
nm). 
• detector, a CCD camera  (Hamamatsu ORCA 285 G), equipped with a 
Computar 16 mm objective; 
• image acquisition (average of 10 single frame consecutive acquisitions) and 
analysis board, a Hamamatsu Wasabi software.  
• Offline image analysis software ImageJ. 
 
The main features of the new CCD camera are:  
 High resolution of 1.37 million pixels (1344×1024 pixels; cell size: 6.45µm; horizontal 
size: 8.67mm, vertical size: 6.6mm);  
 A/D converter at 12 bit;  
 Readout noise: 8 electrons r.m.s;  
 Dark current: 0.8e-/pix/s; 
 Full well capability (typical): 18000 e- 
 Amplification gain conversion coefficient 4.6 electrons/ADC counts;  
 Camera gain between 0 (0 dB) and 255 (20 dB);  
 Exposure time from 10 µs to 10 s; 
 Peak quantum efficiency (60%) at 500 nm  (Figure 4.2 left side); 
 Progressive scan interline CCD chip without mechanical shutter; 
 About 10 µs electronic shutter to capture fast events;  
 Binning 2x2, 4x4, 8x8 function to improve sensitivity and achieve a frame rate of 16, 
27, 41 Hz respectively; 
 Dynamic range (typical): 2250:1; 
 Low dark noise with Peltier cooling (cooling temperature: +5 0C) for a dynamic 
range of more than 60 dB; 
 Full remote control from PC via IEEE 1394 bus7; 
 Camera head weight: 1.3 Kg. 
 
                                            
7 The Firewire interface was developed by Apple Computers in the mid 1990’s and was adopted by the an 
independent trade association called the 1394 Trade Association after the IEEE 1394 computer interface 
standard. Firewire can be operated as a synchronous device which allows high speed bandwidth for short 
periods of time.  
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Figure 4.1: A: Frequency doubled pulsed Nd:YAG laser (λ = 532 nm, energy/pulse = 30 mJ).  B: Iris 
diaphragm C: Beam enlarging lens D: Flat mirror E: Stereomicroscope (Olympus SZ-40) at 1.3 X F: Cooled 
CCD monochrome digital camera (Hamamatsu ORCA 285 G) equipped with cut-on long-wavelength pass 
filters (λ > 600 nm)  G: Tungsten lamp with fiberoptic illuminators. 
 
 
  
 
Figure 4.2 Sensitivity spectrum (left side) and system configuration of our CCD camera Hamamatsu Orca 
285 (right side).  
4.3 Materials and methods 
a. Spatial resolution measurements 
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In order to estimate the spatial resolution of our in vivo imaging system, we used a 
borosilicate glass capillary (5 µL volume, nominal external and internal diameter of 1 mm 
and 260 µm, respectively), filled with HP solution and inserted post mortem under the skin 
of a sacrificed mouse. The HP concentration was reduced 1:4 with respect to that used for 
the successive HP-FRI measurements. About 15 mm of capillary length was inserted under 
the skin. Before inserting it, we imaged by fluorescence about 25 mm of capillary length in 
air. We observe explicitly that in this manner the fluorescent source is placed at the same 
depth (about 1 mm under mouse skin) as the tumors we image. 
 
b. The new in vivo HP-FRI modality 
 
The dose of 400 µl of aqueous solution of HP dichlorohydrate (Vit-porphyrin II, 
Teofarma, Italy), at the concentration of 4 mg HP/ml distilled water, corresponding to a 
dose of 28 mg HP/Kg mouse body weight, was injected im in the right posterior leg of the 
mouse, on the opposite side with respect to the tumor.  
As in the previous experiments, we used six-week-old Crl:CD-1 athymic nude mice 
(Charles River Laboratories, Calco, Italy). 
The tumor cell lines subcutaneously inoculated in the mice are: i) MDAMB361 cells (for 
brevity, MDA cells), derived from a mammary human carcinoma; or ii) ARO cells, derived 
from an anaplastic human thyroid carcinoma. Cells were cultured in Dulbecco’s 
Modification of Eagles’ Medium (DMEM) culture medium supplemented with 10% fetal 
calf serum, penicillin (50 U/ml) and streptomycin (50 g/ml). About 107 cells were injected 
in the back of the mice and the in vivo FRI measurements were performed 30-31 days later 
and from 6 h up to 30 h after the HP injection. Ten minutes before measurements, the 
animal was anaesthetized by injecting 300 µl of a solution obtained by dissolving, in 20 ml 
physiological solution (NaCl 0.9% water solution), 0.5 ml of a solution of tribromoethanol 
(Avertin) in 2-metil-2-butanol at the concentration of 1 mg/ml. 
We have imaged two MDA tumor bearing mice, called mouse α and β with system 
lenses (FOV: 13×10 cm2 and 5×4 cm2, respectively), and one ARO tumor bearing mouse, 
called mouse γ with stereomicroscope (FOV: 1.1×0.9 cm2). 
In this new FRI apparatus, the measurements protocol includes in the red light image 
and fluorescence image. The first is obtained by white light illumination (fiberoptic 
illuminator, 50 W tungsten lamp, G in the Figure 4.1) and with the cut-on filter (λ > 600 
nm) in front of the CCD, showing visually the position and the dimensions of the 
interesting structures on the animal. The second image offers the map of the fluorescence 
emission registered with an exposure time ranging from 5 s to 10 s and a camera gain 
between 50 and 120. Hence, the exposure time corresponds to 50 or 100 laser pulses per 
image. In order to compare images with different gain and exposure times the image data 
matrix (pixel values) was suitably scaled. Furthermore, to each image we have subtracted 
the CCD camera background noise image (including readout noise), acquired in the dark 
(with diaphragm closed and minimum (zero) time acquisition and zero gain). We outlined 
that in these FRI measurements the image of laser beam 2-D profile at 532 nm doesn’t is 
acquired, because we can infer from the previous measurements that the laser fluctuations 
don’t affect significantly the imaging quantitative determinations when the image is the 
result of a media on numerous (>30) consecutive acquisitions, as it happens in our case. 
All the images are acquired as 12 bit images, but are represented here as 8 bit images. 
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Immediately after in vivo fluorescence imaging measurements, the two MDA tumor 
bearing mice were sacrificed and histological sections were obtained from tumor tissues. 
 
c. Early tumor detection 
 
The HP dichlorohydrate (Sigma, Italy) dose, modality and localization on the mouse 
and mouse type are the same than the previous point b. 
 We have used the ARO tumor cells because of their high degree of malignancy that 
justifies the necessity of early detection. The doubling time in vitro of this cell line is 
approximately 20 h.  
As preliminary experiment, we considered only one mouse, called mouse #0. The 
fluorescence measurements were performed the fifth day after the 106 cells injection, and 
after 6 h from HP injection. The mouse was also imaged five days after the tumor cell 
injection but before the fluorescent marker injection, in order to provide a control image. 
The animal was anaesthetized by injecting 50 µl of a solution of chloral hydrate 10 mg/ml 
in NaCl 0.9%. The measurements protocol is the same than the previous point b. 
Then, we have imaged 10 mice ARO tumor bearing numbered from 1 up 10. The camera 
lens provided a field of view of 10.2×7.8 cm2 in order to view the whole mouse body. The 
fluorescence measurements were performed the third day after the cell injection, and after 
6 h from HP injection and repeated daily in the successive four days. The eighth day after 
cells inoculation a second HP injection (with the same dose of the first) was done and a 
second set of FRI measurements was performed identical to the first. Some mice dead 
before the performing all measurements. 
Fluorescence images, all visualized using the same gray level scale, were processed 
according to the steps illustrated in the point b. Furthermore, the fluorescence intensity 
profile along a straight line across the fluorescent tumor area was determined, the constant 
grey level, I0, for the healthy tissue surrounding the tumor and the maximum gray level, 
Imax, in the fluorescent tumor region were determined, and the maximum optical contrast 
Tumor/Background (T/B) ratio was calculated as Imax/I0. 
 
4.4 Results and their discussion 
a. Spatial resolution measurements 
The Figure 4.3 shows the line profile of the fluorescence image (drawn across the capillary 
diameter and integrated along a length of the capillary of the about 15 mm) of the HP 
filled capillary in the air (left side) and under mouse skin (right side). In the former case, 
the line profile present a Gaussian shape with a FWHM value of 240±20 µm, in accordance 
with the nominal internal diameter of the capillary, while in the latter case the FWHM 
value increase up to 770±20 µm, due to the light scattering effects by the mouse skin. By 
subtracting in quadrature the FWHM value measured in air, we obtained a value of 
730±30 µm for the FWHM system resolution estimated for our in vivo fluorescence 
imaging system. 
 E
rr
o
re
. 
Lo
 s
ti
le
 n
o
n
 è
 d
e
fi
n
it
o
. 
 
 
Figure 4.3. Fluorescence intensity profile across the diameter of a capillary filled with HP solution in air 
(left side) and then inserted under the mouse skin (right side); the relative FWHM value with their error are 
also reported. The profiles have been integrated for a length of several mm along the capillary (see text). In 
the top figure, the capillary tube walls are evident, as small peaks at about 1 mm distance, ascribed to the 
effect of internal diffuse reflection of fluorescence light at the glass-air interface. 
 
b. The new in vivo HP-FRI modality 
 
The mouse α with a mammary MDA tumor, as observed in red light, shows three small 
tumors (a, b and c) on the back (Figure 4.4, top side). The corresponding HP fluorescence 
image (Figure 4.4, bottom side) shows the highly fluorescent HP injection site in the right 
posterior leg (detail d), and a diffuse fluorescence in the back with some brightest points 
which correspond to the tumor regions (a, b and c). Here, a fifth region (e), apparently a 
healthy area in the red light image  and not correlated visually with any normal or tumor 
structure, presents an enhancement of fluorescence optical contrast with respect to the 
surrounding region. The histological analysis shows that this fluorescent region (e) 
corresponds to a tumor region. Thus, the features of our HP-FRI system allow us the 
detection of tumor area apparently healthy. We could talk of reduction of false negative, 
also if improperly, because referred to an unique case. 
The mouse shows also a fluorescent region on the left flank in a rough anatomical 
correspondence with the stomach (Figure 4.5). 
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Figure 4.4. (Top) Red light image (exposure time 200 ms, gain 50) of the tumor area of mouse α showing 
the three tumor masses marked as a, b, c. The fluorophore injection site is marked as d. The fifth fluorescent 
region (e) doesn’t correlate visually with any normal or tumor structure. (Bottom) Fluorescence image 
(exposure time 10 s, gain 50) of the whole mouse. The horizontal white bar corresponds to 1 cm.  
 
Figure 4.5. Fluorescence image (exposure time 10 s, gain 50) of the mouse # 2, 24h after HP injection. Here 
the image was plotted in logarithmic scale to show the correspondence of the fluorescent region with the 
mouse stomach location. The circle on the right is a fluorescent marker. The horizontal white bar 
corresponds to 1 cm.  
 
The mouse β, bearing mammary MDA tumors, as observed in the red light (Figure 4.6, 
top), shows a tumor with three lobes; the two larger ones (A and B) are supposed, by 
visual inspection, in an advanced state of necrosis. The fluorescence image (Figure 4.6, 
bottom) confirms the finding of a tumor structure where two lobes (A and B) are less 
fluorescent with respect to the surrounding healthy tissues, and the last lobe (C) appears 
slightly fluorescent.  
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Figure 4.6. (Top) Red light image (exposure time 10 ms, gain 0) of the tumor area for mouse β showing the 
three tumor lobes marked as A, B, C. (Bottom) Fluorescence image (exposure time 10 s, gain 50) of the same 
tumor area. The horizontal white bar corresponds to 1 cm.  
 
 
 
 
  
Figure 4.7. Macroscopic image of the tumor tissue of mouse β: a) paraffin inclusion of the whole tumor; b) 
histological section of the same region stained with hematoxilyn - eosyn ; microscopic image of stained 
histological sections of lobe A showing damaged (necrotic, haemorrhagic) tumor cells (c) and viable tumor 
cells of lobe C (d). In a) the contours of the tumor lobes are roughly drawn. 
 
The histological examination of this tumor biopsy (shown in paraffin inclusion and as a 
stained histological section in Figure 4.7 a and b, respectively) supports this conclusion. 
Indeed the micrographies of the tumor tissue of lobe A (Figure 4.7 c) and lobe B show 
damaged (necrotic, hemorrhagic) cells especially in the lobe central region, while the lobe 
C (Figure 4.7d) shows scarce necrosis and hemorrhagic phenomena and 1-2 mitoses per 
microscope field. The fraction of viable cells is approximately, 72%, 67% and 95 % for the 
lobes A, B, C respectively.  
In conclusion, visually recognized tumor area does not fluoresce, while the histological 
analysis shows that the non-fluorescent tumor area is constituted of necrotic/hemorrhagic 
cells. We could so suppose that this tumor necrosis state prevents accumulation of the 
dichlorohydrate HP, as has been found for other HP compound.  
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Figure 4.8 Tumor (a) and healthy areas (c) fluorescence images for mouse γ. Plot represents profile in the 
tumor area (b) and in healthy areas (d) along the line drawn on the images. The horizontal white bar 
corresponds to 1 mm. Exposure time is 10 s; gain 120. 
 
The mouse γ shows an ARO tumor region with a two lobes structure in the in vivo HP 
fluorescence image (Figure 4.8 a) acquired with the stereomicroscope (FOV of 1.1×0.9 cm2). 
It is also possible to distinguish this structure from the fluorescence intensity profile along 
the line drawn across the tumor region (Figure 4.8 b), where the smaller lobe has a FWHM 
linear size of about 1 mm. In Figure 4.8 c (same FOV) is reported the HP fluorescence 
image of a region of the left flank of the same mouse corresponding to healthy tissue areas 
(intestinal tract). In the Figure 4.8 d the fluorescence intensity profile along the line drawn 
across this fluorescent region is showed.  Hence, if the sensitivity and spatial resolution 
performances are combined with the magnification provided by the use of the 
stereomicroscope, some rough “structural features” can be visualized, as tumor lobes. 
By these first in vivo HP-FRI measurements with the new apparatus, we can infer a 
series of observations about the system features. The high sensitivity of the new CCD 
camera and the higher dose of administered fluorescent marker with respect to the 
previous experiments allows the skin autofluorescence, red fluorescence of the skin  when 
excited at 532 nm, and background fluorescence, due to the low accumulation of the 
exogenous HP in healthy tissues, to be detected. The detection of fluorescence skin has the 
advantage of providing the localization of the hyperfluorescent region on the mouse body 
and, however, doesn’t prevent the detection of the tumor areas by an increased fluorescent 
contrast of the tumor area with respect to the healthy tissue. Indeed, the tumor area 
appears clearly more fluorescent than the surrounding healthy tissues.  On the other hand, 
the resolution of the structures appearing both in tumors and organs fluorescence images 
is strongly affected by the high value of the scattering coefficient of the mouse skin, as it is 
note in literature and as it results also from our spatial resolution measurements. Finally, 
the tumor HP dichlorohydrate uptake is selective, although nonspecific and by 
mechanisms not absolutely understood, as explained in Chapter 2. Indeed, our HP 
compound allows for the fluorescent labelling of different tumor types (we have seen 
ARO and NPA, and now also mammary) for a diagnostic purpose, while doesn’t allows 
for monitoring of molecular or genetic pathways of the diseases for a biomolecular study. 
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c. Early tumor detection 
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Figure 4.9 Images of mouse #0. The mouse is imaged, before HP injection, in the red light (a), in the 
autofluorescence light (b and c) and, after HP injection, in the HP fluorescence light (d). The horizontal white 
bar corresponds to 1 cm. The black line across the suspected tumor region in c and d indicates the location of 
the fluorescence intensity profile reported in Figure 4.10. In red light image (a) exposure time: 1,5 s; gain: 0; 
in fluorescence images (b, c, d) exposure time is 10 s; gain 50. 
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Figure 4.10 Fluorescence intensity profiles of tumor area in Figure 4.9 c (solid black line) and in Figure 4.9 
d (dotted line) along the lines drawn on the suspected tumor regions.  
 
Figure 4.9 shows the sequence of in vivo images for mouse #0, corresponding to: whole 
mouse, back view, image in the red under white light illumination (Figure 4.9 a); whole 
mouse, back view, fluorescence image before HP injection (Figure 4.9 b); mouse flank with 
tumor, fluorescence image before HP injection (Figure 4.9 c); mouse flank with tumor, 
fluorescence image after HP injection (Figure 4.9 d). Hence, Figures 4b and 4c show the 
autofluorescence of the mouse, namely the red fluorescence of normal tissues when 
excited at 532 nm. Figure 4.9 d shows the increased fluorescence in selected regions on the 
mouse, due to the exogenous HP fluorescent marker, particularly in the tumor region.  
In Figure 4.10  is plotted the profile of fluorescence intensity along the line drown in 
mouse images Figure 4.9  c and Figure 4.9  d. The optical contrast, calculated as the ratio 
between the maximum and minimum value, is 1.6 for the tumor region in Figure 4.9 c and 
2.2 in Figure 4.9 d.  
Hence, the sensitivity and spatial resolution performances of the system allow for the 
detection of an early stage tumor, as the ARO tumor in Figure 4.9, implanted just 5 days 
before the fluorescence measurements. We can estimate that, starting from 106 injected 
cells, we have a number of ARO tumor cells of the order of tens of millions cells, 
corresponding to a volume of few cube millimeters. However, the tumor area appears 
clearly more fluorescent than the surrounding healthy tissues and the tumor tissue itself 
prior the HP administration. On the other hand, the relatively low fluorescence ratio 
tumor/healthy tissue due to the autofluorescence and/or fluorescence background 
remains one of the most limits to the detection sensitivity of the fluorescence systems.  
We note also the bright spot appearing on the left flank of the mouse before HP 
injection (Figure 4.9 b), a fluorescence signal coming from a region corresponding to the 
mouse stomach. We have observed a single large fluorescence area located in the stomach 
region of the mice also in the Figure 4.5 and 4.8 b. Since this fluorescence appears also 
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without HP administration (Figure 4.9 b), we speculate that it could be due to the natural 
derivatives of Chlorophyll-a present in the mice food, whose fluorescence spectrum is 
similar to that of HP (241,242). Although it is generally recommendable to adopt for the 
mice a diet chlorophyll-free to avoid the presence of fluorescence signals “spurious”, in 
our work this organs fluorescence doesn’t affect the detection of the fluorescence of the 
tumor area, because the corresponding regions are well spatially separated. We note that 
the internal organs that, as tumor masses, are subcutaneous can be imaged by optical 
fluorescence since the radiation at the wavelength 530 nm has a penetration depth in 
tissues less than 1 centimeter (2,243).  
It is distinguishable in the Figure 4.9 c and d a shadow, due to the fluorescence of the 
black cardboard under the mouse body. 
 
Day after cells 
inoculation 
Imax/I0 
1 1.58 
2 1.38 
3 1.21 
4 1 
5 1 
6  
7  
8 1.28 
9 1.35 
10 1.33 
11 1 
12 1 
 
Table 1:  The values of the optical contrast of the tumor region with respect the surrounding healthy region 
are reported for the mouse #1 whose time sequence fluorescence images is showed in the Figure 4.11.  The 
maximum optical contrast is obtained between 6-24 h after the first HP injection. After the second HP 
injection on the eighth day after tumor cells inoculation the optical contrast doesn’t reach values so high as 
after the first, although again it is higher in the first 24 h and decrease to unity the fourth day.  
 
Figure 4.11 shows the time sequence of the red light (first column) and the 
corresponding fluorescence (second column) images of the mouse #1 for the first five days 
following the HP administration. In this measurements series it is provided that the 
position of the mice in the CCD camera FOV and with respect to irradiation geometry was 
about the same, so minimizing the signal fluorescence variations due to the not perfectly 
uniform irradiation distribution. On each fluorescence image a straight line was drawn 
under the right leg, where it is known that the tumor cells inoculation has been performed, 
along the region with increased fluorescence signal.  It is to be noted that the tumor, in 
these first days after cells inoculation, wasn’t visible at naked eye: only a posteriori, when 
the tumor have developed, it was possible to verify that this region so individuated 
corresponded with the tumor. Along this line the tumor profile fluorescence intensity, 
showed in the third column, was determined. The fluorescence line profile across the 
tumor region exhibits the following features: 
a) constant level, corresponding to the fluorescence level of the healthy tissue; 
b) sharp peak of fluorescence, corresponding to the tumor region;  
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c) fluorescence quickly dropping, due to a geometric effect of the mouse body. 
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Figure 4.11 Time sequence of the red light images (first column), corresponding fluorescence images 
(second column) and tumor profile fluorescence intensity (third column) of the mouse #1 for the first five 
days following the HP administration. 
The constant grey level, I0, for the healthy tissue surrounding the tumor and the 
maximum gray level, Imax, in the fluorescent tumor region were determined for all 
 E
rr
o
re
. 
Lo
 s
ti
le
 n
o
n
 è
 d
e
fi
n
it
o
. 
measurements days and the optical contrast was calculated as the ratio Imax/I0 and 
reported in the Table 1, from which we can observe that: 
a) the contrast fluorescence ratio decreases with the increasing delay from the HP 
administration and vanishes after the third day from the first HP administration; 
b) some other fluorescent regions are visible on the mouse body, corresponding to the 
HP injection site (left leg) and to some internal organs where HP accumulates as well; 
c) the most suitable time to detect the fluorescence of the tumor is between 6 h and 24 h  
from the first HP administration; 
d) the second Hp administration on the eighth day after tumor cells inoculation doesn’t 
allow returning of the optical contrast to the values obtained after the first HP injection; 
e) again, also after second HP injection it can be seen that the optical contrast is higher in 
the first 24 h and it became unitary after the third day.    
The control image of the mouse before HP injection indicates that fluorescence contrast 
between tumor and healthy region is absent (data not shown). 
Again, we started from 106 injected cells, so we have imaged, at least in the first 
measurements day, tumors constituted by tens of millions ARO cells with a volume of few 
cube millimetres. From fluorescence imaging measurements we have estimated that the 
system resolution is about 700 µm for imaging in vivo masses at about one millimeter 
below the mouse skin. Nevertheless, we investigated tumors whose dimensions are in the 
order of few millimeters. This is related to the biological difficulty of implanting a tumor 
by using a limited number of cells. In addition, in order to be sure of the effective tumor 
implantation, a delay of at least 3 days is normally required. 
Hence, we showed that HP as a fluorescent marker is suitable for detecting the early 
stages of tumor development, provided that the imaging system has sufficient spatial 
resolution and photometric sensitivity to detect small tumors via their fluorescence. 
Nevertheless, this detection has characterized by a low optical contrast, as typically for the 
family of our fluorescent marker (see paragraph on porphyrins in the chapter 2). 
Moreover, it is limited to a time window of 48 h after the first HP injection and isn’t 
repeatable after few days from the first HP injection, related to the different uptake and 
washout timings of the HP compound in the tumor and in the healthy tissue. Indeed, it 
can be inferred from our measurements that our HP compound accumulates in the tumor 
tissue preferentially with respect to the healthy, but with a washout time lower, so that 
some quantity of the HP compound remains in the healthy tissue also when it have been 
expulsed from the tumor and it add itself to the HP administrated with the second 
injection.  
The tumor early detection is a clinical requirement of primary importance. Many FRI 
techniques aim to this scope with different strategies for florescent labeling. In general, the 
specific or “smart” targeting can obtain information on molecular or genetic pathways of 
the oncological diseases, while the targeting with fluorescent protein can supply a high 
optical contrast also for diseased internal organs. In the first case (244, 245), it is required a 
large amount of work before the FRI measurements in order to obtain the fluorescent 
labeling through a biomolecular study that allows for the identification of the best 
combination between the fluorochrome and the specific ligands of the tumor cells. In the 
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second case (246-248) the fluorescence labeling of tumor cells is genetically performed 
before their injection, so that the tumor cells only are fluorescent. This approach does not 
allow to detect tumors that have unknown localization and nature. 
 
4.5 Improvements and future project 
A number of improvements can be investigated for our optical in vivo imaging 
system for each component. 
• Source: We are testing as excitation light source a 150 W halogen lamp with 
fiberoptic illuminator. This illumination system, indeed, is more compact and 
cheaper with respect to the picoseconds laser source, although it requires more 
stringent conditions on filter excitation that must excite the fluorochrome in a 
narrow wavelength band.  
• Irradiation and collection geometry: we are testing a macroscope, a new Leica 
instrument, suitably designed for FRI measurements in vivo on small animals. The 
laser or lamp beam is fiber transported in the instrument and the FOV is 
continuously variable from few mm2 to 20 cm2 allowing for the whole animal 
imaging or zooming on a specific region.  
• Fluorochrome: we have testing the FRI system with a fluorochrome of simple use 
like the HP compound, which allows for fluorescent labelling by a simple 
injection. Now we are ready to apply our FRI system on other type of 
fluorochrome. Also remaining in the porphyrin family, have been engineering a 
new generation of porphyrin encapsulated in nanostructures. In this manner the 
HP can behave as a specific fluorochrome. From the overview of the Chapter 2, it 
is clear that the possible biomedical applications are very numerous and 
interesting for the entire group of the molecular biology.  
• Detector: new generation of CCD camera with an increased sensitivity in the red-
NIR have been produced in the last years. 
• External dark box: it can be added to the system in a form stable and of simple 
access to the sample and the other internal optical components.    
• Methods to enhance signal/background ratio: methods able to reduce the negative 
incidence of the autofluorescence on signal/background ratio can be implemented 
by a digital subtraction procedure (249) as follows. First, two images are acquired, 
one with the background filter and one with the primary excitation filter. For both 
of these images, the same emission filter is used. The scale factor is a ratio of the 
autofluorescent signal measured using the background filter to the autofluorescent 
signal measured using the excitation filter. It accounts for different levels of tissue 
autofluorescence due to different excitation wavelengths and filter transmission 
characteristics. The scaled background image is subtracted from the primary 
excitation filter image resulting in a significant reduction in autofluorescence 
while leaving most of the fluorophore signal. 
Furthermore, free-chlorophyll diet for the mouse is to be adopted, to reduce the 
background fluorescence.  
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4.6 Conclusions 
 
With the technological improvements carried out by ORCA CCD camera, we are 
handling with a modality imaging absolutely different with respect the previous. Indeed, 
we can reveal also the autofluorescence and fluorescence background of mice body: so we 
can obtain an immediate anatomical localization of the tumor region also in the 
fluorescence imaging, but we have also a lower optical contrast, since the not perfectly 
uniform irradiation doesn’t allows for the digital subtraction operation we performed in 
our previous FRI measurements.  
Nevertheless, we interrogate the HP-FRI system about the ability to detect tumor in an 
early stage obtaining positive response. The system, conjugating the HP selective tumor 
uptake and the high sensitivity, resolution spatial and photometric range of CCD camera, 
allows to detect tumor non visible at naked eye only three days after cells inoculation.  
However, this detection capability is limited to a temporal window of 48 h and to an 
optical contrast not very high (<2); furthermore, this detection mode doesn’t seem 
repeatable at brief temporal intervals. These features prevent this method to can be used to 
monitor the time evolution of a set tumor, but allows for an early detection tumor by a non 
toxic HP compound without photosensitization consequences.      
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Conclusions 
 
We have implemented a FRI system by using a non tumor-specific fluorochrome 
like a HP dichlorohydrate, a compound of porphyrins family, whose fluorescence 
emission has been excited by a laser source. The final scope of the work was the in vivo 
detection, possibly in an early stage, of subcutaneous solid tumor with high malignancy 
degree on small animals.  
In the field of the FRI technique, HP-FRI is characterized from the use of a non 
specific fluorochrome. This type of compounds has been largely studied in the past years 
because of their tumor selective uptake, which has been exploited especially for 
photodynamic purposes. In the photodynamic therapy (PDT) the interest for porphyrin 
compounds is increased in the years producing a large number a new photosensitizes, the 
so called “second generation porphyrins”, in the attempt of decreasing the 
photosensibilitation effects and allowing for a better therapeutic effect. Although the PDT 
is the main application of the porphyrin compounds, they have been applied also in the 
photodiagnosis (6).  
As a first step in this research field, we implemented a FRI system as simple as 
possible from both instrumental and biological point of view. So we used a laser VIS light 
source, guarantying the high monocromaticity and power of the excitation light; a CCD 
camera with intermediate sensitivity; a non tumor-specific fluorochrome as a HP 
compound that doesn’t require complicate fluorescence labeling procedures, but only its 
simple systemic injection as a water solution. It was shown that simple HP-FRI technique 
we developed is a useful tool for diagnostic purposes: it’s able to image the fluorescence 
intensity increase in the region where tumor cells were inoculated and the tumor grows. 
The non-specific uptake of HP by tumor cells/tissue, while doesn’t allows for monitoring 
of molecular or genetic pathways of the diseases for a biomolecular study, allows for the 
detection of different tumors with the same labeling procedure for diagnostic purposes. 
Furthermore, we investigated the detectability of two different types of tumor, having 
different malignancy degree, with a bimodal system composed by our HP-FRI and a 
radionuclide imaging based on a semiconductor pixel detector of the Medipix family at 
high spatial resolution. So we were able to discriminate the different uptake of the 
gamma/fluorescent marker in the tumor. 
 Successively we improved the system detection by adopting a high sensitivity CCD 
camera, allowing for a more advanced imaging modality, where the detection of skin 
autofluorescence and background fluorescence has the advantage of providing the 
localization of the hyperfluorescent region on the mouse body and, however, doesn’t 
prevent the detection of the tumor areas by an increased fluorescent contrast of the tumor 
area with respect to the healthy tissue. On the other hand, the resolution of the structures 
appearing both in tumors and organs fluorescence images is strongly affected by the high 
value of the scattering coefficient of the mouse skin, as it results also from our spatial 
resolution measurements. In addition, the HP compound was shown to be a suitable 
fluorochrome for the early tumor detection. Indeed, the cell injection region can be imaged 
by its  fluorescence contrast  already on the third day after the tumor cells inoculation, 
when the tumor is not distinguishable at naked eye, neither palpable. The 
tumor/background optical contrast is maximum between 6 h and 24 h after a first HP 
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injection. Then it decreases with the time so that the third day after HP injection it 
vanishes; again, it increases 6-24 h after a second HP injection, but with values lower than 
those reached after the first injection and, finally, vanishes once again. It can be 
hypothesized that the timing of HP uptake and washout is different for the tumor tissue 
with respect to the healthy one: the HP accumulates in the tumor tissue preferentially with 
respect to the healthy, but with a washout time lower, so that some quantity of the HP 
exogenous remains in the healthy tissue also when it have been expulsed from the tumor 
and it add itself to the HP administrated with the second injection. Consequently, the 
background/tumor optical contrast is lower after the second HP injection than after the 
first.  
The tumor early detection is a clinical requirement of primary importance. Many 
FRI techniques aim to this scope with different strategies for florescent labeling. In general, 
the specific or “smart” targeting can obtain information on molecular or genetic pathways 
of the oncological diseases, while the targeting with fluorescent protein can supply a high 
optical contrast also for diseased internal organs. In the first case (244, 245), it is required a 
large amount of work before the FRI measurements in order to obtain the fluorescent 
labeling through a biomolecular study that allows for the identification of the best 
combination between the fluorochrome and the specific ligands of the tumor cells. In the 
second case (246-248) the fluorescence labeling of tumor cells is genetically performed 
before their injection, so that the tumor cells only are fluorescent. This approach does not 
allow to detect tumors that have unknown localization and nature. The non specific HP 
targeting is simple to perform requiring only a systemic injection; the HP is non toxic and, 
in the doses we used, doesn’t show photosensitization effects in mice; the HP is 
photobleaching resistant and chemically stable. The preferential accumulation in tumor 
after a systemic injection indicates that the HP compound is suitable in particular to the 
tumor early detection. Nevertheless, the optical fluorescence contrast remains low (<2) 
and the detection limited to a temporal window of about 48 h after the HP injection, that 
prevents from the monitoring the tumor time progression for long intervals.  
The system is susceptible of a series of improvements concerning the compactness 
of the irradiation source, the control of the irradiation geometry, the sensibility of the CCD 
camera. It is suitable to other biomedical applications, as the detection of tumor 
progression, of metastases formation and dissemination, the efficacy test on anticancer 
drug, etc., changing the fluorochrome type, i. e. the targeting strategies. The FRI system is 
also suitable for the integration with radionuclide system imaging (250) since the optical 
and radionuclide modality supply complementary information on the fluorescently and 
radionuclide labeled biomedical targets, as our preliminary tests seem indicate.  
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